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Abstract 
Murine Ly49 receptors are predominantly expressed on natural killer (NK) cells and 
play a key role in regulating immunological activity.  The Ly49 family contains both 
inhibitory and activating receptors, which bind class I major histocompatibility complex 
(MHC I) or MHC-like molecules.  Regulation of NK cell activity is the result of finely 
balanced signalling, which is delivered by the two receptor types upon ligand binding.  Once 
activated, NK cells play an essential role in the elimination of cancerous and virus infected 
cells.  
Ly49B differs from other members of the Ly49 family in that it is expressed on the 
surface of myeloid, rather than NK cells.  It shares only 50 % sequence identity with other 
Ly49s and contains an additional 20 amino acids at its carboxyl-terminus.  Furthermore, there 
are significant variations between Ly49Bs from different mouse strains.  These inter- and 
intra-molecular variations suggest that different allelic forms could possess distinct structural 
and functional properties when compared with one another and with other members of the 
Ly49 family.  This thesis seeks to provide an in-depth characterisation of the biochemical 
properties of Ly49B in comparison to other Ly49 receptors. 
In this study a series of Ly49B mutants, created by site-directed mutagenesis, was 
used to identify residues critical for monoclonal anti-Ly49B antibody and ligand binding.  
Flow cytometric analysis of the mutants revealed that C57 Ly49B-specific residues, L166 
and K167, are important for the integrity of the monoclonal 1A1 anti-Ly49B antibody 
epitope.  The equivalent BALB/c Ly49B residues, W166 and N167, together with residue 
C251 were shown to play an essential role in MHC class I ligand binding. 
Immunoprecipitation and Western blotting were used to demonstrate that Ly49B 
exists in multiple molecular forms in transfected and native cells, each of which most likely 
represents the receptor at different stages of glycosylation.  Similar results have never before 
been presented for any Ly49 receptor.  Finally, a method for refolding and purification of the 
extracellular portion of Ly49B was developed, following expression in Escherichia coli. 
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Chapter 1. Introduction 
 An organism’s ability to maintain an internal homeostasis and protect itself from 
external factors are fundamental requirements for survival.  The smarter those strategies are, 
the broader the organism’s potential niche and the more competitive it becomes.  In higher 
Eukaryotes the immune system plays a crucial role in protecting against pathogens and 
homeostatic deviations such as cancer. 
The immune system broadly comprises innate and adaptive components (Janeway 
2001).  Innate responses are immediate, first line defences maintained by the complement 
system together with several white blood cell types including macrophages, natural killer 
(NK) cells, eosinophils, neutrophils  and basophils.  Adaptive responses, on the other hand, 
develop several days post-infection; they are specific for a given pathogen, confer long-
lasting protective immunity for the host and involve T cells and antibody-producing B cells 
(Janeway 2001). 
Historically, the adaptive part of the immune system has been considered a more 
attractive mechanism for explaining how the body fights infection.  As such, the majority of 
immunological research has tended to lend its focus to that field.  The range of currently 
available vaccines and the use of monoclonal antibodies in cancer therapy are just two 
examples of how this research has been applied in practice.  However, more recently 
immunologists have realised that the adaptive part of the immune system works in tandem 
with the innate system and that the former cannot be fully appreciated without understanding 
the latter.   
Natural killer (NK) cells are an integral part of the innate immune system. They 
constitute 5-10 % of the circulating lymphocytes in mammalian blood and are characterised 
in humans by expression of the CD56 marker and by the NK1.1 marker in murine species 
(Janeway 2001; Zimmer 2010).  The majority of human and murine NK cells also express 
CD16, which is additionally found on macrophages and neutrophils (Cassatella et al. 1989).  
NK cells produce a number of signalling molecules of the immune system, known as 
cytokines, including interferon gamma (IFN-γ) and tumour necrosis factor (TNF) (Zimmer 
2010).  However, NK cells are best known for their cytotoxic activity against tumours and 
virus-infected cells, which is accomplished by the release of granzymes and perforins 
(Zimmer 2010).   
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1.1. NK cell activation 
1.1.1. The Major Histocompatibility Complex 
The major histocompatibility complex (MHC) is a region of highly polymorphic 
genes located on chromosome 17 in mice and chromosome 6 in humans (Figure 1.1) 
(Trowsdale 1993; Stroynowski 1990).  For historical reasons, human MHC molecules are 
referred to as HLA (human leucocyte antigen) molecules, while mouse MHC molecules are 
referred to as H-2 (histocompatibility 2) molecules.  There are at least 128 functional genes 
encoded in the human MHC locus and approximately 20 % of them have functions in 
immunity (Janeway 2001).   
There are two major classes of MHC genes: MHC class I and MHC class II.  The 
remaining genes are sometimes referred to as MHC class III and include genes that encode 
proteins with known immunological functions (for example complement components and 
cytokines) and others with no known immune function (Trowsdale 1993; Stroynowski 1990; 
Janeway 2001).   
 
Figure 1.1. Genomic organisation of the major histocompatibility complex.  A) Simplified diagram of the 
human MHC complex. B) Simplified diagram of the mouse MHC complex.  Letters in superscript indicate 
different haplotypes of inbred strains of mice. Blue=classical class I genes, Green=classical class II genes.  
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Class I and class II genes are divided into classical and non-classical.  The classical 
genes encode MHC class I and II molecules (Figure 1.2) and the non-classical, MHC class I 
and II-like molecules, which are structurally similar to the classical MHC molecules, as well 
as proteins involved in processing of MHC class I and II molecules.  All genes that encode 
the various chains of class I and class II MHC molecules exist as multiple copies within the 
MHC, with the exception of the β2 microglobulin chain of MHC class I, which is encoded on 
a different chromosome.  Each cell expressing MHC genes displays several different MHC 
molecules. (Trowsdale 1993; Stroynowski 1990; Janeway 2001).   
MHC class I and class II molecules are able to bind short peptides and present them to 
CD8 positive and CD4 positive T cells, respectively (Vyas et al. 2008).  MHC molecules 
interact with T cells via T cell receptors (TCR) and CD4/CD8 molecules.  The peptides in the 
binding grooves of MHC molecules are usually endogenous, in which case they are referred 
to as “self” peptides.  Presentation of “self” peptides to T cells keeps them in an inactive 
state.  However, during infection by pathogens MHC molecules bind peptides of foreign 
origin and present them to T cells, resulting in their activation.  MHC class I molecules are 
able to present peptides from intracellular pathogens and, for this reason, are constitutively 
expressed on all nucleated cells in the body.  MHC class II molecules present peptides that 
originate from extracellular pathogens and are expressed on a restricted number of cells 
called antigen presenting cells (APCs).  APCs include B cells, dendritic cells and 
macrophages.  The aforementioned diversity of MHC molecules that are expressed on a 
single cell allows presentation of a greater number of peptides, thereby increasing the chances 
of recognising infective agents (Vyas et al. 2008).  
Figure 1.2. Schematic structure of classical MHC 
molecules. The MHC class I molecule is made up of a 
heavy α chain (~43 kDa) non-covalently linked to a 
smaller peptide (~11 kDa) called the β2 
microglobulin (β2m).  The α chain forms three 
globular α domains (α1, α2 and α3) stabilised by 
disulphide bonds.  A hydrophobic section of the 
molecule anchors MHC class I in the cell membrane.  
The α1 and α2 domains form a peptide binding 
groove.  The MHC class II molecule is made up of an 
α chain of ~34 kDa and a β chain of ~28 kDa, both of 
which anchor the protein in the membrane.  The α 
and β chains form two globular domains.  α1 and β1 
form a peptide binding groove similar to that found in 
the MHC class I molecule.  α=α chain, β=βchain, 
β2m= β2- microglobulin, 1-3= globular domains, red 
circle = peptide in peptide binding groove. 
α3
α2
α2
α1α1
β2
β1
β2m
MHC class I MHC class II 
Membrane
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1.1.2. “The missing self” hypothesis  
It is not known for certain how NK cells recognise diseased cells but the key advance 
in our current understanding was made by Klas Kӓrre who proposed the “missing self” 
hypothesis (Kӓrre 1981) in the early 1980s.  Tumours and virus-infected cells are sometimes 
characterised by the low level expression of MHC class I molecules, which makes them 
difficult to recognise by T cells (Browning 1999).  Kӓrre proposed that NK cells, just like T 
cells, recognise class I MHC molecules.  However, rather than being activated by the 
presence of exogenous peptide in the MHC groove, NK cells instead react when MHC levels 
are abnormally low (Kӓrre 1981).  This revolutionary theory was confirmed several years 
later by Wayne Yokoyama, who showed that IL-2 activated mouse NK cells, which express   
Ly49A do not lyse cells expressing H-2
d 
or H-2
k 
MHC class I molecules, which are 
effectively lysed by Ly49A deficient NK cells.  The protection from lysis by Ly49A 
expressing cells did not apply to cells expressing H-2D
b
 molecules.  Transfection of 
susceptible cells with H-2D
d
, but not H-2K
d
 or H-2L
d
, made them resistant to lysis by Ly49A 
positive NK cells.  The resistance of H-2D
d
-transfected cells could be abolished by 
monoclonal anti-Ly49A or anti- H-2D
d 
antibodies (Karlhofer et al. 1992).  These experiments 
have shown that Ly49 receptors expressed on the surface of NK cells can specifically 
recognise particular alleles of MHC class I molecules on target cells and deliver an inhibitory 
signal upon ligand binding.  In the absence of “self” MHC ligand, NK cells therefore become 
activated.  The “missing-self” hypothesis provides an elegant explanation as to why NK cells 
are non-reactive against the body’s own, healthy cells but noxious towards diseased cells. 
. 
 
 
Figure 1.3. A schematic diagram of NK 
cell activation.  a) The NK cell adopts an 
anergic state when balanced signals are 
delivered from inhibitory and activatory 
receptors.  b) NK cell activation occurs 
when the inhibitory signal is missing. 
Figure taken from French and Yokoyama 
2006. 
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It is now known that there are several families of NK cell receptors (Figure 1.4), 
including both activating and inhibitory members, which exert control over NK cell 
activation through balanced signalling (Figure 1.3) (Dimasi and Biassoni 2005; Karlhofer et 
al. 1994; Zimmer 2010).  NK cells simultaneously receive both types of signal upon 
interaction with target cells.  If the target cell is healthy, the inhibitory signal overrides the 
activating signal, rendering the NK cell inactive.  However, if the target cell is diseased and 
expression of inhibitory receptor ligands is downregulated, NK cells become activated. The 
majority of ligands for activating NK cell receptors have not yet been identified but there is 
evidence that the mouse cytomegalovirus m157 glycoprotein, which is an MHC class I-like 
molecule, is recognized by the activating Ly49H receptor (Lopez-Botet et al. 2004; Smith et 
al. 2002).   
Examples of NK cell receptor families include rodent Ly49 and NKRP1 receptors, 
which are structurally related and belong to the C-type lectin superfamily.  CD94-NKG2 
receptors, which form heterodimers on the surface of NK cells and interact with MHC class I 
molecules on target cells, are another example C-type lectin-like NK cell receptors and are 
found in both rodents and humans (Yokoyama and Plougastle 2003; Zimmer 2010).  Killer 
immunoglobulin-like receptors (KIRs) are primate functional orthologues of Ly49 receptors 
but differ structurally from C-type lectin-like molecules (Figure 1.4). 
 
 
Figure 1.4. Examples of human and mouse NK cell receptor families. Receptor family names are shown in 
red.  Lectin-like = receptors that belong to the structural C-type lectin superfamily, Ig = receptors that belong 
to the structural immunoglobulin superfamily. 
 
Ly49 NKRP1 CD94/NKG2 KIR
Human
Mouse (Rat)
Ig-likeLectin-like
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1.2. The Ly49 family 
 The genes that encode mouse Ly49 receptors are clustered at the telomeric end of 
chromosome 6 within the NK gene complex (NKC), along with several other types of NK 
receptors including CLR, NKRP1 and CD94/NKG2 receptors (Yokoyama and Plougastle 
2003; Zimmer 2010).  The only known human Ly49 homologue, Ly49L, is encoded on 
chromosome 12 and was found to be a pseudogene (Westgaard et al. 1998).  To date 23 
members of the Ly49 family have been identified (each indicated by a unique character, A to 
W), as well as at least 15 allelic variants.  Different strains of mice contain unique sets of 
Ly49s (Yokoyama and Plougastle 2003); the C57 strain, for example, contains 11 functional 
Ly49 genes and 4 pseudogenes (Figure 1.5), whereas the BALB/c strain contains only 8 
Ly49 genes, two of which are pseudogenes (Anderson et al. 2001; Dimasi et al. 2002).  
 
 
Figure 1.5. The Ly49 locus of the C57 mouse strain.  Genes encoding inhibitory Ly49s that are expressed on 
NK cells are indicated in green.  Activating Ly49s are indicated in blue.  Arrows representing non-functional 
pseudogenes are hatched.  Ly49s expressed on myeloid cells are indicated in red.  Ly49B is physically separated 
from the rest of the Ly49 genes by a region of roughly 450 kb. (adapted from master’s thesis of Katarzyna 
Mickiewicz, 2009) 
 
The majority of Ly49s (but not all) are expressed in an unusual stochastic and mono-
allelic manner (Held and Kunz 1998; Gays et al. 2011).  Typically, a single mouse NK cell 
will express only 2-3 Ly49 receptors of the available pool and each of them from only one of 
the parental alleles.  Different NK cells within a population express different sets of Ly49s.  
This mode of expression enables the generation of a diverse NK cell repertoire, which is able 
to recognise a variety of MHC class I alleles. 
1.3. Glycosylation of surface proteins  
 
Both Ly49s and their ligands are heavily glycosylated.  Glycosylation is a form of an 
enzyme dependent, co-translational or post-translational modification of proteins, lipids and 
other organic molecules, which relies on attachment of carbohydrates to a specific site of the 
modified molecules (Taylor et al. 2006).  It occurs in ER, Golgi apparatus, cytoplasm and 
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nucleus of eukaryotic cells.  Glycosylation is also a common event in archaea but very rarely 
occurs in bacteria (Taylor et al. 2006).  Glycan modifications are important for correct 
folding of many eukaryotic proteins, they confer stability of some secreted proteins and also 
play a role in cell to cell adhesion (Taylor et al. 2006).   
There are five types of glycosylation: 
 N-glycosylation, which involves attachment of glycans to a nitrogen of asparagine 
or arginine side chains.   
 O-glycosylation, where glycans are attached to hydroxy oxygen of serine, 
threonine, tyrosine, hydroxylysine, or hydroxyproline side chains, or to oxygens 
of lipids such as ceramide.  The process occurs specifically in Golgi apparatus.  
 Phospho-Serine glycosylation, where glycans are attached to serine through a 
phosphate 
 C-mannosylation, involving attachment of a sugar to a carbon of a tryptophan side 
chain  
 Glypiation (GPI anchors), which is the addition of a GPI anchor that links proteins 
to lipids through glycan linkages. 
The majority of secreted and surface-associated eukaryotic proteins, including Ly49s, 
undergo N-glycosylation.  As these proteins travel from the ER to the cell surface glycans are 
attached at critical asparagine residues, which are then cleaved and modified (Taylor et al. 
2006; Moremen et al. 2012).  The subsequent stages in the N-glycosylation pathway are 
illustrated in Figure 1.6 (Moremen et al. 2012).  Glycosyltransferases in the cytosol initially 
facilitate the assembly of a glycan from monosaccharides.  The monosaccharides are attached 
stepwise onto a so-called “lipid anchor”, which is situated within the endoplasmic reticulum 
(ER) membrane.  The assembled glycan is referred to as a lipid-linked oligosaccharide 
(LLO).  The LLO is then flipped onto the luminal side of the ER where it can be further 
modified and serve as a donor for glycosylation.  Eukaryotic LLOs contain a conserved core 
comprising Glc3Man9GlcNAc2, where Glc is glucose, Man is mannose and GlcNAc is N-
acetylglucosamine.  Ribosomes inside the cytoplasm assemble with a protein called SEC61 
translocon within the ER membrane.  mRNAs that encode Asn-X-Ser/Thr acceptor sequons 
(AKA glycosylation motifs) are translated into proteins, which enter the ER via the SEC61.  
Upon protein entry into the ER, LLO-associated glycans are transferred en bloc to critical 
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asparagine residues with the acceptor sequons by oligosaccharyltransferase (OST).  The 
resulting glycoprotein is partially folded and undergoes further glycan modifications, 
beginning with the removal of two glucose residues (glycan trimming) by α-glucosidase I 
(GIsI) and the α-glucosidase II α-β heterodimer (GIsIIα/β), which also facilitates protein 
folding.  
 
Figure 1.6. N-glycosylation of eukaryotic proteins.  a) co-translocation and glycosylation b) protein folding 
and quality control. c) re-gucosylation of misfolded proteins d) ER disposal of terminally misfolded proteins 
Figure taken from Moremen et al. 2012. 
Proteins with terminal glucose modifications are targets for the two lectins; calnexin 
(CNX) and its membrane bound homologue, calreticulin (CRT).  CNX and CRT retain 
glycoproteins until they are properly folded and help prevent their aggregation.  Dissociation 
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from CNX/CRT results from the removal of the remaining glucose residue by GIsIIα/β.  In 
the event of improper folding, glucose can be re-added by UDP-glucose glycoprotein 
glucosyltransferase 1 (UGGT1) and the glycoprotein re-introduced into the CNX/CRT cycle, 
which continues until the protein is correctly folded.  The CNX/CRT cycle is assisted by 
ERp57 and Bip chaperones.  During this process glycoproteins can be targeted by ER 
mannosidase I (ERManI), which removes one of the mannose residues.  Terminally 
misfolded glycoproteins are subjected to further glycan trimming in the presence of ER 
degradation-enhancing α-mannosidase-like proteins (EDEMs), disentangled from aggregates 
and reduced using Bip and ERp57 proteins, before finally being translocated into the 
cytoplasm.  Here, the denatured glycoproteins are ubiquitinated, processed by valosin 
containing protein (VSP) and completely de-glycosylated by PNGase before being targeted 
for degradation in the proteasome. 
Correctly folded glycoproteins leaving the CNX/CRT cycle are usually associated 
with Man9GlcNAc2 or Man8GlcNAc2 structures and are targets for the ER-Golgi intermediate 
compartment marker, ERGIC53, which acts as a broad specificity receptor for all large-
mannose chains. Vesicular integral protein 36 (VIP36), VIP36-like protein (VIPL) and 
mannan-binding protein also facilitate transport of glycoproteins to the Golgi.  In the Golgi 
glycoproteins undergo further mannose trimming, by the Man5GlcNAc2 by the cis-Golgi α-
mannosidases; IA, IB and/or IC.  Glycoproteins, that resist trimming to Man5GlcNAc2 can be 
retrieved by VIP36 and subjected to new rounds of trimming.  Structures Man9GlcNAc2 to 
Man5GlcNAc2 are referred to as high-mannose forms.  Proteins possessing these kinds of 
modifications are rarely released from cis-Golgi and do not normally reach the cell surface.  
High-mannose modifications therefore can act as a reliable marker for immature proteins.  
The majority of glycoproteins undergo further modification in medial-Golgi, where two 
further mannose residues are removed, while three gycNac and one fructose residues are 
added.  Finally, in trans-Golgi, three galactose residues followed by three N-
acetylneuraminic acid residues are added and the protein with this complex oligosaccharide 
modification can be targeted for the membrane or secretion.  
1.4. Molecular characterisation of Ly49 receptors  
The first attempts to characterise Ly49s began during the early 1980s.  At the time 
very little was known about this family of receptors and several immunoprecipitation (IP) 
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experiments were carried out to determine the specificity of newly developed monoclonal 
antibodies, which were generated against previously unidentified surface molecules.  Studies 
would eventually go on to demonstrate that the molecules were in fact Ly49 receptors. 
 Chan et al. developed YE1/48 and YE1/32 monoclonal antibodies that recognised a 
protein, which was expressed on the surface of EL-4 and MBL-2 T cell lymphomas and, to a 
lesser extent, normal splenocytes and thymocytes (Takei 1983; Chan and Takei 1986; Chan 
and Takei 1988).  The cells were surface radiolabelled with 
125
I isotope and lysed.  Lysates 
were subjected to immunoprecipitation with YE1/48 and YE1/32 monoclonal antibodies.  
The eluted proteins were then analysed by SDS-PAGE with and without the reducing agent, 
2-mercaptoethanol (2ME), and visualised using autoradiography.  Immunoprecipitated 
material migrated on SDS-PAGE as a 45-50 kDa dispersed band under reducing conditions 
and as an 85-100 kDa band under non-reducing conditions, suggesting that the molecule of 
interest was a disulphide-linked dimer.  Since the monomer migrated at roughly half the size 
of the dimer, it was proposed that the molecule of interest was a homodimer.    An additional 
high molecular weight band appeared in some of the reduced and non-reduced samples, 
suggesting that the immunoprecipitated antigen may be capable of multimerisation.  
 The dispersed nature of the bands was thought to be due to glycosylation of the 
protein.  The protein was therefore treated with a range of concentrations of endoglycosidase 
F, which removes all N-linked glycans that are attached to polypeptides at asparagine 
residues.  On analysis by SDS-PAGE, the reduced IP material migrated at a molecular weight 
of 42 kDa (no glycosidase), 38 kDa (12.5 U/ml glycosidase for 3 h) and 32 kDa (50 U/ml 
glycosidase for 22 h), which suggested that the monomer had at least 3 N-glycosylation sites.  
The 38 kDa and 32 kDa bands persisted, after prolonged exposure to the enzyme, suggesting 
that the dimeric molecule may in fact be a heterodimer made of two subunits of 38 and 32 
kDa in size.  Alternatively, the protein core of the subunits could have been the same but one 
of the subunits could possess a carbohydrate modification, which was resistant to enzymatic 
treatment.  Interestingly, all of the samples contained some residual non-reduced material, 
suggesting that the dimeric protein was robust and resistant to reduction.  A high molecular 
weight band, of a similar size to that previously described, was also present in all of the 
samples.  
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When the YE1/48 antigen was purified from EL-4 cells and separated by diagonal 
SDS-PAGE, two very similar subunits were detected; one more acidic than the other (Chan 
and Takei 1988).  Tryptic peptide profiles of the two subunits were different but much more 
similar than, for example, profiles of T cell receptor subunits.  These results provided further 
evidence that the core peptides of the two antigen subunits might in fact be the same, but that 
they might undergo different posttranslational modifications. 
Around the same time, Nagasawa and colleagues immunised BALB/c mice with EL-4 
cells and developed a monoclonal antibody, termed 1A, which reacted with two T lymphoma 
cells of C57 origin (EL-4 and CGVBL).  However, the 1A antibody did not react with normal 
C57 splenocytes, thymocytes, C57 T cell clones or other T and B lymphomas, as revealed by 
complement-mediated cytotoxicity or indirect immunofluorescent staining (Nagasawa et al. 
1987).  The antibody was used to immunoprecipitate an as-yet unknown molecule, which 
migrated on SDS-PAGE gels as a dispersed band of ~43 kDa under reducing conditions and a 
band of ~85 kDa under non-reducing conditions.  Interestingly, small amounts of the antigen 
were also immunoprecipitated from normal splenocytes and thymocytes.  The authors 
concluded that the antigen may not have been accessible by the antibody on the surface of the 
cells, thus explaining why it was not detected by FACS analysis.  However, following lysis 
the relevant epitopes became available.  
When the antigen was subjected to 2D SDS-PAGE and peptide mapping, similar 
results were obtained as for the antigen identified by Chan et al., except the more acidic 
subunit could not be surface labelled by 
125
I.  Chan et al. also described difficulties 
encountered in surface labelling of the acidic subunit, although they did eventually succeed. 
Further investigation revealed that all three of the aforementioned antibodies 
(YE1/48, YE1/32 and 1A) bind the same dimeric protein but that they might recognise 
different epitopes.  Eventually cDNA of the YE1/48 antigen was obtained and sequenced, 
revealing that the protein of interest contained 262 amino acids and had a predicted molecular 
weight of 30.5 kDa (Chan and Takei 1989; Yokoyama et al. 1989).  44 amino acids were 
predicted to comprise the cytoplasmic domain, 22 amino acids the transmembrane region and 
196 amino acids the extracellular domain.  The protein had characteristics of a type II 
transmembrane protein, with an intracellular N-terminus and a C-terminus exposed to the 
surface.  Three putative N-glycosylation sites were identified in the sequence.  For 
30 
 
consistency in the immunological nomenclature the YE1/48 antigen was named Ly49.   
Southern blot analysis using Ly49 cDNA probes revealed a multiple band pattern, suggesting 
cross-hybridisation with other related proteins (Chan and Takei 1989; Yokoyama et al. 1989).  
Ly49 appeared to be a prototypic member of a newly identified family of receptors and was 
therefore named Ly49A.  Similar results to those described by Chan et al. and Nagasawa et 
al. regarding the molecular nature of Ly49A were obtained for IL-2-activated NK cells 
(Mason et al. 1996; Ortaldo et al. 1999), M14T cells (Roland and Cazenave 1992) as well as 
in COS transfectants (Yokoyama et al. 1989), and C1498 transfectants (Scarpellino et al. 
2007).  Several studies also confirmed the results for EL-4 cells (Roland and Cazenave 1992; 
Yokoyama et al. 1989; Chang et al. 1996).   
In 1988 Mason et al.  used immunoprecipitation to confirm that an antibody they had 
developed (4D11) recognises a unique antigen on mouse spleen and liver NK cells. The 
antigen ran on SDS-PAGE gel in the range of 85-89 kDa under non-reducing and reducing 
conditions. (Mason et al. 1988). They failed to comment on a band of ~40 kDa in size, which 
most likely represented a monomer and was present even in the non-reduced samples.  This 
finding was potentially highly significant, suggesting that the identified antigen may exist in 
NK cells as a monomer.  They called the antigen LGL-1, but it has since been renamed 
Ly49G2.  Subsequent studies, in which higher amounts of reducing agent were used revealed, 
that Ly49G2 was a disulphide linked dimer, which was notoriously difficult to reduce most 
likely due to the presence of multiple internal disulphide bridges (Mason et al. 1995; Mason 
et al. 1994; Chang et al. 1999). 
Another group from the University of Texas generated the SW5E6 antibody, which 
bound ~50 % of mouse NK cells.  The antigen recognised by SW5E6 migrated by SDS-
PAGE as a band of ~54 kDa under reducing conditions and as a ~110 kDa band under non-
reducing conditions (Sentman et al. 1989).  The antigen was later identified as Ly49C 
(Mason et al. 1996; Ortaldo et al. 1999; Scarpellino et al. 2007).  Similar experiments, 
revealing the dimeric nature of Ly49s have since been performed on Ly49H, Ly49Q, Ly49P 
and Ly49I (Smith et al. 2000; Toyama-Sorimachi et al. 2004; Ortaldo et al. 1999; Scarpellino 
et al. 2007).  The identified molecular sizes of the monomers and dimers as well as methods 
used for the characterisation of those and others NK cell receptors are summarised in 
Appendix II. 
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When in 1996 Ly49D was characterised, a sequential immunoprecipitation was 
performed with 1A, 4D11 and SW5E6 antibodies before probing with a putative 12A8 anti-
Ly49D antibody to confirm its specificity (Mason et al. 1996).  IP material from the 
subsequent stages was analysed by SDS-PAGE under reducing and non-reducing conditions 
and revealed a pattern characteristic for previously observed glycosylated Ly49 monomers 
and dimers.  However, when the individual monomers and dimers were compared with each 
other on the same gel, they ran at slightly different sizes, indicating that 12A8 specifically 
recognises Ly49D and not any of the previously characterised Ly49s. 
Ly49A and Ly49C are co-expressed on the surface of approximately 5 % of C57 NK 
cells and show very close homology in their amino acid sequences (Brennan et al. 1995).  In 
order to determine whether or not they are able to form heterodimers, COS cells were co-
transfected with Ly49A and Ly49C, lysed and subjected to sequential IP with anti-Ly49A in 
the first round and anti-Ly49C in the second round and vice versa.  If Ly49A and C had been 
able to form heterodimers, the fraction precipitated by the first antibody should have been re-
precipitated by the second.  SDS-PAGE analysis revealed that this was not the case, 
suggesting that Ly49A and Ly49C monomers are not able to dimerise on the surface of COS 
transfectants and most likely exist exclusively as homodimers on the surface of cells, in 
which they are natively expressed (Brennan et al. 1995).  The experiment did not exclude the 
possibility that the two subunits may be differentially modified.  
Examples of other murine NK cell receptors that have been examined by Western 
blotting and immunoprecipitation include CD94 (Perez-Villar et al. 1996; Lazetic et al. 
1996), rat Ly49i2 (Naper et al. 1998; Naper, et al. 2002a), NKR-P1C (Kveberg et al. 2006a) 
and KLRH1 (Naper et al. 2002b) and the results are summarised in Appendix II.  More 
information regarding the molecular nature of Ly49 receptors has since been elucidated 
through the use of crystallographic studies, details of which are described in Section 1.6. 
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1.5. The Ly49 ligand binding 
 
1.5.1. Ligand specificity 
 
The primary function of Ly49 receptors concerns regulation of NK cell activation, 
which is achieved through binding of Ly49 ligands.  MHC class I molecules act as ligands for 
inhibitory Ly49s.  As described in Section 1.1.2, functional studies have revealed that the 
specificity of each Ly49 receptor is restricted to a particular individual or set of MHC class I 
molecules.  Ly49A has been shown to inhibit lysis of target cells expressing H-2D
d 
and H-
2D
k
 MHC class I molecules (Karlhofer et al. 1992).  Antibodies directed against Ly49A or its 
ligand are able to block the inhibition.  Similar experiments have shown that Ly49G2 
associates with H-2D
d 
(Mason et al. 1995). 
The specificity of Ly49 receptors has also been studied in vivo.  Ly49G2-expressing 
NK cells have been shown to reject bone marrow allografts expressing H-2
b
 but not H-2
d
, 
confirming H-2
d
 specificity of Ly49G2 (Raziuddin et al. 1996).  Bone marrow graft rejection 
experiments also confirmed that H-2K
b
 acts as a ligand for Ly49C and the closely-related 
Ly49I (Yu et al. 1996).  
Cell-cell adhesion assays have been used to show the direct association of Ly49A 
with H-2D
d
 (Daniels et al. 1994; Takei et al. 1997).  COS-7 cells transfected with Ly49C 
were shown to associate with cells expressing H-2
b
, H-2
d
, H-2
k 
and H-2
s
, while cells 
transfected with Ly49I were shown not to associate with any of the tested MHC expressing 
cells, which is in contrary to graft rejection experiments (Brennan et al. 1996a; Brennan et al. 
1996b).  
Another direct association assay that has been used to demonstrate Ly49 interactions 
involved coating plates with isolated, soluble MHC class I molecules.  EL-4 lymphoma cells 
expressing Ly49A have been shown to bind to plastic microtiter plates coated with H-2D
d
, H-
2D
k
, and H-2K
b
, but not H-2K
d
, H-2K
k
, or H2-D
b
 and the binding was inhibited by A1 anti-
Ly49A antibody (Kane 1994).  A more robust assay has since been developed to assess direct 
Ly49-ligand interactions, in which α chains of mouse MHC class I molecules are expressed 
in E.coli, then refolded in the presence of human β2m and assembled into soluble tetramers 
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that are conjugated to fluorophores (Hanke et al. 1999).  The tetramers were incubated with 
cells expressing Ly49 receptors and binding assessed using flow cytometry.  
Seven different Ly49 receptors (A, B, C, E, F, G2 and I ) were tested with a variety of 
tetramers (H-2K
b
, H-2D
b
, H-2K
d
, H-2D
d
, H-2L
d
, H-2D
k
) (Hanke et al. 1999).  Ly49A was 
shown to specifically bind H-2D
d
 and H-2D
k
 tetramers and Ly49G2 bound weakly to H-2D
d
, 
which confirmed previous findings.  Ly49C associated with all of the tested tetramers apart 
from H-2L
d
, which was consistent with most of the cell adhesion assays; although H-2D
b
 was 
previously shown not to associate.  The authors concluded that binding of tetramers would be 
much stronger than a single MHC class I molecule, thus explaining why an association 
between H-2D
b 
and Ly49C was not previously detected.  Ly49B and Ly49F showed very 
little reactivity with any of the tested tetramers.  Ly49I was shown to associate with H-2K
d 
and H-2D
d
; this was in contrast with data obtained in the cell adhesion assays, which 
indicated that H-2K
b
 is a specific Ly49I ligand.  The discrepancy was thought to be due to the 
specificity of Ly49I for a specific peptide bound to the MHC class I molecule.  Five different 
peptides bound to H-2K
b
 molecules were tested with only two of them enabling binding by 
Ly49I.  Ly49C was also tested in parallel for peptide specificity and was shown to bind H-
2K
b
 regardless of which of the five peptides it associated with.  Ly49A tested in similar 
studies also showed no selectivity for different peptides (Correa and Raulet 1995; Orihuela et 
al. 1996).  
Co-crystal structures of Ly49A and Ly49C with their ligands (described in detail in 
Section 1.6.2) show that the binding site between Ly49s and their ligands involves residues 
in all three α-chain domains of MHC class I and β2m.  Tetramer binding assay was repeated 
using MHC molecules that were refolded with mouse, rather than human, β2m (Scarpellino et 
al. 2007).  Unexpectedly, Ly49A was found to react, not just with H-2D
k
 and H-2D
d
, but also 
with H-2K
d
 and very weakly with H-2K
b
 and H-2D
b
.  Ly49C reacted with all of the tested 
tetramers which is consistent with the Hanke et al. tetramer binding experiment.  
Interestingly Ly49B was also found to react with all of the tested tetramers, which is in stark 
contrast to what was found in the previous study.  However, it was since hypothesised that 
the lack of interaction of Ly49B with tetramers in the Hanke et al. study was due to the 
presence of HA-tag (Scarpellino et al. 2007).  A weak interaction was observed between 
Ly49G2 and H-2D
d
 and between Ly49I and both H-2K
b
 and H-2K
d
.  Ly49Q was shown to 
bind H-2K
b
 as a primary ligand; an interaction was also observed with H-2D
d
, albeit only 
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roughly half as strong.  Ly49D, E, F and H showed very little reactivity with all of the tested 
ligands.  
The significance of species-specific residues of β2m was investigated in another 
study, which showed that replacing murine β2m with human β2m in H-2Db, H-2Kb and H-
2D
d
 tetramers resulted in a loss of binding by Ly49A and Ly49C (Michaelsson et al. 2001).  
Sequence analyses, combined with in silico analyses of available crystal structures, revealed 
that lysine at position 3, threonines at positions 4 and 28 and glutamine at position 29 could 
be directly involved in the interactions between Ly49A and H-2D
d
 (Michaelsson et al. 2001). 
An alternative explanation was that replacement with the human β2m affects folding of α 
chain, thereby indirectly influencing binding by Ly49 receptors.  Another study, which 
utilised site-directed mutagenesis, revealed that residues glutamine 29 and lysine 58 of β2m 
are critical for Ly49A binding (Wang et al. 2002a).    
Prior to solving co-crystal structures of Ly49A and Ly49C with their ligands, several 
studies indicated that Ly49A interacts with the α2 domain of H-2Dd, with further possible 
contributions from the α1 domain.  Chimeric MHC class I molecules, in which the α1, α2 and 
α3 domains of H-2Dd were replaced by the corresponding domains of H-2Db, were 
transfected into YB2/0 cells.  Transfectants were then tested for association with RNK cells 
expressing Ly49A.  Only transfectants expressing chimeric molecules with the α2 domain of 
H-2D
d 
origin were able to associate with Ly49A-expressing cells, suggesting that the α2 
domain alone is responsible for the allelic specificity of Ly49A (Sundback et al. 1998).  
Another study has shown that incubation of H-2Dd-expressing cells with antibody directed 
against α1/α2, but not α3, had an inhibitory effect on binding Ly49A-expressing CHO cells 
(Daniels et al.1994).  The role of the α1 motif and N-terminal residues of α2 in Ly49A 
binding was further confirmed by another study where ten recombinant H-2D
d
/H-2K
d 
molecules were tested for binding to Ly49A (Matsumoto et al. 1998) 
Murine Ly49 NK cell receptors belong to the C-type lectin superfamily, which is 
characterised by a carbohydrate recognition domain (CRD) and the ability to bind sugars in 
the presence of calcium.  Despite this, Ly49s were shown to bind their MHC class I ligands 
in a calcium-independent manner.   To address the question of whether or not Ly49s can bind 
carbohydrates, such as other C-type lectins, a variety of readily available potential ligands 
were tested.  Sulfated glycans, including fucoidan and dextran sulfate, were shown to inhibit 
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Ly49A- and Ly49C-mediated adhesion (Brennan et al. 1995; Daniels et al. 1994).  Fucoidan 
was able to block binding of anti-Ly49A and anti-Ly49C monoclonal antibodies to cells 
transfected with Ly49A and Ly49C (Brennan et al. 1995; Lian et al. 1998).  These findings 
demonstrate that Ly49A and Ly49C may possess a functional carbohydrate-binding domain.  
However, the tested polysaccharides are not natural, endogenous Ly49 ligands and the 
significance of these data is unclear.  It is possible that Ly49s possess other, as-yet 
unidentified, exogenous ligands, which could, for example, originate from pathogens and 
become important during infection. 
1.5.2. The role of ligand glycosylation in Ly49-MHC class I interactions 
Both Ly49s and their MHC class I ligands are heavily glycosylated.  Several studies 
have been carried out in order to assess whether or not glycosylation of MHC class I 
molecules is important for their interactions with Ly49 receptors.  Treatment of H-2D
d
-
transfected cells with the glycosylation inhibitor, tunicamycin, has been shown to reduce 
Ly49A-mediated NK cell inhibition (Daniels et al. 1994).  Treatment of cells expressing 
Ly49C ligands with fucosidase had a similar effect on inhibitory Ly49C function (Brennan et 
al. 1995).  These results suggest that the level of ligand glycosylation might contribute to 
binding affinity between Ly49 and MHC class I molecules. 
 The exact nature of MHC glycans is unknown.  However, the ability of Ly49s to bind 
sulphated polysaccharides and no others, together with the binding assays previously 
outlined, indicate that MHC class I sugars may be sulphated.  This prediction has been 
confirmed by Chang et al., who showed that the SO4 2- label on H-2D
d
 is removed by N-
glycosidase F but resistant to endoglycosidase H, suggesting that the glycans are indeed 
sulfated and that the sulfate groups are located on mature, N-linked oligosaccharides (Chang 
and Kane 1998).  H-2D
d
-Ly49A interactions were diminished by treatment of target cells 
with a sulfation inhibitor (sodium chlorate), suggesting that sulfate modifications can 
influence Ly49-MHC binding.  
 The position of most N-glycans can be predicted since they are usually attached to 
asparagine residues that occur in the tripeptide sequence, Asn-X-Ser or Asn-X-Thr, where X 
may be any amino acid except proline (Taylor et al. 2006).   Mouse MHC class I molecules 
possess two conserved N-glycosylation sites at positions 86 and 176 located in the α1 and α2 
domains, respectively (Chang and Kane 1998).  Two independent groups have created H-2D
d
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glycosylation mutants to assess the role of glycan modifications in the binding of Ly49A 
(Matsumoto et al. 1998; Lian et al. 1998).  Interestingly, one of the studies reported that both 
N86 and N176 mutants were recognised by Ly49A, suggesting that glycosylation is not 
essential for MHC binding (Matsumoto et al. 1998).  The second study, on the other hand, 
indicated that glycosylation at N176, but not N86, is important for binding (Lian et al. 1998).  
Both groups created their mutants by site directed mutagenesis.  However, the first group 
achieved it by replacing asparagine residues with glutamine, when the second one replaced 
serine 88 and threonine 178 with glycine.  Both methods appeared to be sufficient to remove 
glycans, as demonstrated by altered migration patterns in SDS-PAGE analyses, following 
immunoprecipitation, when compared with wild type MHC molecules.   
Correct folding of the mutants was confirmed by FACS analysis and staining with 
monoclonal antibodies.  The expression levels of mutants on transfected cells were found to 
be comparable to wild type H-2D
d
.   However, one cannot discount the possibility that the 
mutageneses introduced discrete changes to the structure of H-2D
d
.  Such changes might not 
have been detected using the methods described, but could still have influenced ligand 
binding.  It seems likely, that the replacement of asparagine with glutamine, which differs by 
just one methylene group, would have a smaller effect on the overall protein structure than 
replacement of threonine with the smallest amino acid, glycine.  Despite the inconclusive 
nature of these results, it would appear that glycosylation of MHC class I molecules is not 
essential for interactions with Ly49 receptors, however, it may affect the strength and, 
perhaps, duration of binding.  
 The most recent study on activatory Ly49H receptor appears to confirm the above 
conclusions (Guseva et al. 2010).  Ly49H recognizes a non-classical MHC class I molecule: 
murine cytomegalovirus (MCMV) m157 protein.  M157 has four N-glycosylation sites and is 
natively expressed in multiple, differentially glycosylated forms.  Single and combinatorial 
asparagine to glutamine mutants were used to establish that glycosylation enhances 
expression of m157 and binding to Ly49H.   Interestingly, glycosylation was also shown to 
be important for the physical transfer of m157 to Ly49H-expressing cells, in a process known 
as trogocytosis. 
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1.5.3. The role of Ly49 glycosylation in Ly49-MHC class I interactions 
The first evidence that Ly49 receptors themselves are glycosylated comes from 
experiments performed in the late 1980s using newly identified monoclonal antibodies 
against Ly49A  was tested and have been described in Section 1.4 (Chan and Takei 1986; 
Chan and Takei 1988; Nagasawa et al. 1987).  Appendix I shows an alignment of all C57 
Ly49s, together with BALB/c Ly49B, with predicted N-glycosylation motifs highlighted.  
Most of Ly49s contain two N-glycosylation motifs in the stalk region at residues 
corresponding to Ly49A 86-88 and 103-105, where the first residue of the motif is asparagine 
and the last, serine.  Curiously, Ly49B lacks the first of these conserved sites, while Ly49Q 
lacks the second.   Several other partially- or non-conserved N-glycosylation motifs can be 
identified in other Ly49 receptors within the stalk regions and CRDs.  Although glycosylation 
motifs may be predicted in silico, the predicted sites do not always correspond to the situation 
in vivo.  For example, if the glycosylation motif is buried well inside the folded protein, it is 
not plausible for a sugar side chain to be attached there. 
Apart from the conserved among Ly49s glycosylation motifs at positions equivalent 
to residues 86-88 and 103-105 in Ly49A, Ly49D activating and Ly49G2 inhibitory receptors 
contain an additional glycosylation site at residues NTT (221-223).  Ly49D also contains a 
second, additional glycosylation motif (NSS) at residues 169-171.  All three of these 
receptors share the same ligand (H-2D
d
), but Ly49D and Ly49G2 bind with lower affinity 
than Ly49A.  Mason et al. created a series of glycosylation mutants of Ly49D, Ly49G2 and 
Ly49A (Mason et al. 2003).  In order to disrupt the Ly49D NTT (221-223) glycosylation 
motif, asparagine 221 was replaced with alanine, arginine or glutamine.  Another mutant was 
also created, in which tyrosine 223 was replaced with arginine.  A library, rather than a single 
mutant, was created to ensure that the glycosylation site was successfully perturbed and to 
assess the role of individual amino acids in binding of Ly49 ligands.  In order to disrupt the 
NTT motif in Ly49G2, two mutants were created with asparagine 221 replaced by glutamine 
and tyrosine 223 with arginine.  The non-glycosylated NTR (221-223) motif in Ly49A was 
replaced with both NST and NRT sequences to introduce a sugar-binding site.  Additional 
constructs were made for the remaining Ly49D glycosylation sites with asparagines, 86, 103 
and 169, replaced with alanine. 
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Of the four Ly49D glycosylation sites, only the most N-terminal site (86-89) appeared 
to be unglycosylated, as observed by SDS-PAGE gel analysis.  All of the mutants, apart from 
N86, migrated more rapidly than the wild type protein.  The Ly49A mutant protein had a 
higher molecular weight than the WT suggesting, that the mutant was successfully 
glycosylated.   The mutants were used in MHC tetramer binding assays, which have shown 
that the presence of sugar at the NTT (221-223) site interferes with H-2D
d
 ligand binding to 
Ly49D, Ly49G2 and Ly49A mutant.   The effect was apparent for all Ly49D glycosylation 
mutants, but the most conserved mutant (N221A) did bind with smaller affinity than N221R, 
and the least conserved mutant T223R did bind with the highest affinity.  Moreover, Ly49D 
N221R and T223R mutants did bind to H-2D
b
 tetramers with higher affinity, suggesting that 
the arginine 223 in Ly49A sequence could be important for binding class I molecules other 
than H-2D
d
. The mutants were also used to assess the role of NTT 221-223 glycosylation in 
Ly49D function.  Disruption of the motif reduced Ly49D-mediated activation in the presence 
of H-2D
d
 targets. Taken together, the above results suggest that the carbohydrate 
modifications, although not essential, can influence the strength of Ly49-ligand interactions. 
 
1.6. Structure of Ly49 receptors 
1.6.1. Overview  
Sequence analysis revealed that Ly49s are type II transmebrane homodimers, i.e. with 
their C-termini exposed to the extracellular space (Figure 1.7A) (Dimasi 2005).  Each 
monomer has got a molecular weight of ~30 kDa and is composed of a globular NK domain 
(NKD) of approximately 120 amino acids, a stalk region of ~70 amino acids, a 
transmembrane domain (TM) of ~20 amino acids and an intracellular signalling domain of 
~45 amino acids (Figure 1.7A).  The Ly49 NKD adopts a C-type lectin-like domain (CTLD) 
fold and its stalk is composed of three consecutive alpha helices.  Monomeric Ly49s dimerise 
through disulphide bonds that form between the two stalk regions (Figure 1.7A).  Signalling 
domains of inhibitory Ly49s contain Immunoreceptor Tyrosine Based Inhibition Motifs 
(ITIMs), which recruit phosphatases that contain Src Homology 2 (SH2) domains.  The 
activating Ly49 transmebrane domain contain a positively charged arginine residue, which 
mediates signalling through interactions with a negatively charged aspartic acid residue 
contained within the DAP12 protein (Figure 1.7A) (McVicar et al. 1998; Anderson et al. 
2001).  
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The structure of the extracellular portion of Ly49s is markedly different to that of 
human KIR receptors, which are composed of 2 or 3 immunoglobulin–like domains (Figure 
1.7B) (Radaev and Sun 2003).  Moreover, KIRs are expressed as type I monomers, i.e. with 
their C-termini located intracellularly, rather than type II dimers.  However, the transmebrane 
and signalling domains are similar in both cases (Figure 1.7).  It is a remarkable example of 
convergent evolution where two molecules with markedly different structures are capable of 
fulfilling the same role.   
 
Figure 1.7. Schematic structure of Ly49 and KIR receptors. A) The left hand panel shows an inhibitory 
receptor.  The right hand panel shows an activatory receptor. Ly49 monomers are composed of a globular NK 
cell domain (NKD), a stalk region, a transmembrane domain and an intracellular domain.  Two monomers are 
linked by disulphide bonds. Within their intracellular domains inhibitory receptors contain ITIM motifs, which 
facilitate inhibitory signalling upon ligand binding.  Within their transmembrane regions activatory receptors 
contain positively charged arginine residues (red), which interact with negatively charged aspartic acid 
residues (blue) in the DAP12 protein.  DAP 12 contains an activatory ITAM motif, which facilitates downstream 
activatory signalling events. B) KIR receptors.  The left hand panel shows an inhibitory receptor and the right 
hand panel an activatory receptor. KIR receptors exist as monomers with 2 or 3 immunoglobulin-like domains 
(Ig).  The monomer also contains a stalk region, transmembrane domain and intracellular domain.  The 
intracellular portions of the inhibitory and activatory KIRs are analogous to those of Ly49 receptors, but KIR 
monomers contain two ITIMs, rather than one. COOH – C’ terminus, NH2- N’ terminus, ITIM - 
Immunoreceptor Tyrosine Based Inhibition Motif, ITAM - Immunoreceptor Tyrosine Based Activation Motif. 
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1.6.2. Crystal structures of Ly49s  
To date the structures of Ly49A, C, G, I and L have all been solved by X-ray 
crystallography: (Tormo et al.1999; Dimasi et al. 2002; Dam et al. 2003; Deng et al. 2008; 
Back et al. 2009).  All of them include the NKD region but only the Ly49L structure contains 
the flexible stalk region.  None of the structures contain transmebrane or intracellular 
domains, in part due to the inherent difficulty in expressing and purifying full length 
eukaryotic transmebrane proteins.  Ly49A and Ly49C were co-crystallised with their MHC 
class I ligands, alleles H-2D
d
 and H-2K
b
, respectively (Tormo et al.1999; Dam et al. 2003).  
1.6.2.1. The CTLD fold 
 The Ly49 NKD folds according to the C-type lectin-like domain (CTLD) model 
adopted by the CTLD superfamily of proteins, which includes mannose-binding protein 
(MBP-A) as a prototypical member (Figure 1.8) (Zelensky and Gready 2005; Weis et al. 
1998).  Many CTLD proteins are calcium-dependent (C-type), carbohydrate-binding lectins, 
that mediate important biological events in animals such as cell-cell adhesion and serum 
glycoprotein turnover. 
Structural and functional data has revealed a high degree of diversity within the 
CTLD family in terms of ligand binding, oligomerisation mode and overall structure (Weis et 
al. 1998).  Unlike true C-type lectins, C-type lectin-like molecules often bind ligands other 
than carbohydrates in a Ca
2+
-independent manner; the Ly49 family is one such example.  
 
Figure 1.8. Structures of Ly49A and Ly49I in comparison with other CTLD superfamily members. Ly49I 
displays a C-type lectin-like fold, in common with Ly49A (PDB entry code 1Q03), NKG2D (1HQ8) and MBP-A 
(1YTT).  Secondary structure elements of Ly49I are labelled consistently with the numbering for MBP-A, and 
are coloured as follows: α=helices, red and yellow; β=strands, green; loop regions, gold. The N- and C-termini 
are also indicated. Disulphide bonds are highlighted in violet.  Calcium ions bound to MBP-A are drawn as 
blue spheres. Figure taken from Dimasi et al. 2002. 
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The core CTLD fold is highly conserved and includes two α-helices (α1 and α2) and 
two antiparallel β-sheets formed by β-strands; (β0, β1 and β5) and (β2, β2’, β3 and β4) 
respectively (Weis et al. 1998; Radaev and Sun 2003).   The CTLD fold is characterised by 
the presence of a double-loop structure known as a ‘loop-in-a-loop’, which is stabilised by 
two highly conserved disulphide bridges located at the bases of the loops.  One of the loops, 
referred to as the long loop is involved in calcium-dependent carbohydrate binding or 
interaction with other ligands.  CTLDs that do not contain the long loop are referred to as 
“compact”.  Examples of compact CTLDs include Link⁄PTR domain and bacterial CTLDs 
(Zelensky and Gready 2005).  Most of the diversity amongst CTLDs originates from the 
aforementioned double loop structure and other, non-conserved loops that might be present. 
1.6.2.2. Crystal structure of Ly49 NKD 
The core structure of all Ly49 NKDs determined so far is the same as that of other 
CTLDs (Zelensky and Gready 2005; Weis et al. 1998). The Ly49 NKD α-helices and β-
sheets are held together by four intrachain disulphide bonds: two of which are conserved 
amongst all animal C-type lectins (residues corresponding to Cys167-Cys253 and Cys232-
Cys245 in Ly49A, Figure 1.8); another is specific to the so-called long form of C-type 
lectins (residues corresponding to Cys145-Cys150 in Ly49A, Figure 1.8); while the last one 
is found only in Ly49s (residues corresponding to Cys163-Cys251 in Ly49A, Figure 1.8).  
There are five loops connecting the core of Ly49 NKDs.  The main difference between 
individual Ly49s comes from loop 3, which links the β2’ and β3 strands through residues 
corresponding to residues 222-235 of Ly49A (Figure 1.8)  (Dimasi et al. 2002).   The Ly49 
NKD fold was found similar to that of the NKD of the human NK receptor NKG2D (Figure 
1.8).  Both receptors lack the Ca
2+
 binding site conserved amongst other members of the 
family.  
Ca
2+
 binding influences ligand specificity and stability of the other members of the C-
type lectin superfamily.  The conformation of the Ly49 NKD described here is stable in the 
absence of Ca
2+
.  Such dramatic changes also affect ligand specificity.  Despite the fact that 
Ly49s belong to a lectin-like family, they do not bind carbohydrates as lectins do. 
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1.6.2.3.  Crystal structure of Ly49 dimers  
Ly49s are thought to dimerise through the formation of disulphide bonds in the stalk 
region (Figure 1.7). Crystal structures of Ly49 NKDs revealed that they are capable of 
forming homodimers, which are stabilised by hydrogen bonds, in the absence of the stalk 
region.  Ly49 dimers can exist in two distinct conformations, termed “open” and “closed” 
(Figure 1.9) (Dimasi et al. 2002; Dam et al. 2006).  The Ly49A dimer was analysed by NMR 
and shown to be capable of adopting both conformations (Dam et al. 2006).  Ly49C and 
Ly49G (Dimasi et al. 2002; Dam et al. 2003) were crystallised in the open conformation, 
Ly49A and Ly49I (Tormo et al. 1999; Deng et al. 2008) in the closed conformation and 
Ly49L in both conformations (Back et al. 2009). 
 
Figure 1.9. Variability in dimerisation mode of Ly49B receptors.  Side views are shown in the top panel and 
top views in the bottom.  All of the structures lack stalk regions; α helices are indicated in green, β strands in 
pink and loops in yellow.  Loop 3 is marked with a red circle and the dimer interface is marked with a red 
square. Figure taken from Back et al. 2009. 
 
In the closed conformation the NKD α2 helices are juxtaposed across the dimer 
interface, the β0 strands of the two monomers interact with each other to form an extended 
antiparallel β-sheet, which is held together by main chain-main chain hydrogen bonds 
(Figure 1.9 A and B).  In the open conformation the α2 helices are not in contact with one 
another and the register between the two β0 strands is shifted by four residues when 
compared to the closed conformation (Figure 1.9 C).  The two conformations most likely 
reflect two distinct modes of ligand binding, each of which is be described in more detail in 
Section 1.5 (Figures 1.17 and 1.18). 
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As explained in Section 1.5.3 glycosylation may play an important role in Ly49 
structure and function.  Unfortunately, Ly49A NKDs destined for crystallisation were 
expressed in E.coli, which is unable to carry out posttranslational modifications including 
glycosylation.  However, it is possible to estimate using the available crystal structures, 
which of the predicted glycosylation sites are likely to be on the surface of the protein, and 
therefore have a glycan attached.  None of the Ly49 structures were solved with the full 
length stalk region so it is only possible to analyse the predicted glycosylation sites within the 
CRDs.   Figure 1.10 shows Ly49G and Ly49I dimers with their glycosylation sites 
highlighted in red (NTT [221-223] for Ly49G and NKT [160-162] for Ly49I).  Considering 
the position of these motifs, on the surface of the CRDs, it seems likely that they may 
undergo glycosylation. 
 
Figure 1.10. Predicted glycosylation sites of Ly49G and Ly49I CRDs.  The glycosylation motifs of each 
monomer are marked in red.  Of the two monomers, one contains a flexible loop at its glycosylation motif, while 
the other contains a beta sheet.  The inconsistency of the electron density map at these sites is due to the 
flexibility of CRDs, however, the highlighted regions represent the same residues within the two monomers. A) 
Ly49G dimer with NTT (221-223) glycosylation motif (PDB accession- 3CAD) B) Ly49I dimer with NKT (160-
162) glycosylation motif (PDB accession- 1JA3). 
 
1.6.2.4. The crystal structure of Ly49-MHC interface  
The first co-crystal structure to be determined was that of Ly49A bound to its H2-D
d
 
ligand (Tormo et al.1999). The structure was solved via molecular replacement at 2.3 Å 
resolution.  The structure suggested that the Ly49A NKD dimer might interact with H-2D
d
 
molecule at two separate interfaces, referred to as site 1 and site 2 (Figure 1.11).  The surface 
adjacent to the MHC class I peptide-binding groove was shown to interact with a single 
molecule of Ly49A at the less extensive site 1, which corresponds to the carbohydrate 
A) B)
Ly49G-1 Ly49G-2 Ly49I-1 Ly49I-2
N221
N160N221
N160
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binding site of other C- type lectins.  The Ly49A NKD interface engaged two of the loops 
and the β4-strand located at the top part of the molecule.  The H-2Dd molecule interacts with 
a region, which is highly polymorphic among MHC class I molecules, incorporating the N 
terminus of the α1 helix and the C terminus of the α2 helix; located just above the N176 
residue.  The interface was dominated with strong electrostatic interactions between the 
receptor and ligand atoms.  Interacting surfaces were precisely matched as indicated by the 
0.78 degree of complementarity, where a shape complementarity of 1 represents a perfect 
interface.  
 
 
 
Figure 1.11. Co-crystal structure of two Ly49A dimeric NKDs bound to a H2-D
d
 MHC molecule.  Two Ly49A 
monomers are highlighted in different shades of green.  The H2-D
d
 MHC α chain is shown in yellow.  β2m is 
shown in magneta.  The peptide in the MHC peptide binding grove is shown in blue.  Asparagine residues of two 
conserved glycosylation sites of  H2-D
d
 are shown in red.  Site 1 and site 2 are circled with black dashed lines 
(PDB accession- 1QO3). 
At the less accessible site 2, the α2 and α3 heavy chains of H-2Dd and β2m form a 
cavity, into which the Ly49A NKD is intercalated.  This area, with a surface of 3,342 Å, was 
shown to be located underneath the peptide binding surface of the MHC-I molecule and 
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extended to the CD8-binding site.  The interface at site 2 was not as precisely matched as site 
1, exhibiting a 0.54 degree of complementarity.   Here, as with site 1, the putative 
carbohydrate-binding site was identified near the MHC class I conserved glycosylation site at 
position N86 of the α1 helix.  21 hydrogen bonds were identified between the partners of the 
complex, facilitating interactions at site 2.  Importantly, the peptide antigen embedded in the 
MHC-binding grove was not involved in interactions at any of these sites, suggesting that, 
although Ly49 receptors are specific for particular MHC alleles, they are not restricted by the 
antigen presented by those molecules.  Moreover the authors showed that site 1 and site 2 on 
H-2D
d 
are topologically distinct from the T cell receptor (TCR) binding site, indicating that 
both Ly49A and a TCR could be bound to one MHC molecule at the same time.  Such an 
arrangement could potentially have implications in the regulation of NK T cells, which 
express both Ly49A and TCR receptors on their surface. 
As explained in Section 1.5.2 H-2D
d
 MHC class I molecule contains two 
glycosylation sites with critical asparagine residues at positions 86 and 176 shown in red in 
Figure 1.11.  Binding of Ly49A to H-2D
d
 MHC-I in physiological conditions was shown by 
one study to be much stronger and more precise in the presence of glycan at position N176 of 
H-2D
d
, but not in the presence of glycan at position N86 (Hanke et al.1999).   
The fact that Ly49A NKD and H-2D
d
 expressed in the absence of putative 
carbohydrates were able to dimerise confirms the studies which have shown that Ly49A and 
H-2D
d
 interactions are not dependent on receptor and ligand glycosylation (Tormo et al. 
1999) but do not the exclude possibility that glycosylation can affect the strength of binding. 
To establish the extent of the glycosylation effect, the MHC molecule would have to be 
expressed in the system able to support the process, for example insects or mammalian cells. 
Two sugar residues, an N-Acetylglucosamine (GlcNAc) and a fructose, were 
modelled onto an MHC-I putative glycosylation site (N176), shown in red in Figure 1.11 
(Tormo et al. 1999).  Both fructose and GlcNAc (to lesser extent) fitted into an open cavity 
formed between H-2D
d 
and the Ly49A NKD.  Moreover, the flat hydrophobic surface of 
Ly49A around this region was large enough to accommodate other modified residues, which 
could also influence the affinity of binding.  Ly49A seems to have evolved from a 
carbohydrate-binding receptor to a protein-binding receptor, whose ligand interaction could 
potentially be fine-tuned by the presence of sugar residues.  
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Figure 1.12 shows a Ly49C monomer bound to a H-2K
b
 molecule (Dam et al. 2003).  
Ly49C engages the surface of H-2K
b
 just below the MHC peptide-binding groove and comes 
into contact with β-2 microglobulin.  Ly49C contains a glycosylation motif at residues NKT 
(160-162), which is conserved in Ly49I, as well as in Ly49H and Ly49J.  The motif lies on 
the surface of the CRD in very close proximity to the MHC-Ly49C interface.  The motif is 
therefore likely to have a glycan attached, which could influence Ly49-ligand interactions.  
 
 
 
 
 
 
 
 
Figure 1.12. Ly49C monomer in complex with H-
2Kb. Ly49C monomer is shown in green and the 
Ly49C glycosylation motif at residues NKT (160-
162) in red. α chain of MHC class I molecule is 
highlighted in yellow, β2-microglobulin  is shown in 
pink and the peptide in the binding groove is light 
blue. Asparagine residues of two conserved 
glycosylation sites of  H2-K
b
 are shown in red (PDB 
accession - 3C8K). 
 
 
 
 
The discovery of sites 1 and 2 in the Ly49A NKD-H-2D
d
 co-crystal raised the 
question of whether or not both of these spatially separated interaction sites are functional.  
Several groups have addressed this question using site-directed mutants of Ly49A and the H-
2D
d 
(Chung et al. 1999; Chung et al. 2000; Matsumoto et al. 2001b).  Surprisingly, all of 
these studies identified site 2 as the primary site mediating interactions between Ly49A and 
H-2D
d
.  Site 1 on the other hand turned out to be a crystallographic artefact. 
 
 
 
Figure 1.13. Ligand binding by Ly49C.  
The Ly49C dimer engages two MHC class 
I molecules through the same region, 
equivalent to site 2 in the Ly49A dimer.  
The region is highlighted in red.  Two H-
2K
b
 molecules are shown in blue.  β2m is 
shown in yellow (Dam et al. 2003). 
 
Peptide α1
α2
α3Ly49C-2Ly49C-1
β2m
H2-Kb-1 H2-Kb-2
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The co-crystal structure of Ly49C and H-2K
b
 revealed that two H-2K
b 
molecules are 
able to interact with the Ly49C dimer simultaneously, engaging with each of the monomers 
through a site analogous to site 2 in the Ly49A NKD-H-2D
d
 co-crystal, suggesting that site 2 
may be the primary interface utilised by all Ly49 receptors for MHC class I binding (Figure 
1.13) (Dam et al. 2003).  Notably, even though the Ly49C-H-2K
b
 interaction site occupied 
the region analogous to site 2 (i.e. just beneath the peptide binding groove), the interacting 
residues at the two interfaces were different (Figure 1.14) (Deng et al. 2008).  Crystal 
structures of both Ly49A-H-2D
d
 and Ly49C-H-2K
b
 complexes have been refined since they 
were first published and Figure 1.14 incorporates these changes.  Table 1.1 lists all of the 
residues that have been found to be involved in forming receptor-ligand interactions in the 
refined structures (Deng et al. 2008).  Since the H-2K
b
 and H-2D
d
 contact residues at both 
interfaces are similar, differences are largely attributable to the individual Ly49 receptors.  
The main difference originates from loop 3, which includes residues 211-231 in Ly49C and 
contains an α-helix. Ly49A loop 3 does not contain this α-helix and spans the region between 
residues 222 and 235.  Additional crystallographic, NMR and SPR analyses have shown 
significant variability in Ly49 regions engaged in MHC binding, particularly loop 3  
(Natarajan et al. 1999; Michaelsson et al. 2000; Sawicki et al. 2001; Dam et al. 2003), 
providing further evidence for the role of this region in determining specificity. 
 
 
Figure 1.14. Comparison of Ly49-MHC-I interfaces.  A) Ly49C-H-2Kb interface, highlighting interactions 
made by residues 211–231 of Ly49C. B) Ly49A-H-2Dd complex, showing interactions made by the 
corresponding region of Ly49A. The side chains of interacting residues are drawn in ball-and-stick 
representation, with carbon atoms in rose (Ly49C), cyan (Ly49A), green (H-2Kb or H-2Dd), or orange (β2m).  
Oxygen atoms are shown in red, nitrogen atoms in blue, and sulfur atoms in yellow.  Salt bridges and hydrogen 
bonds are represented by solid and dotted lines, respectively Figure taken from Deng et al. 2008. 
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Based on successful structural analyses and sequence comparisons, the Ly49 
receptors have been divided into four groups (I-IV), each of which has the potential to bind 
MHC class I molecules in a distinct manner (Figure 1.15) (Sawicki et al. 2001).   
Group I Ly49s recognize both MHC class I H-2D and H-2K alleles; the archetypal 
member of this group being Ly49C.  Group II is epitomised by Ly49A; it is defined by the 
ability of its members to recognise only H-2D alleles and by the presence of a continuous 
loop 3 (Wang et al. 2002a).  Based on sequence variation in loop 6, groups I and II were 
further divided into subgroups Ia, Ib, IIa and IIb, each of which recognizes different variants 
of the H-2D and H-2K alleles.  Groups III and IV are represented by only one member each, 
Ly49Q and Ly49B, respectively.  The manners in which groups III and IV bind their ligands 
remain to be established. 
 
Figure 1.15. Structural classification of Ly49 NK receptors.    A)  Structure-based sequence alignment of the 
MHC-binding regions of Ly49 NKDs.  Residues highlighted in red indicate putative MHC-contacting residues 
that are strictly or mostly conserved in group I or II.  Blue residues indicate variability.  B)  Dendrogram of 
Ly49 NK receptors Figure taken from Deng et al. 2008.   
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Table 1.1. Interactions between Ly49 and MHC-I molecules in the Ly49C-H-2Kb and Ly49A-H-2Dd 
complexes. Residues of H-2Kb or H-2Dd forming hydrogen bonds or salt bridges (bold letters) with Ly49C or 
Ly49A are in red. The number of hydrogen bonds or salt bridges formed between two residues is shown in 
parentheses if more than one. Residues of H-2Kb or H-2Dd forming van der Waals contacts with Ly49s are in 
black. Hydrogen bonds and salt bridges were calculated using cut off distances of 3.4 Å and 4.0 Å, respectively. 
The cut off distance for van der Waals contacts was 4.0 Å.  Residues from the L3/α3 region of Ly49C and Ly49A 
are shown in blue.  Residues from the L6 loop are shown in green. Numbering of residues in Ly49C was 
respective to equivalent residues in Ly49A rather than exact residues in Ly49C Figure taken from Deng et al. 
2008. 
 
 
1.7. Ly49-MHC class I trans and cis interactions 
 
The discovery that Ly49A could potentially recognise its ligand through two different 
sites led to the hypothesis that Ly49s may utilise those spatially distinct sites to bind MHC 
class I molecules on the surface of other cells or in the plane of the same cell forming trans or 
cis interactions respectively (Doucey et al. 2004).  It was shown that Ly49A-mediated 
inhibition of NK cells was much less efficient in the case of NK cells co-expressing Ly49A 
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and H-2D
d
 than in NK cells expressing only the Ly49A receptor.  Both cell types were 
cultured in the same environments, expressed similar levels of Ly49A and were equally well 
activated.  These results therefore indicated that H-2D
d
 expressed on NK cells determines the 
capacity of Ly49A to inhibit NK cell function.  Confocal microscopy images have shown that 
Ly49A and H-2D
d
 expressed on the same NK cell co-localised on the cell surface. Ly49A 
and H-2D
d
 readily co-immunoprecipitated from lysates derived from Ly49A and H-2D
d
-
expressing cells, showing that those two molecules interact directly (Doucey et al. 2004).   
To determine, whether Ly49A and H-2D
d
 interact in cis through site 1 or site 2, β2m-
deficient/Ly49A positive cells were first transfected with H-2D
d
 and human or mouse β2m 
(Doucey et al. 2004).  Soluble H-2D
k 
MHC
 
class I tetramers, which can also act as Ly49A 
ligands, were shown to bind ~25 % weaker to cells co-transfected with mouse β2m and H-
2D
d
 than to non-transfected counterparts.  However, H-2D
k
 tetramer staining was virtually 
100% efficient in cells co-transfected with human β2m and H-2Dd, indicating that cis-
interactions may be dependent on species-specific residues in β2m.  Since interactions at site 
2, but not site 1 are partially dependent on β2m, it was concluded that cis interactions are 
mediated through site 2.  Surprisingly, trans-interactions were also shown to be dependent on 
mouse β2m, indicating that trans-interactions may also be mediated through site 2. This 
provided further evidence that site 1 is non-functional (Doucey et al. 2004).  Figure 1.16 
shows the proposed model of cis and trans interactions. In trans the Ly49 molecule is in an 
extended conformation but in cis Ly49 is back-folded on its stalk to facilitate interactions 
through the same site as is utilised in trans.  Further studies have shown that several other 
Ly49 receptors are capable of association with their ligands in cis (Scarpellino et al.  2007).   
 
 
Figure 1.16. Hypothetical Model for trans and cis 
interactions of Ly49 Receptors with MHC-I Ligands. 
Ly49s interact with MHC class I molecules utilising 
the same binding site both in trans and in cis.  In trans 
the Ly49 stalk is extended.  In cis the Ly49 globular 
domain is back-folded on the stalk. Ly49 is shown in 
blue, the α1/α2 domain of the MHC class I molecule is 
shown in purple, the α3 domain of MHC class I is 
shown in green, the β2m is shown in yellow and the 
peptide in the MHC peptide binding groove is shown in 
red. 
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It was proposed that the open and closed conformations of Ly49 receptors identified 
in several crystal structures (Figure 1.9) might mediate MHC class I recognition in trans and 
cis (Back et al. 2009; Ito et al. 2009).  The recently solved structure of Ly49L, which 
demonstrated the flexible stalk region for the first time, led to a model in which the 
bivalently-engaged Ly49 NKD is folded back on the stalk when in trans, thereby forcing it 
into an open conformation.  In the cis interaction, with only one MHC molecule bound, the 
stalk is extended and the NKD adopts a closed conformation (Figure 1.17) (Back et al. 2009; 
Ito et al. 2009).    
 
 
Figure 1.17. Current hypothetical Model for trans and cis interactions of Ly49 Receptors with MHC-I 
Ligands Current hypothetical Model for trans and cis interactions of Ly49 Receptors with MHC-I Ligands 
(A) Trans interaction of a Ly49 receptor with two MHC-I molecules, based on the structures of Ly49L-EC and 
the Ly49C-H-2Kb complex (PDB accession code 3C8K). The a1, a2, and a3 domains of the MHC-I heavy chain 
are shown in cyan.  b2m is shown in green.  The Ly49 NKD is shown in red.  The a3S helix of the Ly49 stalk and 
the LS loop connecting a3S to the NKD are shown in blue.  The disulphide bond linking the a3S helices is shown 
in magenta.  The predicted a1S and a2S helices of the stalk are drawn arbitrarily in orange and yellow, 
respectively, with the putative disulphide bond in magenta.  The Ly49 homodimer on the NK cell binds two 
MHC-I molecules on the target cell.  In order to bind in trans, the stalks must adopt a backfolded conformation, 
as the N-termini of the Ly49 monomers point away from the NK cell membrane (Ly49s are type II 
transmembrane proteins). (B) Cis interaction of Ly49 with MHC-I.  The LS loops connecting the a3S helices to 
the NKDs are drawn arbitrarily.  The Ly49 homodimer binds one MHC-I molecule on the NK cell itself.  In this 
case, the stalks must assume an extended conformation, as the N termini of the Ly49 monomers point towards 
the NK cell Figure taken from Back et al. 2009. 
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 This model was further scrutinised using a series of Ly49A mutants with varying 
stalk length and measuring the distance between the ligand-binding domain and the cell 
membrane using fluorescence resonance energy transfer (FRET).  Co-expression of the 
MHC-I ligand reduced FRET in the case of Ly49A mutants with shorter stalks, indicating 
that cis interactions are associated with conformational change in Ly49A (Back et al. 2011).  
The significance of cis interactions is uncertain, but it has been proposed that they may 
prevent inappropriate NK cell activation (Doucey et al. 2004; Back et al. 2007). 
1.8. Ly49 signalling 
1.8.1.  Inhibitory pathway 
As previously stated, Ly49s, just like human KIRs, can be categorised according to 
their activating or inhibitory nature (Anderson et al. 2001; McVicar and Burshtyn 2001).  
Each inhibitory Ly49 monomer possesses a single ITIM in its intracellular domain (Long et 
al. 1997), whereas inhibitory KIRs, on the other hand, which always exist as monomers, 
possess two ITIMs.  It is therefore possible that dimerisation of Ly49s is required for efficient 
signalling (Anderson et al. 2001). 
Figure 1.18 summarises the pathway involved in the inhibitory signalling of NK cell 
receptors.  Upon ligand binding, ITIMs become tyrosine phosphorylated, most likely by 
members of the Src and Syk/ZAP-70 tyrosine kinase families (Burshtyn et al. 1996; Hoglund 
and Brodin 2010).  Levels of ITIM phosphorylation have been shown to be much higher 
when inhibitory receptors are co-cross-linked to activating receptors, suggesting that ITIMs 
are phosphorylated as a result of the inhibitory receptor being brought into close proximity 
with the activation pathway that is to be inhibited (Blery et al. 1997; Mason et al. 1997).  
Once phosphorylated, ITIMs become recruitment points for Src homology 2 (SH-2) domain-
containing SHP-1 or SHP-2 protein tyrosine phosphatases.  SHIP-1 phosphatase, which is 
thought to play a role in negative intracellular signalling through its degradation of 
phosphatidylinositol 3,4,5-triphosphate,  was recently shown to constitutively associate with 
some ITIM containing Ly49 receptors (Wang et al. 2002b; Wahle et al. 2006).  Recruitment 
of SHP-1, SHP-2 or SHIP-1 is believed to lead to dephosphorylation of substrates critical to 
the cellular activation pathway such as the guanine nucleotide exchange factor VAV1, which 
results in repression of activating signal propagation (Olcese et al. 1996;  Hoglund and 
Brodin 2010).  Phosphorylation and dephosphorylation of VAV1 is thought to act as a central 
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integration point of inhibitory and activating pathways of NK cell receptors (Figure 1.18-1) 
(Mesecke et al. 2011).  An alternative inhibition pathway is proposed to involve tyrosine-
protein kinase ABL1-mediated phosphorylation of the adaptor protein, CRK, which disrupts 
an activation complex composed of E3-ubiquitin ligase Casitas B-linage lymphoma (CBL or 
c-Cbl), CRK and the guanine exchange factor, C3G (Figure 1.18-2) (Peterson and Long 
2008).  However, this mechanism awaits further confirmation by other groups.  Finally, CBL 
is thought to exert an inhibitory effect on phosphorylated VAV1, which must be overcome 
for the activating signal to proceed (Figure 1.18-3) (Bryceson et al. 2006; Kim et al. 2010).   
This mechanism is thought to be involved in modulating the threshold for the activating 
signal and is unlikely  to be directly linked to the ligation of the inhibitory receptors.   
 
Figure 1.18) Inhibitory signalling pathways in NK cells. 1. Inhibition via dephosphorylation of VAV1, 2. 
Inhibition via disruption of CRK-CBL-C3G activation complex, 3. Inhibition of phosphorylated VAV1 by CBL. 
Taken from Hoglund and Brodin (2010). 
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1.8.2. Activating pathway  
Activating Ly49s and KIRs lack intracellular ITIMs and instead possess a positively 
charged arginine residue in their transmembrane regions (McVicar and Burshtyn 2001, 
Lanier 2003).  The type I transmembrane homodimer DAP12 associates with activating 
Ly49s via a negatively charged aspartic acid.  DAP12 contains an Immunoreceptor Tyrosine-
based Activation Motif (ITAM) in its signal transduction chain and coupling of activating 
Ly49s and KIRs to DAP12 leads to recruitment and phosphorylation of the tyrosine kinases 
including Syk and ZAP70. Downstream events include the phosphorylation of phospholipase 
C, C-Cbl,  SLP-76, 3BP2, which in turn activate protein VAV1 and its homologue VAV2. 
Tyrosine phosphorylation of VAV1 and VAV2 leads to activation of mitogen activated 
protein kinase (MAPK) cascade and cellular responses in the form of degranulation and the 
production of cytokines (McVicar et al. 1998, Lanier 2003).  
It is worth noting that one of the Ly49s, Ly49E, contains both an ITIM in its 
intracellular domain and a positively-charged arginine in its transmembrane region.  
However, it has been shown to act as an inhibitory receptor upon binding the unusual ligand, 
urokinase plasminogen (Van Den Broeck et al. 2008). 
1.9. Ly49B  
The majority of Ly49 receptors are expressed predominantly on NK cells, however, 
expression has also been observed in T cells and NK T cells (Yokoyama and Plougastel 
2003).  Surprisingly, the Ly49s encoded at the two extremes of the NK locus, Ly49B and 
Ly49Q, have been shown to be expressed on non-overlapping populations of myeloid cells 
(Toyama-Sorimachi et al. 2004; Gays et al. 2006).  Multiple populations of Gr-1- and 
CD11b-positive myeloid cells, with morphologies characteristic of granulocytes and 
macrophages, were found to express Ly49B.  CD11c-, B220-, CD4- and CD8-positive 
plasmacytoic dendritic cells, on the other hand, were found to express Ly49Q.  These 
findings indicate that Ly49B and Q receptors most likely play distinct roles from other 
Ly49s; as such, their characterisation is of particular interest. 
Ly49B has been found on myeloid cells in both lymphoid and non-lymphoid tissues, 
including spleen, bone marrow, lymph nodes, thymus and lung.  However, Ly49B has been 
shown to be particularly abundant on macrophages of the gut.  Furthermore, expression of 
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Ly49B is up-regulated in the presence of the inflammatory cytokines, IFN-γ, IFN-α and 
lipopolysaccharide (LPS) from bacterial cell walls (Gays et al. 2006).  These results suggest 
that Ly49B is likely to play an important role in homeostasis of the gastrointestinal tract 
through regulation of immune responses to pathogens.  Interestingly, Ly49B transcripts are 
present in both NK cells and T cells (particularly CD8-positive cells), which suggests that 
Ly49B expression on the surface of these cells may be induced in specific circumstances 
(Gays et al. 2006).  Low expression levels of Ly49B were detected in immature NK cell lines 
cultured in the presence of IL-2 and mature NK cells incubated with IL-12 and IL-18 (Gays 
et al. 2006).  Like interferons, IL-2, IL-12 and IL-18 are also inflammatory cytokines and 
their effect on Ly49B expression in NK cells provides further indication that Ly49B may play 
an important role in the prevention of pathogenesis.  
1.9.1. Sequence comparison of Ly49B with other Ly49s  
Appendix I shows an alignment of all known C57 Ly49 receptor sequences, as well 
as that of BALB/c Ly49B.  Most Ly49 receptors share 60-90 % amino acid identity, while 
Ly49B displays only ~50 % homology with other family members.  Moreover, the C-
terminus of Ly49B contains an additional 20 amino acids, which are not present in any of the 
other Ly49s.  Significant sequence variability is also observed in Ly49Bs from different 
mouse strains; in particular C57 and 129, which differ by 12 amino acids compared to the 
BALB/c and CBA strains (residues highlighted in purple in Appendix I).  Eleven of these 
variable residues reside in the carbohydrate recognition domain (CRD); the other is located in 
the transmembrane (TM) domain. Perhaps, the most notable difference amongst these is the 
substitution of cysteine 251, which is conserved in nearly all other C-type lectins, for arginine 
in the C57 and 129 strains (Zelensky and Gready 2005).  This switch would prevent the 
formation of a conserved disulphide bond found in all crystal structures of CTLDs solved to 
date.  The only known CTLD sequences that do not contain this conserved cysteine, are those 
of CLR family receptors and their human orthologue, LLT1 (Boles et al. 1999; Plougastel et 
al. 2001).  A monoclonal antibody, named 1A1, was previously generated in our laboratory 
and has been shown to specifically recognize the C57 form of Ly49B, not the BALB/c form 
(Gays et al. 2006). 
Apart from cysteine 251 in BALB/c Ly49B and conserved cysteines throughout the 
sequence, both Ly49B forms contain four non-conserved cysteines: two of which lie in the 
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stalk region and two in the CDR (residues highlighted in dark green in Appendix I).  The 
extracellular domain of both Ly49Bs lacks the highly conserved WAW motif (bold residues 
in Appendix I) and has radically different amino acid sequence from residues 230 to 240.  
Both forms of Ly49B contain four glycosylation motifs with critical asparagine residues at 
positions 94, 105, 114 and 177 (highlighted in red in Appendix I).  The N105 glycosylation 
motif in Ly49B is shifted by 4 residues in relation to a conserved glycosylation motif in other 
Ly49s.  Notably, this conserved motif contains cysteine in other Ly49s, which does not occur 
in Ly49B.  The Ly49B glycosylation motif with N114 is also present in Ly49C (Appendix 
I).  The remaining motifs are specific for Ly49Bs.  All of these variations are likely to 
influence the tertiary structure of Ly49B, which is predicted to differ significantly from those 
of other Ly49s. 
1.9.2. Ly49B specificity and signalling 
 Ligand binding analyses using soluble MHC class I tetramers were somehow 
controversial.   As outlined in Section 1.5.1 study by Hanke et al. have shown that Ly49B did 
not bind to any of the tested MHC class I tetramers and studies by Scarpellino et al. have 
shown that Ly49B did bind to whole range of tested MHC class I molecules.  The 
discrepancy was thought to be due to the presence of HA-tag in the first study, which could 
have interfered with MHC tetramer binding.  However, as yet, the controversy was not 
unambiguously solved in direct comparison of tetramer staining of HA-tagged and untagged 
Ly49B. 
Interestingly, as illustrated by the alignment shown in Appendix I, residues 
equivalent to four out of 12 variable Ly49B residues (167, 209, 236 and 242) were shown to 
come into contact in with the ligand in Ly49C-H-2K
b
 and Ly49A-H-2D
d
 co-crystal structures 
(Deng 2008).  However, due to the various differences described in Section 1.9.1., it is highly 
likely that the residues responsible for Ly49B ligand binding are different to those of other 
Ly49s. 
 Analysis of the Ly49B sequence has shown that it contains an ITIM-like sequence 
(VTYTTL-underlined in the Appendix I) in the cytoplasmic domain, which is preceded and 
followed by five amino acids conserved among the inhibitory Ly49s (Zimmer 2010).  It is 
therefore predicted that Ly49B is likely to deliver an inhibitory signal upon ligand binding.  
Immunoprecipitation of Ly49B transfected into RNK cells in the presence or absence of 
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irreversible protein-tyrosine phosphatase inhibitor have shown that Ly49B recruits SHIP-1 
phosphatase in the absence of the inhibitor and SHP-1 and SHP-2 phosphatases, when the 
inhibitor is present (Gays et al. 2006).  It has been speculated that Ly49B recognises 
endogenous ligand and constitutively associates with SHIP-1, resulting in delivery of an 
inhibitory signal, which prevents spontaneous myeloid cells activation and controls their 
expansion.  However, in a pathological situation Ly49B is up-regulated and develops new 
interactions with SHP-1 and SHP-2.   In that respect Ly49B is likely to act as a receptor that 
dampens activation of myeloid cells in a healthy physiological situation and stimulates them 
in the presence of pathogens (Gays et al. 2006).  Further investigation is needed to 
unambiguously establish the nature of Ly49B signalling. 
1.10. Project aims 
This thesis seeks to provide an in-depth characterisation of the biochemical properties 
of Ly49B in comparison to other Ly49 receptors.  Chapter 3 describes the flow cytometric 
analysis of cells transfected with mutant variants of Ly49B.  The primary objective of this 
analysis was to solve the controversy regarding the ligand specificity of Ly49B, as well as to 
identify residues that are responsible for binding of MHC class I molecules and the 1A1 
monoclonal anti-Ly49B antibody.  The roles of glycosylation and the extended C-terminal 
region were also assessed in the context of ligand and antibody binding. 
Traditionally, one of the principal techniques used in the biochemical characterisation 
of Ly49s involves immunoprecipitation of surface-labelled receptors, followed by Western 
blotting.  In doing so, the signal generated from the label is used to visualise the receptor by 
Western blotting.  Throughout chapter 4, as well as employing this method, a different 
approach has been used, in which monoclonal antibodies specific to either the receptor or its 
tag were used to perform the blots.  This approach enabled visualisation of both the intra- and 
extracellular populations of receptors, thus providing a unique insight into the biology of 
Ly49B and other Ly49 receptors. 
The main objective of Chapter 5 was the refolding and purification of the extracellular 
portion of Ly49B.  Development of a strategy that involved small- and large-scale expression 
of the extracellular portion of both the C57 and BALB/c forms of Ly49B in E. coli is 
described in detail, as well as the numerous, subsequent attempts at protein refolding and 
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purification.  An antibody binding assay and circular dichroism were used to assess the 
integrity of the reconstituted receptor and to establish that it was correctly refolded. 
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Chapter 2. Materials and Methods 
 
2.1. Bacterial strains  and growth conditions 
All strains of bacteria used in this study are listed in Table 2.1.  Transformation of 
chemically-competent bacteria was performed by standard heat shock treatment.  
Transformants were selected on LB agar plates containing appropriate antibiotics (kanamycin 
at a final concentration of 50 µg/ml and/or chloramphenicol at 34 µg/ml; tetracycline at 12.5 
µg/ml; streptomycin at 50 µg/ml) and grown at 37 °C for 16 hours.  Monoclonal cultures 
were then set up and grown in Luria-Bertani broth (LB) under selective conditions for 16 
hours at 37 °C, 200 rpm before being used in plasmid DNA extractions or to inoculate full-
scale grow-ups for protein expression. 
Table 2.1. Bacterial strains used in this study for construct preparation and protein expression. 
Strain  Characteristics Source   
E. coli XL1B Standard cloning strain Stratagene 
E. coli BL21 (DE3) E. coli BL21 derivative expression strain with 
DE3, a λ prophage encoding T7 RNA 
polymerase and lacking lon and omp genes 
encoding T7 proteases. Encodes tRNAs 
recognizing rare codons. 
Novagen 
E. coli BL21 (DE3) CodonPlus type 
RIL 
E. coli BL21 DE3 derivative expression strain 
encoding tRNAs recognizing rare codons. 
Novagen 
E.coli BL21 (DE3) Tuner E.coli BL21 DE3 derivative lac permease (lacY) 
deletion mutant. The mutation allows uniform 
entry of IPTG into all cells in the population, 
which produces a concentration-dependent, 
homogenous level of induction carrying  
 
Novagen 
E.coli BL21 (DE3) Origami 2 E.coli BL21 DE3 derivative lac permease (lacY) 
and trxB/gor deletion mutant. The thioredoxin 
reductase 
(trxB) and glutathione reductase (gor) 
 mutations  greatly enhance disulphide bond 
formation in the cytoplasm 
The trxB and gor mutations are 
selectable on streptomycine and tetracycline, 
respectively. 
 
Novagen 
E.coli Stbl2 (DE3) Cloning strain for unstable sequences 
 
Invitrogen 
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2.2. Cloning  
2.2.1. Cloning of the constructs for cell lines transformation 
Table 2.2 contains a list of the primers used for cloning in this study.  For insert 
amplification a mix containing Velocity polymerase (Bioline) at a final concentration of 20 
U/ml, dNTPs (NEB) at 0.02 mM, primers at 0.4 µM in 1xGC buffer (Finzzymes) was used 
with the following cycling conditions: initial melting stage (98 °C for 1 min), followed by 30 
cycles of amplification (98 °C for 30 sec, 55 °C for 30 sec, 72 °C for 1.5 min), followed by a 
final extension stage (72 °C for 5 min).   
PCR products were purified using MinElute PCR purification kit (QIAGEN), and the 
amplified inserts were digested for 1 h at 37 °C with NotI, BamHI and DpnI restriction 
enzymes (NEB) at final concentration of 100 U/ml.  The digested inserts were subjected to 
agarose gel electrophoresis, purified using MinElute Gel Extraction Kit (QIAGEN) and 
ligated into pMXs-IP shuttle vector using T4 DNA ligase (Promega) at a final concentration 
of 0.5 U/µl.  Cloned plasmids were transfected into E. coli Stbl2, grown up under selective 
conditions using Chloramphenicol and purified by miniprep according to the laboratory 
protocol.  Positive clones were identified by performing analytical restriction digests using 
PstI restriction endonucleases (Promega) and by full sequencing of the cloned regions (by 
DBS Genomics, Durham).  
For site directed mutagenesis (SDM), overlapping primers were designed for each of 
the constructs (listed in Table 2.2) and used at a final concentration of 1 µM in a mix with 
Velocity polymerase (Bioline) at a final concentration of 20 U/ml, dNTPs (NEB) at 0.2 mM, 
a pMXs-IP plasmid containing desired template insert at a final concentration 2 µg/ml in 
1xGC buffer (Finzzymes) with the following cycling conditions: initial melting stage (98 °C 
for 1 min), followed by 25 cycles of amplification (98 °C for 30 sec, 55 °C for 30 sec, 72 °C 
for 8 min), followed by a final extension stage (72 °C for 16 min).  The SDM products were 
digested for 3 h at 37 °C with DpnI at a final concentration 0.3 U/µl, verified by agarose gel 
electrophoresis and used for transfection into E.coli Stbl2 as described for plasmids with the 
cloned inserts. Positive clones were identified by performing analytical restriction digests 
using PstI restriction endonuclease (NEB) and by full sequencing of the cloned regions (by 
DBS Genomics, Durham). 
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Table 2.2. Primers used in this study.  
 
2.2.2. Cloning of Ly49B for refolding and purification  
ORFs encoding the full-length extracellular domains (EC) and natural killer domains 
(NKD) of C57 and BALB/c Ly49B were amplified from full length genomic Ly49B 
sequence from plasmids generated previously in the lab (lab stocks D1756 and D1697 for 
C57 and BALB/c respectively) using KOD polymerase (Novagen) with the primers listed in 
No.      Name Sequence 5’ to 3’ 
KP1 Ly49B-EC-f1   AAGACATATGCACATTTTCCGGGATGGACAA 
KP2 Ly49B-ECFx-f1  AAGACATATGATCGAGGGAAGGCACATTTTCCGGGATGGACAA 
KP3 Ly49B-NKD-f1  AAGACATATGTCACAGAACAAAGGCAAGCAAGT 
KP4 Ly49B-NKDFx-f1  AAGACATATGATCGAGGGAAGGTCACAGAACAAAGGCAAGCAAGT 
KP5 Ly49B-r2  AAGAGGATCCTCATTAACTTTCATCTTCATCCCT 
KP6 pET-Seq-f1  CACGATGCGTCCGGCGTAGA 
KP7 pET-Seq-r1  GCTAGTTATTGCTCAGCGG 
KP8 L59V-f CTTCTGCTGGTAACTGTGGCAGTGTTGGTGATACACATTTTC 
KP9 L59V-r CACAGTTACCAGCAGAAGGAAACAGAGGATTCC 
KP10 W166L-f GATAAAAAATTGAATGGATGTAAACAGATCTGCCAGGATTAC 
KP11 W166L-r GATCTGTTTACATCCATTCAATTTTTTATCATCCATGATGAAATAATAAC 
KP12 N167K-f GATAAAAAATGGAAAGGATGTAAACAGATCTGCCAGGATTAC 
KP13 N167K-r GTTTACATCCTTTCCATTTTTTATCATCCATGATGAAATAATAAC 
KP14 V59L-f CTTCTGCTGCTAACTGTGGCAGTGTTGGTGATACACATTTTC 
KP15 V59L-r CACAGTTAGCAGCAGAAGGAAACAGAGGATTCC 
KP16 Ly49ABGHQ-Bam-f CGTTAGGATCCGCCACCATGAGTGAGCAGGAGGTCACT 
KP17 Ly49E-Bam-f CGTTAGGATCCGCCACCATGAGTGAACCAGAGGTCACT 
KP18 Ly49AHA-Not-r  CGTTAGCGGCCGCTCAGGCGTAGTCGGGCACGTCGTAGGGGTAATGAGGGAATTTATCCAGTCT 
KP19 Ly49GHA-Not-r   CGTTAGCGGCCGCTCAGGCGTAGTCGGGCACGTCGTAGGGGTAATGAGGAAATTTATCCAGTCT 
KP20 Ly49EHA-Not-r CGTTAGCGGCCGCTCAGGCGTAGTCGGGCACGTCGTAGGGGTAACCAGGGAAATGATCCAGTT 
KP21 Ly49QHA-Not-r CGTTAGCGGCCGCTCAGGCGTAGTCGGGCACGTCGTAGGGGTAACTGTTGTTGGGGAGCGAATCA 
KP22 3W166L-f GATAAAAAATTGAATGGATGTAAACAGATCTGCCAGGCTTAC 
KP23 3N167K-f GATAAAAAATGGAAAGGATGTAAACAGATCTGCCAGGCTTAC 
KP24 Ly49B-His-HA-r CGTTAGCGGCCGCTCAGGCGTAGTCGGGCACGTCGTAGGGGTAGTGAGGGAATTTATTCAATCTC 
KP25 Ly49B-BK-f CGTTAGGATCCGCCACCATGAGTGAGCAGGAGGTCACT 
KP26 Ly49B-His-r CGTTAGCGGCCGCTCAGTGAGGGAATTTATTCAATCTC 
KP27 N105Q-f GTTAAGACAGAAGTCTTCAGAGTGTAAGG 
KP28 N105Q-r GAAGACTTCTGTCTTAACATTTCTTCCATTAAG  
KP29 N114Q-f GGCCCTCCAGGATAGCCTGCACTACCTCAACAG 
KP30 N114Q-r GGCTATCCTGGAGGGCCTTACACTCTGAAG 
KP31 N177Q-f GGATTACCAGTTAACTCTTTTGAAGACAAATG  
KP32 N177Q-r GTTAACTGGTAATCCTGGCAGATCTGTTTAC 
KP33 R251C-f GAGGATGACTGTGCTAGAAATCATGGTTGTATTTGTGAAAAGAG 
KP34 R251C-r CTAGCACAGTCATCCTCTTCTGTAGAAAATGAATTTAGATATGCACAC 
KP35 AW166L-f GAAAACATTGAGTGGATGTAAACAGACCTGCCAGAGTTCCAG 
KP36 AW166L-r GGTCTGTTTACATCCACTCAATGTTTTTCTGTCCATGACGAAATAATAACATTTCATACC 
KP37 AS167K-f GAAAAACATGGAAAGGATGTAAACAGACCTGCCAGAGTTCCAG 
KP38 AS167K-r GGTCTGTTTACATCCTTTCCATGTTTTTCTGTCCATGACGAAATAATAACATTTCATACC 
KP39 N167S-f GATAAAAAATGGAGTGGATGTAAACAGATCTGCCAGGATTAC 
KP40 N167S-r GTTTACATCCACTCCATTTTTTATCATCCATGATGAAATAATAAC 
KP41 N94Q-f GTCATGAAACAGGACAGCTCCTTAATGGAAGAAATGTTAAGAAATAAGTCTTCAGAG 
KP42 N94Q-r GGAGCTGTCCTGTTTCATGACCTGGTACTCTTGACGGAGG 
KP43 2N105Q-f GTTAAGACAGAAGTCTTCAGAGTGTAAGGCCCTCAATGATAGCCTGC 
KP44 2N105Q-r GAAGACTTCTGTCTTAACATTTCTTCCATTAAGGAGCTGTC 
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Table 2.2.  PCR was carried out in 1x KOD1 reaction buffer, 2 mM MgCl2, 0.2 mM each 
dNTP and 0.4 µM each primers with the following cycling conditions: initial melting stage 
(95 °C for 1 min), followed by 25 cycles of amplification (95 °C for 30 sec, 58 °C for 30 sec, 
72 °C for 15 sec), followed by a final extension stage (72 °C for 2 min).  Amplicons 
containing the 5’ Factor Xa cleavage site, introduced by PCR amplification, were cloned into 
the pET28b expression vector (Novagen) downstream of the polyhistidine (His) tag.  Those 
without the factor Xa site were cloned into pET24a (Novagen) using NdeI and BamHI 
restriction sites in all cases.  PCR products were purified using MinElute PCR purification kit 
(QIAGEN), digested with NdeI and BamHI restriction enzymes (NEB), purified using 
MinElute Gel Extraction Kit (QIAGEN) and ligated into pET24a and pET28b vectors using 
T4 DNA ligase (Promega).  Cloned plasmids were transfected into E. coli XL1B, grown up 
under selective conditions and purified using a QIAprep Spin Miniprep kit (Qiagen) 
according to the manufacturer’s protocol.  Positive clones were identified by performing 
analytical restriction digests using PvuII and SalI restriction endonucleases (Promega) and by 
full sequencing of the cloned regions (by DBS Genomics, Durham).  
2.3. DNA agarose gel electrophoresis  
Agarose gels were prepared using 0.7 – 1 % agarose (w/v) in TBE buffer (40 mM Tris 
(pH 8.3); 40 mM boric acid, 1 mM EDTA) and supplemented with 1 µg/ml ethidium 
bromide.  Gels were run at 70 V for 1 hour in 1xTBE running buffer (Lonza) and run along 
100 bp DNA ladder or 1 kb DNA ladder (New England BioLabs). 
2.4. Mouse cells, tumour cell lines and transfection  
The cell transfectants generated in this study and previously in the lab are listed in the 
Table 2.3.  For transfection, YB2/0 or RNK/0 cells were concentrated to 1x10
6
/ ml and 0.5 
ml aliquots were mixed with 40 µl of plasmid DNA at 100 µg/ml and electroporated at 960 
µFd and 300 V.   The cells were cultured in 24 well plates in D10F medium (Dulbecco’s 
Modified Eagle Medium (DMEM + 10 % FBS) for 16 h and then transferred to flasks with 5 
ml of D5F medium (DMEM + 5 % FBS) with 0.5 µg/ml puromycin.  After 16 h puromycin 
concentration was increased to 1.5 µg/ml.  The cells were cultured in the flasks for 
approximately 2 weeks until the puromycin selected transfectants formed dense population 
and the remaining cells died.  The cells were then transferred into 24 well plates and 
maintained in DF5 1.5 µg/ml puromycin.  Expression levels of the transfected proteins were 
assessed by FACS analysis.  
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Table 2.3. Transfectants used in this study.* = transfectants generated previously in the lab, 20= Ly49B 
mutants lacking last 20aa.   The amino acid code indicates variable residues between C57 and BLAB/c Ly49B.  
C57 specific residues are shown in black and BALB/c residues are shown in red. 
Transfected  construct Name abbreviation Amino acid code Cell type Selective 
marker 
C57 Ly49B * C57  VLKAAEPVENRN YB2/0 G418 
BALB/c Ly49B * BALB LWNDSKLDQSCT YB2/0 Puromycin 
C57 Ly49B HA  C57-HA VLKAAEPVENRN-HA YB2/0 Puromycin 
BALB/c Ly49B HA*  BALB-HA LWNDSKLDQSCT-HA YB2/0 G418 
C57 Ly49B FLAG * C57-FLAG VLKAAEPVENRN-FLAG RNK/0 G418 
CLRg HA* Clrg - YB2/0 Puromycin 
Ly49Q HA* Q - YB2/0 G418 
Ly49A HA A - YB2/0 Puromycin 
Ly49E HA* E - YB2/0 Puromycin 
Ly49G HA G - YB2/0 Puromycin 
C57 Ly49B-V59L C57-V59L       LLKAAEPVENRN YB2/0 Puromycin 
BALB/c Ly49B-N167K BALB-N167K LWKDSKLDQSCT YB2/0 Puromycin 
BALB/c Ly49B-N167S BALB-N167S     LWSDSKLDQSCT YB2/0 Puromycin 
Chimera 1* - LWNDSKLDENRN YB2/0 Puromycin 
Chimera 2* - VLKAAEPVQSCT YB2/0 Puromycin 
Chimera 2-V59L 2.1 LLKAAEPVQSCT YB2/0 Puromycin 
Chimera 2-L166W 2.3 VWKAAEPVQSCT YB2/0 Puromycin 
Chimera 2-K167N 2.4 VLNAAEPVQSCT YB2/0 Puromycin 
Chimera 3* - LWNAAEPVENRN YB2/0 Puromycin 
Chimera 3-L59V 3.1 VWNAAEPVENRN YB2/0 Puromycin 
Chimera 3-W166L 3.2 LLNAAEPVENRN YB2/0 Puromycin 
Chimera 3-N167K 3.3 LWKAAEPVENRN YB2/0 Puromycin 
Chimera 3-L59V-W166L   3.4 VLNAAEPVENRN YB2/0 Puromycin 
Chimera 3-L59V-N167K   3.5 VWKAAEPVENRN YB2/0 Puromycin 
Chimera 4* - VLKDSKLDQSCT YB2/0 Puromycin 
Chimera 4-V59L 4.1 LLKDSKLDQSCT YB2/0 Puromycin 
Chimera 4-L166W 4.2 VWKDSKLDQSCT YB2/0 Puromycin 
Chimera 4-K167N 4.3 VLNDSKLDQSCT YB2/0 Puromycin 
Chimera 4-V59L-L166W   4.4 LWKDSKLDQSCT YB2/0 Puromycin  
Chimera 4-V59L-K167N   4.5 LLNDSKLDQSCT YB2/0 Puromycin 
Chimera 5* - VLKDSKLDENRN YB2/0 Puromycin 
Chimera 6* - LWNAAEPVQSCT YB2/0 Puromycin 
Chimera 6-L59V 6.1 VWNAAEPVQSCT YB2/0 Puromycin 
Chimera 7 - LWNAAEPVENCN YB2/0 Puromycin 
Chimera 7-L59V 7.1 VWNAAEPVENCN YB2/0 Puromycin 
Chimera 7-L59V-W166L 7.2 VLNAAEPVENCN YB2/0 Puromycin 
Chimera 7-L59V-N167K   7.3 VWKAAEPVENCN YB2/0 Puromycin 
Chimera 7-HA* - LWNAAEPVENCN-HA YB2/0 Puromycin 
Chimera 7-L59V-HA 7.1-HA VWNAAEPVENCN-HA YB2/0 Puromycin 
Chimera 7-L59V-W166L-HA 7.2-HA VLNAAEPVENCN-HA YB2/0 Puromycin 
Chimera 7-L59V-N167K-HA 7.3-HA VWKAAEPVENCN-HA YB2/0 Puromycin 
Ly49B BALB/c N94Q BALB-A - YB2/0 Puromycin 
Ly49B BALB/c N105Q BALB-B - YB2/0 Puromycin 
Ly49B BALB/c N114Q BALB-C - YB2/0 Puromycin 
Ly49B BALB/c N177Q BALB-D - YB2/0 Puromycin 
Ly49B BALB/c N105Q-
N114Q 
BALB-BC - YB2/0 Puromycin 
Ly49B BALB/c N94Q-N105Q-
N114Q-N177Q-HA 
BALB-ABCD-HA   - YB2/0 Puromycin 
Ly49B C57 N94Q-N105Q-
N114Q-N177Q 
C57-ABCD - YB2/0 Puromycin 
Ly49B C57 N94Q-N105Q-
N114Q-N177Q-HA 
C57-ABCD-HA - YB2/0 Puromycin 
BALB/c Ly49B-20-H BALB-20-H - YB2/0 Puromycin 
BALB/c Ly49B-20-H-HA BALB-20-H-HA - YB2/0 Puromycin 
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Six week old female C57 mice were used to obtain spleen and bone marrow cells.  All 
procedures were approved by the UK licensing authorities.  C57 spleen (S) cells were 
obtained by smashing the spleens with forceps and the bone marrow (BM) cells were eluted 
from femurs and tibias following removal of the bone heads using narrow gauge needles.  5 x 
106 cells of each kind were cultured at in DMEM (Invitrogen) made up in highly purified 
water and supplemented with 2× nonessential amino acids, 5 × 10
−5
 M 2-ME,  10 % FBS 
(Sigma-Aldrich) and 10 % heat inactivated horse serum in 90 mm bacteriological grade Petri 
dishes with 5 % macrophage colony stimulating factor (MCSF) for 10 days.  The non-
adherent and adherent cells were then harvested together using Ca2+ and Mg2+ free PBS with 
0.5 mM EDTA, divided into 18 x 1 ml aliquots containing 1x106 cells, six of which were 
cultured in low adherence 24 well plates for 2 days with 104 U/ml IFN-α, another six with 2 
mg/ml LPS and the remaining six with nothing.  Non-adherent and adherent cells were 
harvested as outlined above.  LNK cells were cultured in 24 well plates in DMEM + 10 % 
FBS with 100 U/ml IL-2. 
2.5. Cell lysate preparation  
Cells were centrifuged for 1 min at 16,000 g and washed once in ice cold PBS.  The 
supernatant was aspirated apart from 25 µl, which was used to create homogenous cell slurry. 
The slurry was lysed using 100 µl or 250 µl of lysis buffer (1 % Triton X-100, 150 mM 
NaCl, 50 mM Tris HCl pH 8.0) per 1x10
6
 of cells and the lysis was allowed to proceed over 
the period of 30min at 4 °C.  Insoluble material was removed by centrifugation at 16,000 g 
for 1 min and the supernatant was transferred into a fresh microfuge tube and mixed with 100 
µl or 250 µl 2xSDS-PAGE loading buffer (+/- 2ME) to give final dilution of 5000 or 2000 
cells/µl.  The samples were stored at -20 °C. 
2.6. Immunoprecipitation 
Cell lysates were diluted 5x in ice cold 1xPBS and 250 µl aliquots containing  4000 
cells/µl were incubated for 5h on a rotating  mixer at 4 °C with 10 µl of Sepharose beads pre-
coated with an appropriate antibody.  The beads were washed 3x in lysis buffer diluted 1/5 in 
1xPBS by centrifugation at 3,500 g at 4 °C. The beads were then resuspended in 250 µl of 
2xSDS-PAGE loading buffer and boiled for 5 min, followed by centrifugation at 3,500 g.  
The supernatant was divided into two aliquots, one of which was mixed with equal amount of 
lysis buffer diluted 1/5 in 1x PBS and the second one with 1/5 lysis buffer solution + 5 % 
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2ME, giving final concentration of the samples at 2000 cells/µl.  The samples were stored at -
20 °C.  
2.7. Flow cytometry 
2x10
5 aliquots of transfected and control cells were suspended in 25 µl of H2FA medium and 
incubated for 20 min at room temperature with 25 µl of an antibody or a MHC class I 
tetramer at a desired concentration (Table 2.4).  The cells were then washed twice with 
H2FA medium and stained for further 20 min with the secondary antibody if required, 
washed once with H2FA and resuspended in 0.5 ml of H2FA medium for flow cytometric 
analysis.  The second incubation step was omitted in case of reagents conjugated directly to 
fluorophores.  FACScan machine (BD Biosciences) was used to collect staining results and 
data were analyzed using FCS Express V2 software (DeNovo Software).   
 
Table 2.4. Reagents used for flow cytometry analysis. 
 
Reagent  
number 
Reagent name  Concentration 
(mg/ml) 
Final 
dilution 
used for 
staining 
Source 
N1244 PE H-2Kb (SINFEKL) MHC class I 
tetramers 
1.2 1/300 NIH Tetramer Facility 
N1245 PE H-2Db (KAVYNFATM) MHC class I 
tetramers 
1.2 1/300 NIH Tetramer Facility 
N1246 PE H-2Dd (RGPGRAFVTI) MHC class I 
tetramers 
1.2 1/300 NIH Tetramer Facility 
N1239 PE mouse anti-Ly49F IgGi  1  Becton-Dickinson 
N837 2G4 rat anti-L49B IgG2c 1 1/30 Produced in the lab 
N838 1A1 rat anti-L49B (C57) IgGi 1 1/30 Produced in the lab 
N924 AF647 streptavidin 2 1/1000 Invitrogen 
N538 JR9 rat anti-Ly49A IgG 1 1/1000 Jacques Roland 
N509 1A rat anti-Ly49A IgG 1 1/200 James Allison 
N358 YE1/48 rat anti-Ly49A IgG 1 1/40 Fumio Takei 
N415 2.4G2 rat anti-CD16/32 IgG2b  1/100 Jay Unkless 
N382 Biotin rat anti mouse-F4/80 IgG 0.5 1/500 BioLegend 
N1059 AF647 MR3 IgG2c isotype control   1/500 Geoff Butcher 
N1058 AF647 2G4 rat anti-Ly49B IgG2c  1/500 Produced in the lab 
N1176 Biotin 2G4 rat anti-Ly49B IgG2c   1/1000 Produced in the lab 
N883 PE streptavidin  0.5 1/1000 Pharmingen 
N156 4D11 rat anti-Ly49G IgG2a  20 1/10,000 Llewellyn Mason 
N865 CM4 rat anti-Ly49E/F IgG2a  1/10 Produced in the lab 
N1217 AF647 chicken anti-rat IgG 2 1/10,000 Invitrogen 
N1222 Biotin 16.43 rat anti-HA IgG2a 1 1/1000 Produced in the lab 
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C57 spleen and bone marrow cells were harvested and incubated for 10 min with a 
saturating concentration of N415 2.4G2 anti-CD16/32 at a final dilution of 1/100 to block 
FcR, followed by 20 min incubation with N382 Biotin F4/80 at a final dilution of 1/500. The 
cultures were divided into four samples, which were stained for 20 min with the following: 
A) medium, B) medium, C) N1059 AF647 MR3 IgG2c isotype control at final 1/500 
dilution, D) N1058 AF647 2G4 anti-Ly49B at final 1/500 dilution.  The samples were then 
washed 2 times with H2FA and samples B-D were additionally stained for 20 min with N883 
PE streptavidin at a final dilution of 1/1000.  In parallel with this, staining of two samples of 
YB2-C57 Ly49B-HA cells was performed with medium and N1058 AF647 2G4 anti-Ly49B 
at a final dilution of 1/500.  
2.8. Biotinylation of cell surface proteins 
Cells were washed 3x with ice cold 1xPBS (pH 8.0) and the concentration was 
adjusted to 25x10
6
 /ml.  The cell slurry was incubated for 30min at room temperature with 10 
mM EZ-Link Sulfo-NHS-LC-Biotin reagent followed by three washes with 1xPBS +100 mM 
glycine (pH 2.4). 
2.9. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS polyacrylamide gels were prepared  using the reagents specified in a Table 2.5 as 
previously described by Laemmli (Laemmli 1970). The gels were run at a constant voltage of 
200 V in 1x SDS-running buffer (25 mM Tris-HCl [pH 8.3], 192 mM Glycine, 0.1 % [w/v] 
SDS) for 1 h 30 min against biotinylated protein marker (NEB).   
Table 2.5. Composition of SDS-PAGE gels. The amounts are sufficient for two 0.75 mm gels. 
Reagent Volume  
15 % Resolving gel 
30 % Bis-acrylamide 5 ml 
H20 2.35 ml 
0.5 M Tris ph 8.8 2.5 ml 
10 % SDS 100 µl 
10 % APS  100 µl 
TEMED 5 µl 
5 % Stacking gel 
30 % Bis-acrylamide 410 µl 
H20 1.8 ml 
0.5 M Tris ph 8.8 315 µl 
10 % SDS 50 µl 
10 % APS  50 µl 
TEMED 5 µl 
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2.10. Western blotting 
SDS-PAGE  gels were washed for 30 min on a rocking platform in 1x transfer buffer 
(25 mM Tris-HCl (pH 8.3), 192 mM Glycine, 10 % methanol) and the resolved proteins were 
transferred into nitrocellulose membrane (Whatman) at 200 V in 1x transfer buffer using 
Biorad Western blot wet apparatus.    The transfer was carried out on ice over the period of 1 
h 30min.  Alternatively, the proteins were transferred for 17 min at 1.3 A and 25 V using the 
Trans-Blot Turbo system (BioRad).  The membranes were blotted for 30 min in 1xPBS/0.1 % 
Tween/ 5 % low fat powder Milk (Marvel) on a rocker at room temperature and then 
incubated overnight in the blocking solution with a primary antibody at 4 °C with rocking.   
The membranes were washed on a rocking platform in 1xPBS/0.1 % Tween solution for 1 h.  
After washing the membranes were incubated on a rocking platform at a room temperature 
for 1 h with a secondary antibody in 1xPBS/0.1 % Tween or  1xPBS/0.1 % Tween/ 5 % low 
fat powder milk (Marvel).  The second round of washing was carried out as described above 
for the period of 2 h.  The proteins of interest were visualised using ECL reagent (Pierce or 
Thermo) and GE Healthcare hyperfilm with varied exposure times, depending on the 
intensity of bands.  The primary and secondary antibodies are specified in Table 2.6.  The 
exact procedure for each experiment is outlined under the relevant figures.     
Table 2.6. Antibodies used for Western blot experiments. NEB- New England Biolabs, SC- Santa Cruz 
Biotechnology, IS-Immune Systems Ltd, ICL-Immunology Consultants Laboratory.  
Reagent 
number 
Reagent name  Concentration 
(µg/ml) 
Source 
N880 1A1 rat anti-Ly49B (C57) IgGi 100 ug/ml Produced in the lab 
N869 Biotin 1A1 rat anti-Ly49B (C57) IgGi 100 ug/ml Produced in the lab 
N1027 Rabbit anti-FLAG IgG 10 ug/ml ICL 
N1028 Rabbit anti-HA IgG 10 ug/ml ICL 
N1089 MR3 rat IgG2c 100 ug/ml ICL 
N1193 Biotynylated marker  - NEB 
N1194 Goat anti-biotin IgG HRPO - NEB 
N1196 Goat anti-mouse IgG HRPO 20 ug/ml ICL 
N1197 Bovine anti-rabbit IgG HRPO 400 ug/ml SCB 
N1176 Bitotyn 2G4 rat anti-Ly49B IgG2c 20 ug/ml Produced in the lab 
N1243 Goat anti-biotin IgG HRPO - NEB 
N1184 2G4-anti-The Ly49B (THE C57 and The BALB/c) 100 ug/ml Produced in the lab 
N1222 Biotinylated 16.43 rat anti-HA  100 ug/ml IS 
N1229 Biotynylated rabbit anti-HA 100 ug/ml IS 
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2.11. Protein expression  
2.11.1. Small-scale expression  
E. coli BL21 (DE3), BL21 (DE3) CodonPlus (RIL), BL21 (DE3) Tuner and BL21 
(DE3) Origami 2 cells were transfected with the cloned plasmids previously described.  10 ml 
aliquots of LB broth containing appropriate antibiotic(s) were inoculated with 500 µl of 16 
hour old culture for each condition and grown at 37 °C, 200 rpm until the OD600 reached 0.6.  
1 ml samples were then removed and centrifuged at 16,000 g for 1 min at room temperature.  
The pellet was resuspended in 50 µl of SDS-PAGE loading buffer and stored at -20 °C.  The 
remaining cultures were induced with IPTG at concentrations of 1 mM, 0.5 mM, 0.25 mM 
and 0.1 mM and incubated at 37 °C, 30 °C or 16 °C, 200 rpm for 16 hours.  1 ml samples of 
culture were harvested, as previously described, every hour post-induction for 6 hours and 
then finally another at 16 hours.  In order to assess expression levels of the recombinant 
proteins under each condition, samples were examined by SDS-PAGE. 
2.11.2. Large-scale expression  
After optimising expression conditions, preparative-scale grow-ups were performed 
using 2 x 1 l of LB broth containing appropriate antibiotic inoculated with 2 x 50 ml of 16 
hour old transfected bacterial culture.  Cultures were grown at 37 °C, 200 rpm until the OD600 
reached 0.6, at which point 1 ml samples were removed and harvested as previously 
described.  The cultures were induced with 1 mM IPTG and grown for either 3 hours at 30 °C 
or 16 hours at 16 °C, 200 rpm.  1 ml samples were taken (as previously described) just prior 
to harvesting in order to test expression levels.  Cells from the 2 l culture were washed in 
1XPBS and centrifuged at 60372 g for 20 min at 4 °C.  The cell pellets were stored at -80 °C.  
Before attempting to purify protein, expression of the recombinant protein was verified by 
comparing uninduced and induced samples by SDS-PAGE. 
2.12. Protein refolding and purification 
2.12.1. Preparation of protein inclusion bodies 
Bacterial pellets from large scale grow-ups were resuspended in cold 1xPBS and  then 
disrupted by sonication at 4 °C, (50%, level 5, 30 pulses) using an HD2070 Banlelin 
SONOPLUS sonicator, and centrifuged at 20,000 g, 4 °C for 30 min.  The pellet containing 
the inclusion bodies was washed with ice-cold Triton X-100 wash buffer (50 mM Tris pH 8.0, 
100 mM NaCl, 0.5 % Triton X-100), re-suspended using a homogeniser and then centrifuged 
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at 25,000 g, 4 °C for 30 min.  This step was repeated until the supernatant became clear, at 
which point a final wash was performed using ice-cold, detergent-free, wash buffer.  The 
inclusion bodies were solubilised in denaturing buffer (6 M guanidine hydrochloride, 50 mM 
Tris pH 8.0, 100 mM NaCl, with or without 10 mM EDTA) at 4ºC overnight on a rotating 
mixer. 
 
2.12.2. Protein refolding 
2 ml or 10 ml of solubilised, denatured protein (20 mg/ml) were incubated with 10 
mM DTT for one hour at room temperature to reduce any cysteine residues present.  The 
reduced protein solution was then either added drop-wise to or dialysed against 500 ml of 
refolding buffer at 4 °C (Table 2.7), stirring at high speed to prevent aggregation; stirring 
was  continued overnight or for 48 hours at 4 °C.  Solutions were centrifuged at 60372 g, 4 
°C, for thirty minutes to remove large aggregates of protein and then in the case of the protein 
refolded by rapid dilution, concentrated to 10 ml, using a 50 ml Centricon or Vivacel 250 ml 
concentrator (Vivascience), with a 10 kDa molecular weight cut off insert. 
 
Table 2.7. Buffers used for refolding of Ly49B in this study.   
 
 
 
 
Buffer # 
 
Buffer composition 
1 200 mM Tris HCl (pH 8.0); 1 M L-arginine; 10 mM EDTA; 0.5 mM oxidised glutathione; 5 
mM reduced glutathione; 
2 200 mM Tris HCl (pH 8.0); 0.4 M L-arginine; 10 mM EDTA; 0.5 mM oxidised glutathione; 5 
mM reduced glutathione; 
3 200 mM Tris HCl (pH 8.0); 0.2 M L-arginine; 0.5 mM oxidised glutathione; 5 mM reduced 
glutathione; 
4 200 mM Tris HCl (pH 8.0); 0.4 M L-arginine; 0.5 mM oxidised glutathione; 5 mM reduced 
glutathione; 
5 200 mM Tris HCl (pH 8.0); 0.4 M L-arginine; 0.5 mM oxidised glutathione; 5 mM reduced 
glutathione; 0.4 M NaCl; 2 M guanidine hydrochloride; 
6 200 mM Tris HCl (pH 8.0); 0.4 M L-arginine; 0.5 mM oxidised glutathione; 5 mM reduced 
glutathione; 0.4 M NaCl; 2 M guanidine hydrochloride; 
7 50 mM Tris HCl (pH 8.0); 0.5 M L-arginine; 9.6 mM NaCl; 1 mM EDTA, 0.4 M Sucrose; 0.5 
mM oxidised glutathione; 5 mM reduced glutathione; 
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2.12.3. Gel filtration chromatography 
Samples were concentrated to 2 ml volumes and their protein concentrations 
determined at 280 nm using the Beer-Lambert equation. The protein was purified using an 
ÄKTA/FPLC chromatographic system and a Superdex-75 10/300 or HiLoad Superdex 75 
prep grade gel filtration column (GE Healthcare). The gel filtration buffer contained 200 mM 
NaCl and 50 mM Tris (pH8.0) and the run was performed at 0.5 ml/min. Peak fractions were 
analysed by SDS-PAGE.  
2.12.4. Immobilized metal ion affinity chromatography (IMAC)  
Recombinant protein possessing a polyhistidine tag was purified using a nickel 
charged 5 ml HiTrap
TM
 Chelating HP Column (GE Healthcare Life Sciences) attached to an 
ÄKTA chromatographic system (GE Healthcare, formerly Amersham Biosciences).  The 
crude protein solution was applied to the pre-equilibrated column at 1 ml/min and eluted at 
over a linear 30 ml gradient of 0-500 mM imidazole in 25 mM Tris-HCl (pH 8.0), 500 mM 
NaCl at 1 ml/min.  3 ml fractions were collected and the protein content of each fraction 
assessed by SDS-PAGE. 
2.12.5. Ion exchange chromatography 
Protein was purified using a 25 ml Sepharose Q column (GE Healthcare Life 
Sciences) attached to an ÄKTA chromatographic system (GE Healthcare). The protein 
solution was applied to the pre-equilibrated column at 1 ml/min and eluted at over a linear 
200 ml gradient of 0-1 M NaCl in 25 mM Tris-HCl (pH 8.0).  3ml fractions were collected 
and the protein content of each fraction assessed by SDS-PAGE. 
2.12.6. Dialysis 
Tubing for dialysis was prepared as described by Maniatis (Maniatis T 1989). 
Dialysis was carried out for 16 h, 24 h or 48 h at 4 °C. The protein was dialysed to 500 ml of 
refolding buffers (listed in Section 2.12.2), 1 l of gel filtration buffer (200 mM NaCl and 50 
mM Tris (pH8.0) with or without 1 mM ETDA) or 1 l of His-trap loading buffer (25 mM 
Tris, 50 mM Imidazole, 500 mM NaCl). 
2.13. Micro-scale nickel affinity pull-down assay 
Ni-NTA agarose beads resin (Qiagen) was prepared as described in product literature 
and equilibrated with binding  buffer (50 mM Tris-HCl [pH 8.0]; 200 mM NaCl; 10 mM 
imidazole).  Approximately equimolar concentrations of Ly49B protein and 2G4 anti-Ly49B 
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antibody (lab stock) were mixed with the beads and incubated on a rotator at room 
temperature for 1 hour.  The controls (with the antibody and the protein on their own) were 
treated the same.  Non-specifically bound protein was removed by performing three washes 
using binding buffer and the remaining protein eluted with elution buffer (50 mM Tris-HCl 
[pH 8.0]; 200 mM NaCl;  200 mM imidazole).  All fractions were analysed by SDS-PAGE. 
2.14. Microscopy 
Phase contrast images of inclusion bodies were captured using an Andor iXonEM+ 
885 EMCCD camera coupled to a Nikon Ti-E microscope using a 100x/NA 1.4 oil 
immersion objective. Images were acquired with NIS-ELEMENTS software (Nikon) and 
processed using ImageJ. 
2.15. Circular dichroism (CD) 
To analyse the protein by the CD, the 1 mg/ml sample was placed in 0.2 mm quartz 
cuvette (Hellma Analytics UK). CD spectra were acquired by a Jasco-810 CD spectrometer 
(Jasco UK). The machine was calibrated with camphorsulfonic acid and the parameters were 
set as described by Chaffey et al. 2008. 
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Chapter 3. Mutational binding analysis of Ly49 receptors 
 
3.1. Introduction  
In this chapter the binding specificity of Ly49B for MHC class I molecules is 
examined.  C57 and BALB/c forms of Ly49B, as well as several other Ly49 receptors, were 
expressed in YB2/0 cells and tested for binding of soluble MHC class I tetramers conjugated 
to fluorophores.  Binding was assessed by flow cytometry, in which cells expressing Ly49 
receptors were incubated prior to the assay with tetramers and washed.  The cells were then 
hydro-dynamically focused, one at the time, through a flow cell and subjected to a beam of 
light (Figure 3.1).  Cells that associated with tetramers generated a positive signal because 
the conjugated fluorophores were excited to a higher energy state and emitted light on their 
return to the lower energy state.  The differing wavelengths of emitted light were then 
converted into electrical signals and processed by the flow cytometer machinery (Ibrahim and 
Van den Engh 2007, Rieseberg et al. 2001).  The intensity of fluorescence was recorded and 
plotted against cell count in the form of histograms. 
 
 
Figure 3.1. Schematic representation of a flow cytometer.  A sample of cells flows through the beam of light. 
Upon encountering each cell, light is scattered and a relative proportion of the scattered light is detected by a 
forward or side scatter lens.  The different emission spectra of attached fluorophores are detected by different 
photomultipliers (PTMs). 
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BALB/c and C57 Ly49B isoforms differ in sequence by 12 amino acids (Figure 3.2).  
A primary objective of this chapter was to formally establish which variable residues in 
Ly49B are responsible for selective binding of the monoclonal 1A1 antibody and, more 
importantly, binding of Ly49B’s putative MHC class I ligands.  A series of Ly49B mutants 
was created by site-directed mutagenesis, transfected into the YB2/0 cell line and examined 
by flow cytometry.  The roles of Ly49B glycosylation and its additional 20 C-terminal amino 
acids were also evaluated in terms of both ligand and antibody binding.  The importance of 
Ly49A amino acids, whose equivalent residues in Ly49B were identified as critical for ligand 
binding, were also assessed.  Finally, the effect of adding a C-terminal hemagglutinin (HA) 
tag to Ly49 receptors was considered, again, in the context of ligand binding. 
 
C57      1  MSEQEVTYTTLRFHKSSGLQNPVRPEETQRPRDVGHRECSVPWKFIVIVLGILCFLLLVT  60 
BALB/c   1  MSEQEVTYTTLRFHKSSGLQNPVRPEETQRPRDVGHRECSVPWKFIVIVLGILCFLLLLT  60 
 
C57     61  VAVLVIHIFRDGQEKHEQEKTLNNLRQEYQVMKNDSSLMEEMLRNKSSECKALNDSLHYL  120 
BALB/c  61  VAVLVIHIFRDGQEKHEQEKTLNNLRQEYQVMKNDSSLMEEMLRNKSSECKALNDSLHYL  120 
 
C57    121  NREQNRCLRKTKIVLDCSQNKGKQVEGYWFCCGMKCYYFIMDDKKLKGCKQICQAYNLTL  180 
BALB/c 121  NREQNRCLRKTKIVLDCSQNKGKQVEGYWFCCGMKCYYFIMDDKKWNGCKQICQDYNLTL  180 
 
C57    181  LKTNDEDELKFLKSQLQRNTYWIALTHHESKEESQQIGDRPSKPVSAARNSVPNREKCAY  240 
BALB/c 181  LKTNDEDELKFLKSQLQRNTYWISLTHHKSKEESQQIGDRPSKLDSAARNSVPNRQKCAY  240 
 
C57    241  LNSFSTEEDDRARNHGCICEKRLNKFPIPGSCAKGRTQSALQRDEDES  288 
BALB/c 241  LSSFSTEEDDCARTHGCICEKRLNKFPIPGSCAKGRTQSALQRDEDES  288 
 
Figure 3.2. Alignment of BALB/c and C57 Ly49B sequences. Green = intracellular region, Yellow = 
transmembrane region, White = stalk region, Blue = NK domain, Purple – variable residues between BALB/c 
and C57 Ly49B sequences. 
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3.2.  Analysis of MHC class I tetramer binding to Ly49 receptors 
 In order to establish which MHC class I molecules associate with Ly49 receptors, a 
series of YB2 transfectants, each expressing one of C57 Ly49B-HA, BALB/c Ly49B-HA, 
C57 Ly49A-HA, Ly49E-HA, Ly49F, Ly49G-HA and Ly49Q-HA was incubated with PE-
conjugated H-2K
b
, H-2D
b
 and H-2D
d
 MHC class I tetramers.  The cells were subsequently 
washed and analysed by flow cytometry for the intensity of fluorescent signal.  Figure 3.3 
shows the results of this staining.  Most interestingly, the C57 Ly49B-HA transfectants did 
not associate with any of the tested tetramers, whereas the BALB/c Ly49B-HA transfectants 
associated with all of the tested tetramers, of which the H-2D
d
 ligand bound most strongly. 
This data indicates that C57 and BALB/c Ly49B may have very different structure and that at 
least in the case of BALB/c Ly49B the presence of C-terminal HA-tag does not interfere with 
ligand binding.  The Ly49A-HA transfectants stained strongly with the H-2D
d
 tetramers and 
exhibited a negligible association with both H-2D
b
 and H-2K
b
.  The Ly49E-HA, Ly49F and 
Ly49G-HA transfectants did not exhibit a significant association with any of the tested 
tetramers.  The L49Q-HA transfectants stained very weakly with the H-2K
b
 tetramer but not 
with any of the others.   
3.3. Mapping of Ly49B residues responsible for selective binding of the 1A1 
antibody  
The BALB/c Ly49B and the C57 Ly49B isoforms differ by 12 amino acids 
(Appendix I).  Two monoclonal anti-Ly49B antibodies were generated previously, referred 
to as 1A1 and 2G4 (Gays et al. 2006).  It was found that 1A1 recognises the C57 form, while 
2G4 recognises both the C57 and BALB/c isoforms of Ly49B (Gays et al. 2006).  The 
finding that C57 and BALB/c Ly49B isoforms also differ in ligand binding pattern (Section 
3.2) suggests that the two proteins may fold in a dissimilar manner and that the variation in 
Ly49B recognition by 1A1 antibody may result from the aforementioned differences.  It was 
hypothesised that the same variable Ly49B residues (or residues in a close proximity) may be 
responsible for selective mode of 1A1 and MHC tetramers binding.  Identification of Ly49B 
residues responsible for 1A1 binding could narrow down the search for residues responsible 
for ligand binding and was therefore a primary objective of this study.  
  
 
Figure 3.3. Staining of various Ly49 transfectants with MHC class I tetramers.  YB2 cells transfected with 
pMXs-IP plasmids encoding C57 Ly49B-HA, BALB/c Ly49B-HA, Ly49A-HA, Ly49E-HA, Ly49F, Ly49G-HA 
and Ly49Q-HA constructs were stained with PE-conjugated H-2K
b
, H-2D
b
  and H-2D
d
 tetramers and control 
antibodies.   The cells expressing HA-tagged constructs were stained with N1222 Biotin 16.43 rat anti-HA 
IgG2a anti-HA antibody control followed by N924 AF647 streptavidin and the cells expressing untagged Ly49F 
with N1239 PE-conjugated mouse anti-Ly49F IgGi antibody.  The intensity of staining was expressed in log 
fluorescence values and marked on the X axis. Black peaks on the histograms represent cells stained with 
medium and the red peaks represent the cells stained with the tetramers or antibodies.  The number in the top 
right corner of each histogram represents log fluorescent value generated by the stained cells minus the 
background generated by the unstained cells.   
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Table 3.1. Full names, abbreviations and amino acid codes of molecules used in Chapter 3. * = transfectants 
generated previously in the lab. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Naturally occurring enzyme restriction sites in the Ly49B sequences allowed 
generation of a series of chimeric C57/BALB/c Ly49B YB2 transfectants with random 
combination of 12 variable amino acids, previously in the lab (Figure 3.4).  Table 3.1 
contains full names of the chimeric molecules and other mutants generated in this study 
together with the names abbreviations and sequence of variable Ly49B amino acids where 
applicable.   
Full construct name Name abbreviation Amino acid code 
C57 Ly49B * C57  VLKAAEPVENRN 
BALB/c Ly49B * BALB LWNDSKLDQSCT 
C57 Ly49B HA  C57-HA VLKAAEPVENRN-HA 
BALB/c Ly49B HA* BALB-HA LWNDSKLDQSCT-HA 
C57 Ly49B-V59L C57-V59L       LLKAAEPVENRN 
BALB/c Ly49B-N167K BALB-N167K LWKDSKLDQSCT 
BALB/c Ly49B-N167S BALB-N167S     LWSDSKLDQSCT 
Chimera 1* - LWNDSKLDENRN 
Chimera 2* - VLKAAEPVQSCT 
Chimera 2-V59L 2.1 LLKAAEPVQSCT 
Chimera 2-L166W 2.3 VWKAAEPVQSCT 
Chimera 2-K167N 2.4 VLNAAEPVQSCT 
Chimera 3* - LWNAAEPVENRN 
Chimera 3-L59V 3.1 VWNAAEPVENRN 
Chimera 3-W166L 3.2 LLNAAEPVENRN 
Chimera 3-N167K 3.3 LWKAAEPVENRN 
Chimera 3-L59V-W166L   3.4 VLNAAEPVENRN 
Chimera 3-L59V-N167K   3.5 VWKAAEPVENRN 
Chimera 4* - VLKDSKLDQSCT 
Chimera 4-V59L 4.1 LLKDSKLDQSCT 
Chimera 4-L166W 4.2 VWKDSKLDQSCT 
Chimera 4-K167N 4.3 VLNDSKLDQSCT 
Chimera 4-V59L-L166W   4.4 LWKDSKLDQSCT 
Chimera 4-V59L-K167N   4.5 LLNDSKLDQSCT 
Chimera 5* - VLKDSKLDENRN 
Chimera 6* - LWNAAEPVQSCT 
Chimera 6-L59V 6.1 VWNAAEPVQSCT 
Chimera 7* - LWNAAEPVENCN 
Chimera 7-L59V 7.1 VWNAAEPVENCN 
Chimera 7-L59V-W166L 7.2 VLNAAEPVENCN 
Chimera 7-L59V-N167K   7.3 VWKAAEPVENCN 
Chimera 7-HA* - LWNAAEPVENCN-HA 
Chimera 7-L59V-HA 7.1-HA VWNAAEPVENCN-HA 
Chimera 7-L59V-W166L-HA 7.2-HA VLNAAEPVENCN-HA 
Chimera 7-L59V-N167K-HA 7.3-HA VWKAAEPVENCN-HA 
Ly49B BALB/c N94Q BALB-A - 
Ly49B BALB/c N105Q BALB-B - 
Ly49B BALB/c N114Q BALB-C - 
Ly49B BALB/c N177Q BALB-D - 
Ly49B BALB/c N105Q-
N114Q 
BALB-BC - 
Ly49B BALB/c N94Q-N105Q-
N114Q-N177Q-HA 
BALB-ABCD-HA   - 
Ly49B C57 N94Q-N105Q-
N114Q-N177Q 
C57-ABCD - 
Ly49B C57 N94Q-N105Q-
N114Q-N177Q-HA 
C57-ABCD-HA - 
BALB/c Ly49B-20-H BALB-20-H - 
BALB/c Ly49B-20-H-HA BALB-20-H-HA - 
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Figure 3.4. Schematic representation of chimeric 
C57/BALB/c Ly49B molecules.  The twelve small squares 
represent the twelve variable residues between C57 and 
BALB/c Ly49B.  The blue squares represent C57 residues.  
Green squares represent BALB/c residues.  C57 Ly49B is 
labelled as C57.  BALB/c Ly49B is labelled as BALB.  
Chimeras 1-7 are labelled 1-7. 
 
 
 
 
To determine which of the 12 amino acids are responsible for 1A1 binding the 
chimeric transfectants were stained with 1A1 and 2G4 antibodies followed by secondary 
antibodies conjugated to fluorophores, washed and analysed by flow cytometry.  It was found 
that chimera 3, which contains BALB/c residues at positions 59, 166 and 167 and the C57 
residues at the remaining variable positions, did not stain with 1A1, whereas chimera 4, 
which has got an opposite combination of residues (C57 residues at positions 59, 166 and 
167, and BALB/c residues at the remaining variable positions) did stain with 1A1 (Figure 
3.5).  
Figure 3.5. Staining of Chimera 3 and 4 Ly49B mutants. YB2 cells transfected with the specified constructs 
were stained with N837 2G4 rat anti-L49B IgG2c or N838 1A1 rat anti-L49B (C57) IgGi monoclonal rat anti-
L49B antibodies and then with a secondary N1217 AF647 conjugated chicken anti-rat antibody. The intensity of 
staining was expressed in log fluorescence values and marked on the X axis. Black peaks on the histograms 
represent cells stained with medium and the red peaks represent the cells stained with the antibodies. C57- C57 
Ly49B, BALB- BALB/c Ly49B, 3- chimera 3, 4- chimera 4.  Colour coding of the schematic representation of 
the constructs- the same as in Figure 3.3. 
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These results suggested that one or more of variable amino acids at positions 59, 166 
and 167 are responsible for the selective mode of 1A1 binding.  To assess which of the three 
residues are critical, a series of mutations was introduced by site directed mutagenesis 
(Figure 3.6) into both the chimera 3 and chimera 4 molecules, as illustrated schematically in 
Figure 3.7.  A Ly49B C57-V59L mutant was also created to unambiguously determine the 
impact of the BALB/c 59 residue on the C57 Ly49B and its schematic representation was 
included in Figure 3.7.    
 
Figure 3.6. Generation of mutant constructs by site directed mutagenesis. The above panel is a representative 
example. The remaining constructs were generated in a similar way. Chim4-V59L (59), Chim4-L166W (166) 
and Chim4-K167N (167) were amplified by PCR using pMX-s-IP vector with Chimera 4 insert as a template,  
overlapping primers  and Velocity polymerase (Bioline).  In the same time controls were run without the 
enzyme. PCR products were then digested by DpnI to remove the template and separated by agarose gel 
electrophoresis. The expected product was to be 6766bp in size. The control lines show that there was no non-
specific amplification and all of the template was digested with DpnI.  
 
Figure 3.7. Schematic representation of chimera 3 and 4 mutants. C57- C57 Ly49B, BALB- BALB/c Ly49B, 3- 
chimera 3, 4-chimea 4. Colour coding- the same as in Figure 3.3. 
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 Plasmids containing the desired sequences were confirmed by performing diagnostic 
restriction digests (Figure 3.8), followed by full sequencing.  Vectors containing the desired 
sequences were amplified and transfected into YB2 cell lines by electroporation.  Figure 3.9 
shows 1A1 and 2G4 flow cytometric staining of the mutants. 
 
Figure 3.8. PstI digest of pMXs-IP vectors with Ly49B Chim4-V59L inserts. The above panel is a 
representative example. All of the remaining constructs were verified by digest in the same way. Minipreps from 
3 colonies transformed with pMXs-IP-Ly49B Chim4-V59L (59.1, 59.2 and 59.3) were digested with PstI and the 
resulting bands were separated by agarose gel-electrophoresis. The plasmids with inserts were expected to give 
bands 4989bp, 1601 and 176bp in size. The smallest band is not visible on the gel.   Control lines (C) contain 
plasmids which were not digested by PstI.  
Mutation V59L did not prevent 1A1 binding of either C57-V59L or mutant 4.1.  
Moreover, switching the BALB/c residue at position 59 to its C57 equivalent, as in mutant 
3.1, was insufficient to restore 1A1 binding.  Based on these results, residue 59 was formally 
excluded as playing a key role in the selective mode of 1A1 binding.   
Mutation L166W was sufficient to prevent 1A1 binding to 4.2 and 4.4 mutants.  The 
same result was obtained for mutation K167N as in mutants 4.3 and 4.5.  These results 
suggest that in isolation the C57 residues at positions 166 and 167 are unable to confer 
binding of 1A1 to the BALB/c molecule; both are needed for the integrity of the 1A1 epitope 
in the BALB/c background. 
Mutation W166L from the BALB/c form to C57 resulted in the restoration of 1A1 
binding in mutants 3.2 and 3.4.  However, the analogous mutation of residue 167 as in 
mutants 3.3 and 3.5 did not have the same effect, implying that L166 alone is necessary and 
sufficient for binding of the 1A1 antibody to C57 Ly49B.  
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In summary, residue 59 does not appear to be important for a selective binding of 1A1 
anti-Ly49B antibody.  The C57 L166 and K167 residues are necessary to impose 1A1 
binding on BALB/c Ly49B molecule.  The C57 L166 is necessary to maintain 1A1 epitope 
by C57 Ly49B. 
 
Figure 3.9. Staining of chimera 3 and chimera 4 Ly49B mutants. YB2 cells transfected with the specified 
constructs were stained with N837 2G4 rat anti-L49B IgG2c or N838 1A1 rat anti-L49B (C57) IgGi monoclonal 
rat anti-L49B antibodies and then with a secondary N1217 AF647 conjugated chicken anti-rat antibody. The 
intensity of staining was expressed in log  fluorescence values and marked on the X axis. Black peaks on the 
histograms represent cells stained with medium and the red peaks represent the cells stained with the 
antibodies. C57- C57 Ly49B, 3- chimera 3, 4- chimera 4.  Colour coding of the schematic representation of the 
constructs- the same as in Figure 3.3. 
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3.4. Mapping of Ly49B residues responsible for the selective binding of MHC 
class I ligands  
 The experiment outlined in Section 3.2 have shown that the BALB/c Ly49B form 
interacts with at least three MHC class I molecules; H-2K
b
, H-2D
b
 and H-2D
d
, whereas the 
C57 Ly49B form does not bind any of the tested tetramers.  In order to establish which 
residues are critical for binding of MHC class I ligands, a series of Ly49B mutants was 
created by site directed mutagenesis, using the previously generated chimeric constructs as 
templates.  The transfectants used for determining which residues are critical for 1A1 staining 
were also included.  Additionally, a BALB/c Ly49B mutant was created with S167 due to the 
strong level of conservation of this residue among several other Ly49s.  All of the tested 
mutants are schematically shown in Figure 3.10 and their full names, corresponding 
abbreviations and amino acid code with the sequence of variable Ly49B residues can be 
found in Table 3.1. The YB2 cells transfected with the mutants, the C57 Ly49B, the BALB/c 
Ly49B and the previously generated chimeric molecules were stained with three MHC class I 
tetramers (H-2K
b
, H-2D
b
  and H-2D
d
), as well as the 2G4 antibody as a control.   
 
Figure 3.10. Schematic representation of Ly49B mutants. C57- C57 Ly49B, BALB- BALB/c Ly49B numbers 1-
7 – chimeras 1-7. Colour coding- the same as in Figure 3.3, apart from the yellow square in mutant BALB-
N167S, which represents serine at position 167 conserved among other Ly49s apart from Ly49B. 
82 
 
Two types of figures were generated for staining of each of the tetramers.  The first 
contains bar charts with average net median fluorescence values for each mutant and 
demonstrates how strongly the tetramers bound.  An additional figure was also prepared 
showing control data for 2G4 binding (Figure 3.11).  The second type of figures contains bar 
charts showing the strength of tetramer binding, expressed as a percentage, in comparison to 
staining with 2G4.  This second set of data accounts for variations in expression levels for 
each mutant. All of the raw staining data are compiled in Appendix III. 
 
   
Figure 3.11. Staining of Ly49B mutants with 2G4 antibody. YB2 cells transfected with the specified constructs 
were stained with biotinylated 2G4 monoclonal rat anti-L49B antibody and then with AF647 conjugated 
streptavidin. The staining was repeated at least 3 times for each of the transfectants and the numbers in the 
centre of the blue bars represent average net median fluorescence values. Error bars (SD) are shown in black. 
C57- C57 Ly49B, BALB- BALB/c Ly49B numbers 1-7 – chimeras 1-7. 
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3.4.1. H-2Kb binding  
 Figure 3.12 shows the flow cytometric staining of mutants described in the Section 
3.4 using the H-2K
b
 tetramer. The results of staining of the C57, BALB/c and Ly49B 
transfectants agree well with previous findings, showing that C57 form does not bind the 
tetramer but the BALB/c form does. The roles of the remaining variable residues assessed 
individually and in combination with one another, are described below. 
  
A)                                                                   B) 
Figure 3.12. Staining of Ly49B mutants with H-2K
b
. YB2 cells transfected with the specified constructs were 
stained with PE-conjugated H-2K
b
 tetramers. A) The staining was repeated at least 3 times for each of the 
positive transfectants and at least 2 times for the negative transfectants. The numbers in the centre of the blue 
bars represent average net median fluorescence values. Error bars (SD) are shown in black. B) The intensity of 
staining was expressed as a percentage of staining with H-2K
b
 tetramer (Figure 17 A) relative to staining with 
2G4 (Figure 16). Kb - H-2K
b
 MHC class I tetramers, C57- C57 Ly49B, BALB- BALB/c Ly49B numbers 1-7 – 
chimeras 1-7. 
Mutation V59L in the Ly49B C57, chimera 2 and chimera 4 backgrounds was not 
sufficient to confer H-2K
b
 binding to those molecules.  Similarly, the reciprocal mutation in 
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chimera 3 had no effect, suggesting that, as with 1A1, residue 59 is not critical for H-2K
b
 
ligand binding.  Surprisingly, L59V mutation in chimeras 6 and 7 resulted in increased 
binding of the tetramer in comparison to 2G4 by 16 % and 34 % respectively.  From these 
results, it would appear that although residue 59 is not directly involved in forming 
interactions with the H-2K
b
 tetramer, it is capable of exerting an influence on the strength of 
the association with the ligand.  Furthermore, it is the C57 residue that promotes the more 
favourable binding of the two residues. 
Mutation L166W in chimera 2, 4 and mutant 4.1 backgrounds did not result in the 
restoration of H-2K
b
 binding.  Similarly, none of the chimera 3 mutants with the BALB/c 
residue, W166, bound the H-2K
b
 tetramer.  Interestingly, mutant 7.3, which only contains 
BALB/c residues at variable positions 166 and 251, exhibited some, albeit very weak, 
binding (10 %).  These results were surprising since several of the mutants that did not bind 
had greater amino acid sequence similarity to wild type BALB/c Ly49B than the mutant 7.3: 
mutant 2.3 contains BALB/c residues, not only at positions 166 and 251, but also at the three 
remaining C-terminal variable positions; mutant 4.2 is identical to BALB/c with the 
exception of residues 59 and 167; and mutant 4.4 is entirely BALB/c apart from residue 167.  
The introduction of BALB/c W166 in the C57 background is not sufficient to produce H-2K
b
 
binding.  Binding can be partially restored when the BALB/c residue is introduced at position 
251 and the remaining variable residues from the C57 background. 
Mutation K167N in the chimera 2, 4 and mutant 4.1 backgrounds led to an induction 
of  H-2K
b
 binding relative to 2G4 at a very low level (8 %, 2 % and 1 % respectively).  None 
of the chimera 3 mutants with N167 associated with H-2K
b
.  Mutant 7.2, which contains 
BALB/c amino acids at positions 167 and 251, exhibited binding at 3 % of the level of 2G4 
staining.  These results indicate that introduction of the BALB/c residue at position 167 
restores binding of the H-2K
b
 ligand to a small extent only if the BALB/c residue is also 
present at position 251.  
H-2K
b
 association was retained in the BALB-N167S mutant.  However, it was 
reduced about 9 times in comparison to the WT.   From this observation it seems that the 
presence of N167 in Ly49B is more favourable for H-2K
b
 binding than the conserved S167.  
Moreover, it might be concluded that S167 in other Ly49s would not prevent them from H-
2K
b
 binding.    
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The strongest binding was observed with mutant 7.1, followed by chimera 7, then 
mutant 6.1 and finally chimera 6; all of these mutants contain BALB/c residues at positions 
166, 167 and 251.  Interestingly, the association was 20 % to 77 % stronger in comparison to 
2G4 than with the WT Ly49B BALB/c.  Chimera 7 associated 23 % more strongly in 
comparison to 2G4 than chimera 6.  The main difference between these two variants is that 
chimera 6 contains three more variable residues of BALB/c origin than chimera 7.  As with 
mutant 7.3, which exhibited greater H-2K
b
 binding than mutants that contained more BALB/c 
amino acids at variable positions (other than 166, 167 and 251), the same subtle difference 
also seems to produce a stronger association for chimera 7.  Furthermore, as previously 
mentioned, the presence of V59 (as found in C57) in mutants 6.1 and 7.1 produced stronger 
binding than in chimeras 6 and 7. 
In conclusion residue 59 does not directly influence H-2K
b
 binding. However, 
adoption of the C57 residue at this position does increase binding strength via residues which 
are directly involved, as compared to adoption of the BALB/c residue.  The most favourable 
combination of residues for H-2K
b
 binding is BALB/c amino acids at positions 166, 167 and 
251 (W, N, C respectively) in the C57 background.  BALB/c residues at position 251 and 
either 166 or 167 are essential to impose marginal H-2K
b
 binding on C57 Ly49B.  
Introduction of further BALB/c residues into the C57 background leads to loss of integrity of 
the H-2K
b
 binding motif by the mutants with BALB/c residues at positions 166 and 251, but 
not those with BALB/c residues at positions 167 and 251. 
3.4.2. H-2Db binding 
 Figure 3.13 shows the results of flow cytometric staining with the H-2D
b
 tetramer. 
Staining of the C57 and BALB/c transfectants was consistent with previous findings, as 
discussed in the introduction.    
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A)                                                                 B) 
Figure 3.13. Staining of Ly49B mutants with H-2D
b
. YB2 cells transfected with the specified constructs were 
stained with PE-conjugated H-2D
b
 tetramers. A) The staining was repeated at least 3 times for each of the 
positive transfectants and at least 2 times for the negative transfectants. The numbers in the centre of the blue 
bars represent average net median fluorescence values. Error bars (SD) are shown in black. B) The intensity of 
staining was expressed as a percentage of staining with H-2D
b
 tetramer (Figure 18 A) relative to staining with 
2G4 (Figure 16). Dd - H-2D
b
 MHC class I tetramers, C57- C57 Ly49B, BALB- BALB/c Ly49B numbers 1-7 – 
chimeras 1-7. 
 
As with flow cytometric staining using the H-2K
b
 tetramer, residue 59 did not appear 
to have a direct effect on H-2D
b
 binding but did influence the strength of binding mediated by 
other crucial residues.  Mutants 6.1 and 7.1 interacted with H-2D
b
 28 % more strongly 
relative to 2G4 than chimera 6 and 7 respectively, suggesting that the C57 residue at position 
59 promotes more favourable binding by the mutants than with the equivalent BALB/c 
residue present. 
All of the mutants that contained BALB/c residues at positions 166 and 251, or 167 
and 251, did support binding of H-2D
b
 regardless of which of the other variable residues were 
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present.  However, the first combination of residues did promote much weaker binding in 
comparison to 2G4 in mutants 2.2 (4 %), 4.2 (3 %), and 4.4 (1 %), than the second 
combination, which was present in chimera 2.3 (30 %), 4.3 (12 %) and 4.5 (13 %).  On the 
other hand, mutant 7.3, which contains BALB/c residues at positions 167 and 251 stained 26 
% stronger in comparison to 2G4 than mutant 7.3, which contains BALB/c residues at 
positions 166 and 251 and stained at 8 % level in comparison to 2G4.  These results suggest 
that BALB/c residues at positions 166 and 251 support stronger H-2D
b
 binding in the C57 
background, but when further BALB/c residues are introduced residues 167 and 251 appear 
to mediate stronger H-2D
b
 binding.  
Mutant BALB-N167S exhibited 41 % reduced binding relative to 2G4 compared to 
the wild type BALB/c Ly49B receptor.  This result is analogous to that which was obtained 
with the H-2K
b
 tetramer. However, the H-2D
b
 tetramer associated 18 % more strongly in 
comparison to 2G4.  The WT BALB/c Ly49B also bound the H-2D
b
 tetramer more strongly 
than the H-2K
b
.  These results suggest that N167 in Ly49B promotes stronger ligand binding 
than the S167, which is highly conserved amongst other Ly49s, would.  Introduction of S167 
did not change the relative relationship between binding strength of the H-2D
b
 and H-2K
b
 
tetramers, with H-2D
b
 consistently acting as the stronger binding ligand. 
As with binding of the H-2K
b
 tetramer, mutants containing BALB/c residues at 
positions 166, 167 and 251 associated with H-2D
b
 most strongly.  The strength of binding 
was comparable between chimeras 6 and 7 (87 % and 77 %) and mutants 6.1 and 7.1 (115 % 
and 105 %), suggesting that when BALB/c residues are present at positions 166, 167 and 251, 
the C57 or BALB/c identity of residues at the remaining variable positions of chimeras 6 and 
7 does not significantly influence ligand binding.  Analogous to the results obtained for the 
H-2K
b
 tetramer, binding of H-2D
b
 to chimeras 7 and 6, as well as mutants 7.1 and 6.1 was 16 
% to 44 % stronger relative to 2G4 than the one exerted by the WT.  However, the increase in 
strength of binding was not as profound as in the case of H-2K
b
 binding. 
In summary, the pattern of H-2D
b
 binding is similar to that of H-2K
b
 binding.  
Residue 59 does not have a direct effect on H-2D
b
 binding but ligand binding is promoted 
with the C57 residue present at this position via its influence on other residues.  The most 
favourable combination is BALB/c residues at positions 166, 167 and 251 (W, N, C 
respectively) in the C57 background.  The results presented here seem to indicate that 
BALB/c residues at either position 166 or 167, combined with the BALB/c residue at 
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position 251, are likely to support H-2D
b
 binding regardless of the background strain of the 
molecule.  This is in contrast with binding of the H-2K
b
 tetramer, which is retained by all of 
the mutants with BALB/c residues at positions 167 and 251, but lost by several mutants with 
BALB/c residues at positions 166 and 251. 
3.4.3. H-2Dd binding  
Figure 3.14 shows the results of flow cytometric staining using the H-2D
d
 tetramer.  
Control staining of transfectants expressing the C57 and BALB/c was in close agreement 
with previous findings.    
Residue 59 had no direct effect on H-2D
d
 binding but as with the results for the H-2K
b
 
and H-2D
b
 tetramers, introduction of the C57 residue at this position did promote H-2D
d
 
binding in certain backgrounds.  Mutant 6.1, for example, interacted 22 % more strongly in 
comparison to 2G4 than chimera 6.  Similarly, mutant 7.1 interacted 16 % more strongly 
relative to 2G4 than chimera 7.  
Mutant 7.3, which contains BALB/c residues at positions 166 and 251 in the C57 
background, was able to support H-2D
d
 binding at 18 % of the level of 2G4 binding.  
Introduction of additional BALB/c residues at positions other than 167 resulted in further loss 
of binding.  These results suggest that the BALB/c residue at position 166 is able to promote 
binding of the H-2D
d
 tetramer if the BALB/c residue is present at position 251 and if all of 
the remaining variable residues are of C57 origin.   
None of the mutants that contain the BALB/c residue at position 167 with C57 
residues at positions 166 and 251 exhibited significant binding to the H-2D
d
 tetramer.  These 
results suggest that, in isolation, residue 167 does not influence H-2D
d
 binding. 
As was the case for the H-2K
b
 and H-2D
b
 tetramers, mutant BALB-N167S exhibited 
reduced H-2D
d
 binding compared to the WT BALB/c Ly49B.  This result indicates that the 
presence of the highly conserved S167 in BALB/c Ly49B does not abolish the H-2D
d
 
interaction, but does reduce its strength. 
H-2D
d
 binding results for mutants with BALB/c residues at positions 166, 167 and 
251 are very similar to those obtained for the H-2K
b
 tetramer.  All of the mutants associated 
23 % to 70 % more strongly relative to 2G4 than the wild type BALB/c Ly49B.  Mutant 7.1 
bound most strongly, followed by chimera 7, mutant 6.1 and finally chimera 6.  It seems that, 
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as with the H-2K
b
 tetramer, C57 residues at positions other than 166, 167 and 251 serve to 
promote interactions with the H-2D
d
 tetramer. 
   
A)                                                                     B) 
Figure 3.14. Staining of Ly49B mutants with H-2D
d
. YB2 cells transfected with the specified constructs were 
stained with PE-conjugated H-2D
d
 tetramers. A) The staining was repeated at least 3 times for each of the 
positive transfectants and at least 2 times for the negative transfectants. The numbers in the centre of the blue 
bars represent average net median fluorescence values. Error bars (SD) are shown in black. B) The intensity of 
staining was expressed as a percentage of staining with H-2D
d
 tetramer (Figure 19 A) relative to staining with 
2G4 (Figure 16). Dd - H-2D
d
 MHC class I tetramers, C57- C57 Ly49B, BALB- BALB/c Ly49B numbers 1-7 – 
chimeras 1-7. 
 
From these results it seems that binding of the H-2D
d
 tetramer generally requires 
Ly49B to possess three BALB/c amino acids at positions 166, 167 and 251 (W, N, C 
respectively).  The only exception being mutant chimera 7.3, which contains BALB/c 
residues at positions 166 and 251 in the C57 background and does still associate with the H-
2D
d
 tetramer; albeit much less strongly. This is in contrast to binding of the H-2K
b
 and H-2D
b
 
tetramers, which can be rescued by several other combinations of amino acids.  
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3.5. Establishing the role of the C-terminal 20 amino acids of Ly49B in ligand 
and antibody binding  
 Ly49B contains 20 additional amino acids at its C-terminus compared to other Ly49s.  
In order to assess their role in ligand and antibody binding, two mutant transfectants were 
created.  One transfectant expressed the BALB/c Ly49B without the 20 C-terminal amino 
acids and with the terminal residue at the truncated end substituted from isoleucine to 
histidine.  The second construct was identical to this molecule but additionally contained a C-
terminal HA-tag.  This second construct was created to assess mutant expression levels using 
an anti-HA antibody in case 2G4 and/or ligand binding was abolished due to the truncated C-
terminus.  The mutants were stained, along with HA-tagged and untagged Ly49B BALB/c 
transfectants, with the H-2K
b
, H-2D
b
 and H-2D
d
 MHC class I tetramers.  The 2G4 anti-
Ly49B antibody and anti-HA antibody were also tested.  Results are presented in two types of 
figures; one with average net fluorescence median values for each molecule and the second 
showing staining of the tetramers, expressed as a percentage, in comparison to staining with 
the anti-HA antibody.  All raw staining data are compiled in Appendix III. 
3.5.1. Antibody binding 
Figure 3.15 A shows staining of the mutants with the 2G4 antibody.  The control 
transfectants stained at a similar level to one another, but staining of the mutants was 
completely abolished.  These results may indicate that there was no surface expression of the 
mutants, or that the protein did not fold correctly in the absence of C-terminal amino acids 
and the 2G4 epitope became inaccessible or destroyed.  For example, the epitope could have 
been masked by incorrectly folded parts of the protein.  Alternatively, if the 2G4 epitope was 
discontinuous, altered conformation of the protein could affect the correct epitope folding.  
In order to assess surface mutant expression levels, anti-HA staining was performed.   
As shown in Figure 3.15 B, untagged constructs did not stain but the HA-tagged control and 
mutant were both positive.  Mutant staining was decreased by ~50 % compared to the 
control, suggesting that either expression levels were lower or that the C-terminus was less 
accessible in the mutated protein.  Unfortunately, expression levels of the untagged mutant 
protein could not be directly assessed; nevertheless, the mutant transfectant was still used for 
staining with the MHC class I tetramers.   
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A)                                                                 B) 
Figure 3.15.  Staining of Ly49B mutants lacking 20 C-terminal amino acids with 2G4 anti-Ly49B and anti-
HA antibodies. YB2 cells transfected with the specified constructs were stained with A) biotinylated 2G4 
monoclonal rat anti-L49B antibody and then with AF647 conjugated streptavidin or with B) biotinylated anti-
HA antibody and then AF647 conjugated streptavidin.  The staining was repeated at least 3 times for each of the 
positive transfectants and at least 2 times for the negative transfectants. The numbers in the centre of the blue 
bars represent average net median fluorescence values. Error bars (SD) are shown in black. BALB- BALB/c 
Ly49B, BALB-20-HA- BALB/c Ly49B lacking C-terminal 20 amino acids and where the last amino acid was 
replaced with histidine, HA-hemagglutinin tag.   
 
 
3.5.2. H-2Kb binding 
Figure 3.16 A shows the results of staining with H-2K
b
 tetramer expressed in average 
net median fluorescence values.  The wild type Ly49B did stain the strongest and Ly49B 20-
H-HA, Ly49B-HA, and Ly49B 20-H stained at a similar level.  The results cannot be directly 
compared since the expression levels of the untagged Ly49B 20-H are unknown.  However, 
since the expression levels of the controls were shown to be similar (Figure 3.16 A) it was 
possible to directly compare the results for Ly49B and Ly49B-HA looking at average net 
median fluorescence values.  Interestingly, H-2K
b
 did bind nearly eight times weaker to the 
HA-tagged construct.  Since the HA-tag was on the C-terminus it is reasonable to conclude 
that the C-terminus is important for H-2K
b
 binding and the tag did interfere with it.  
Figure 3.16 B takes into account the expression levels of the tagged constructs 
assessed with anti-HA antibody and shows that the removal of C-terminal 20 amino acids 
resulted in a modest 4 % increase in H-2K
b
 binding, which suggests that the C-terminal 
amino acids do not significantly affect H-2K
b
 binding. 
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A)                                                                 B) 
Figure 3.16. Staining of Ly49B mutants lacking 20 C-terminal amino acids with H-2K
b
. YB2 cells transfected 
with the specified constructs were stained with PE-conjugated H-2K
b
 tetramers. A) The staining was repeated at 
least 3 times for each of the transfectants and the numbers in the centre of the blue bars represent average net 
median fluorescence values. Error bars (SD) are shown in black. B) The intensity of staining was expressed as a 
percentage of staining with H-2K
b
 tetramer (Figure 21 A) relative to staining with anti-HA (Figure 20 B). Kb - 
H-2K
b
 MHC class I tetramers,  BALB- BALB/c Ly49B, BALB-20-HA- BALB/c Ly49B lacking C-terminal 20 
amino acids and where the last amino acid was replaced with histidine, HA-  hemagglutinin tag.   
 
3.5.3. H-2Db  binding  
Figure 3.17 A shows the results of H-2D
b
 binding expressed in net average median 
fluorescent values.  Ly49B BALB did stain the most strongly, then Ly49B BALB-HA 
followed by Ly49B 20-H and Ly49B 20-H-HA, which stained at a similar level.  Again the 
results cannot be directly compared, because of the uncertain expression levels of the mutant 
without HA-tag.  Like in the case of H-2K
b
, H-2D
b
 binding was reduced for HA-tagged 
Ly49B in comparison to the untagged construct.  However, the effect was not as prominent 
(about three times reduction in comparison to eight times), suggesting that the C-terminus is 
not as important for H-2D
b
 binding as it is for H-2K
b
.  
Figure 3.17 B shows that HA-tagged Ly49B did stain at a similar level to its 
counterpart lacking the 20 C-terminal amino acids.  It seems that this region does not 
significantly influence H-2D
b
 binding. 
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A)                                                                  B) 
Figure 3.17. Staining of Ly49B mutants lacking 20 C-terminal amino acids with H-2D
b
. YB2 cells transfected 
with the specified constructs were stained with PE-conjugated H-2D
b
 tetramers. A) The staining was repeated 
at least 3 times for each of the transfectants and the numbers in the centre of the blue bars represent average 
net median fluorescence values. Error bars (SD) are shown in black. B) The intensity of staining was expressed 
as a percentage of staining with H-2D
b
 tetramer (Figure 22 A) relative to staining with anti-HA (Figure 20 B).  
Db - H-2D
b
 MHC class I tetramers, BALB- BALB/c Ly49B, BALB-20-HA- BALB/c Ly49B lacking C-terminal 20 
amino acids and where the last amino acid was replaced with histidine, HA- hemagglutinin tag.   
 
3.5.4. H-2Dd binding  
The results of H-2D
d
 binding are very similar to the results obtained for H-2K
b
 
tetramer.  Figure 3.18 A shows that the presence of HA-tag on the full length Ly49B 
construct did reduce H-2D
d
 binding in comparison to the untagged version by approximately 
eight times.      
  
A)                                                             B) 
Figure 3.18. Staining of Ly49B mutants lacking 20 C-terminal amino acids with H-2D
d
. YB2 cells transfected 
with the specified constructs were stained with PE-conjugated H-2D
d
 tetramers. A) The staining was repeated 
at least 3 times for each of the transfectants and the numbers in the centre of the blue bars represent average 
net median fluorescence values. Error bars (SD) are shown in black. B) The intensity of staining was expressed 
as a percentage of staining with H-2D
d
 tetramer (Figure 23 A) relative to staining with anti-HA (Figure 20 B). 
Dd - H-2D
d
 MHC class I tetramers, BALB- BALB/c Ly49B, BALB-20-HA- BALB/c Ly49B lacking C-terminal 20 
amino acids and where the last amino acid was replaced with histidine, HA- hemagglutinin tag.   
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Association of H-2D
d
 with the Ly49B 20-H-HA was about 6 % stronger than with the 
HA-tagged full length construct (Figure 3.18 B).  Analogous to the H-2K
b
, binding of H-2D
d
 
seem to be unaffected by the presence of the 20 or absence of C-terminal amino acids.  
 
3.6. Establishing the role of Ly49B glycosylation in ligand and antibody binding 
 Both Ly49B forms contain four N-glycosylation motifs containing crucial asparagine 
residues at positions 94, 105, 114 and 177 (Appendix I).  In order to assess their role in 
ligand and antibody binding, a library of Ly49B mutants was created (Table 3.1), in which 
the glycosylation motifs were disrupted by exchanging the asparagine residues for glutamine. 
The library included: four single Ly49B BALB/c mutants, targeting each of the four 
aforementioned residues; one double mutant, in which residues 105 and 114 were mutated; a 
HA-tagged Ly49B BALB/c mutant (BALB-ABCD-HA) with all four residues exchanged; 
and HA-tagged and untagged versions of Ly49B C57 with all four residues mutated.  The 
mutants were expressed in YB2 cells and stained using three MHC class I tetramers (H-2K
b
, 
H-2D
b
 and H-2D
d
) and the 2G4 anti-Ly49B antibody.  Cells expressing the relevant 
constructs were also stained with 1A1 anti-Ly49B and anti-HA antibodies. Raw staining data 
are compiled in Appendix III. 
3.6.1. Antibody binding 
 In order to assess expression levels of the mutant receptors, 2G4 flow cytometric 
staining was performed.  As shown on Figure 3.19, Ly49B BALB/c N114Q expressed at a 
similar level to wild type Ly49B BALB/c.  Transfectants expressing the three remaining 
single glycosylation site mutants stained slightly weaker, indicating that expression levels 
were reduced in these strains.  The double Ly49B BALB/c N105Q-N114Q mutant stained at 
50 % of the level of WT Ly49B BALB/c.  The BALB-ABCD-HA mutant stained about 8 
times weaker than the HA-tagged WT Ly49B BALB/c.  The greatest reduction in binding 
was observed for the two C57 mutants, both of which stained at roughly 2 % of the level of 
the WT proteins.   
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Figure 3.19. Staining of Ly49B glycosylation mutants with 2G4 anti-Ly49B. YB2 cells transfected with the 
specified constructs were stained with biotinylated 2G4 monoclonal rat anti-L49B antibody and then with 
AF647 conjugated streptavidin. The staining was repeated at least 3 times for each of the transfectants and the 
numbers in the centre of the blue bars represent average net median fluorescence values. Error bars (SD) are 
shown in black. The full names of the constructs are specified in Table 3.1.  
 
To assess whether the observed reduction in staining was due to reduced expression 
levels or compromised binding by the 2G4 antibody, additional stainings were performed 
with 1A1 and anti-HA antibodies.   1A1 staining of the untagged C57 mutant transfectants 
was again roughly 2 % of the level of cells expressing the untagged wild type receptor, while 
the HA-tagged C57 mutant stained at roughly 1.5 % of the level of the equivalent wild type 
transfectants (Figure 3.20 A).  The results of anti-HA staining of the HA-tagged Ly49B 
BALB/c and the BALB-ABCD-HA mutant were similar as for 2G4 staining, indicating a 10-
fold decrease with the mutant transfectant compared to the wild type (Figure 3.20 B). 
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A)                                                                   B) 
Figure 3.20. Staining of Ly49B glycosylation mutants with 1A1 anti-Ly49B and anti-HA antibodies. YB2 
cells transfected with the specified constructs were stained with A) 1A1 monoclonal rat anti-L49B antibody and 
then with a secondary AF647 conjugated chicken anti-rat antibody, or with B) biotinylated anti-HA antibody 
and then AF647 conjugated streptavidin.  The staining was repeated at least 3 times for each of the 
transfectants and the numbers in the centre of the blue bars represent average net median fluorescence values. 
Error bars (SD) are shown in black. The full names of the constructs are specified in Table 3.1.   
 
 In general, staining with all three antibodies was much weaker for the multiple 
glycosylation mutants.  It seems highly unlikely that binding of all three antibodies was 
equally affected by the removal of glycans, so the reduction in the levels of staining most 
likely reflects a reduction in expression levels of the mutant receptors.  It seems that an 
absence of glycosylation results in impaired surface expression levels of Ly49B. 
3.6.2. H-2Kb staining 
Figure 3.21 shows the results of flow cytometric staining using the H-2K
b
 tetramer.  
None of the C57 WT or mutant transfectants stained positively, which is consistent with the 
finding that C57 Ly49B does not associate with H-2K
b
.  Interestingly, H-2K
b
 binding by the 
Ly49B BALB/c N105Q and Ly49B BALB/c N114Q single mutants was 19 % and 24 % 
stronger, respectively, than WT Ly49B BALB/c, relative to 2G4 staining.  However, staining 
of the double mutant Ly49B BALB/c N105Q-N114Q was only 3 % stronger than WT Ly49B 
BALB/c, relative to 2G4 staining.  These results suggest that glycosylation of arginine at 
Ly49B BALB/c positions 105 and 114 may limit H-2K
b
 binding. 
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A)                                                                     B) 
Figure 3.21. Staining of Ly49B glycosylation mutants with H-2K
b
. YB2 cells transfected with the specified 
constructs were stained with PE-conjugated H-2K
b
 tetramers. A) The staining was repeated at least 3 times for 
each of the positive transfectants and at least 2 times for the negative transfectants. The numbers in the centre of 
the blue bars represent average net median fluorescence values. Error bars (SD) are shown in black. B) The 
intensity of staining was expressed as a percentage of staining with H-2K
b
 tetramer (Figure 26 A) relative to 
staining with 2G4 (Figure 24). The full names of the constructs are specified in Table 3.1.  Kb – H-2Kb MHC 
class I tetramers. 
 
 The Ly49B BALB/c N94Q and Ly49B BALB/c N177Q single mutants stained at a 
comparable level to WT Ly49B BALB/c, suggesting that on their own glycans attached at 
positions 94 and 177 do not influence H-2K
b
 binding.  The HA-tagged BALB/c mutant with 
all glycosylation sites removed stained at 50 % of the level of the WT Ly49B BALB-HA, 
indicating that glycosylation of all four sites may disrupt assembly of the H-2K
b
 binding 
motif. 
3.6.3. H-2Db  staining 
As shown on Figure 3.22, the wild type and mutant C57 transfectants did not exhibit 
H-2D
b
 binding.  The Ly49B BALB/c N105Q and Ly49B BALB/c N114Q single mutant 
transfectants stained 12% and 31% more strongly, respectively, than wild type Ly49B 
BALB/c, relative to 2G4.  Interestingly, the double Ly49B BALB/c N105Q-N114Q mutant 
stained 20 % weaker than wild type Ly49B BALB/c, in comparison to 2G4.  This suggests 
that glycosylation of residues 105 and 114 may partially prevent H-2D
b
 from binding to WT 
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Ly49B BALB/c but that glycans at these positions may simultaneously be important for 
promoting correct folding of the protein and thus the integrity of the H-2D
b
 binding motif. 
   
A)                                                                  B) 
Figure 3.22. Staining of Ly49B glycosylation mutants with H-2D
b
. YB2 cells transfected with the specified 
constructs were stained with PE-conjugated H-2K
b
 tetramers. A) The staining was repeated at least 3 times for 
each of the positive transfectants and at least 2 times for each of the negative transfectants. The numbers in the 
centre of the blue bars represent average net median fluorescence values. Error bars (SD) are shown in black. 
B) The intensity of staining was expressed as a percentage of staining with H-2D
b
 tetramer (Figure 27 A) 
relative to staining with 2G4 (Figure 24). The full names of the constructs are specified in Table 3.1.  Dd - H-
2D
b 
MHC class I tetramers. 
 
 Using the H-2D
b
 tetramer, the Ly49B BALB/c N94Q mutant stained with the same 
intensity as WT Ly49B-BALB/c, which implies that glycosylation of residue 94 does not 
have a direct effect on H-2D
b
 binding.  Staining of the Ly49B BALB/c N177Q mutant was 
19 % weaker than WT BALB/c, in comparison to 2G4, suggesting that the glycan, which 
attaches to residue 177, may promote slightly stronger binding of the H-2D
b
 ligand.  The 
BALB-ABCD-HA mutant bound H-2D
b
 only marginally weaker than BALB-HA, which 
suggests that perhaps the positive effect on the binding exerted by the glycan attached at 
position 177 is equalised by the negative effect exerted by the glycans at positions 105 and 
114.  
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3.6.4. H-2Dd binding 
Figure 3.23 shows the compiled results of flow cytometric staining with the H-2D
d
 
tetramer.  As with the other two tetramers, no H-2D
d
 binding was detected for any of the C57 
transfectants.  Single mutations of N105Q and N114Q enhanced H-2D
d
 binding by 
approximately 20 % in comparison to the wild type Ly49B BALB/c while the double mutant 
with both of these residues mutated stained slightly weaker than the wild type BALB/c 
Ly49B transfectant.  From these results one can infer that glycans at positions 105 and 114 
may directly restrict H-2D
d
 binding, but simultaneously promote optimal folding of Ly49B 
and indirectly affect the conformation of the H-2D
d
 binding motif.  
    
A)                                                                      B) 
Figure 3.23. Staining of Ly49B glycosylation mutants with H-2D
d
. YB2 cells transfected with the specified 
constructs were stained with PE-conjugated H-2D
d
 tetramers. A) The staining was repeated at least 3 times for 
each of the positive transfectants and at least 2 times for the negative transfectants. The numbers in the centre of 
the blue bars represent average net median fluorescence values. Error bars (SD) are shown in black. B) The 
intensity of staining was expressed as a percentage of staining with H-2D
d
 tetramer (Figure 28 A) relative to 
staining with 2G4 (Figure 24). The full names of the constructs are specified in Table 3.1.  Dd –H-2Dd MHC 
class I tetramers. 
 
As with the H-2K
b
 tetramer, H-2D
d
 binding was not directly affected by Ly49B 
glycosylation at positions 105 and 177, as shown in the results of staining using the Ly49B 
BALB/c N94Q and Ly49B BALB/c N177Q mutants, both of which associated with the H-
2D
d
 tetramer to the same extent as the wild type Ly49B BALB/c receptor.  Comparable 
results were also obtained for the BALB-ABCD-HA mutant, which stained with the same 
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intensity as the BALB-HA transfectant.  Based on these findings, it can be concluded that 
glycosylation is not crucial for association of Ly49B BALB/c with the H-2D
d
 tetramer. 
 
3.7. Mapping of Ly49A residues responsible for binding of MHC class I ligands 
and anti-Ly49A antibodies 
The staining of chimeric Ly49B mutants pointed strongly to residues 166 and/or 167 
playing a crucial role in binding of the monoclonal 1A1 antibody and MHC class I ligands.  
In the BALB/c form Ly49B residues 166 and 167 are tryptophan and asparagine, 
respectively.  The tryptophan 166 is conserved amongst all other Ly49s with the exception of 
Ly49B C57, which contains leucine at the corresponding position (Appendix I).  The 
asparagine residue of BALB/c located at position 167 is replaced by lysine in C57 Ly49B, by 
arginine in Ly49Q and serine in all other Ly49s (Appendix I). 
In order to check whether introduction of the Ly49B C57 residues at positions 
corresponding to Ly49B 166 and 167 residues in Ly49A would affect binding of monoclonal 
antibodies and ligands, two HA-tagged mutants were created; Ly49A-W166L-HA and 
Ly49A-S167K-HA.  Since the corresponding Ly49A residues to Ly49B residues 166 and 167 
are at positions 160 and 161 respectively, ultimately, the first construct contained W to L 
mutation in Ly49A sequence at position 160 and the second one mutation S to K at position 
161.  The HA-tag was introduced to accurately determine expression levels of the mutant 
receptors.  YB2 cells were transfected with the single residue mutants (and Ly49A-HA as a 
control), then stained with three monoclonal anti-Ly49A antibodies (JR9, A1 and YE1/48) 
and MHC class I tetramers (H-2K
b
, H-2D
b
 and H-2D
d
).  The raw staining data are compiled 
in Appendix IV. 
3.7.1. Antibody binding 
Staining of mutant transfectants with the anti-HA antibody revealed that expression 
levels were similar for the control Ly49A-HA and Ly49A-S167K-HA transfectants, but about 
eight times lower for the Ly49A-W166L-HA transfectant (Figure 3.24 A).  Staining using all 
three monoclonal anti-Ly49A antibodies revealed that binding of the Ly49A-W166L-HA 
mutant was completely abolished (Figures 3.24 A, B and C), suggesting that W166 is 
essential for maintaining the integrity of all three antibody epitopes and, most likely, for 
maintaining the tertiary structure of Ly49A.  
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All three monoclonal antibodies bound the Ly49A-S167K-HA mutant at a similar 
level to Ly49A-HA. These results indicate that the presence of lysine, rather than serine, at 
position 167 does not influence staining using monoclonal antibodies for Ly49A. 
  
A)                                                                   B) 
   
C)                                                                  D) 
Figure 3.24. Staining of Ly49A-HA, Ly49A-S167K-HA and Ly49A-W166L-HA transfectants with anti-HA, 
JR9, 1A and YE1-48 monoclonal antibodies. YB2 cells transfected with the specified constructs were stained 
with A) biotinylated anti-HA antibody and then AF647 conjugated streptavidin, or with B) JR9 anti-Ly49A 
antibody and then AF647 conjugated chicken anti-rat antibody, or with C) 1A anti-Ly49A antibody and then 
AF647 conjugated chicken anti-rat antibody, or with D) YE1/48 anti-Ly49A antibody and then AF647 
conjugated chicken anti-rat antibody. The staining was repeated at least 3 times for each of the positive 
transfectants and at least 2 times for the negative transfectants. The numbers in the centre of the blue bars 
represent average net median fluorescence values. Error bars (SD) are shown in black. HA- hemagglutinin tag.  
3.7.2. Ligand binding  
 Figure 3.25 demonstrates that switching residue 166 from tryptophan, which is highly 
conserved amongst Ly49s, to leucine, as occurs in Ly49B C57, resulted in a complete loss of 
ligand binding.  From these results one can conclude that tryptophan 166 is essential for 
ligand binding by Ly49A. 
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A)         B) 
  
C)        D) 
  
E)        F) 
Figure 3.25. Staining of Ly49A-HA, Ly49A-S167K-HA and Ly49A-W166L-HA transfectants with H-2K
b
, H-
2D
b
 and H-2D
d
 tetramers. YB2 cells transfected with the specified constructs were stained with PE-conjugated 
H-2K
b
 (A and B), H-2D
b
 (C and D) and H-2D
d
 (E and F) tetramers. A, C and E) The staining was repeated at 
least 3 times for each of the positive transfectants and at least 2 times for the negative transfectants. The 
numbers in the centre of the blue bars represent average net median fluorescence values. Error bars (SD) are 
shown in black. B, D and F) The intensity of staining was expressed as a percentage of staining with the 
specified tetramer relative to staining with anti-HA (Figure 29 A). HA- hemagglutinin tag. Kb - H-2K
b 
MHC 
class I tetramers, Db – H-2Db MHC class I tetramers, Dd - H-2Dd MHC class I tetramers 
 
Surprisingly, the Ly49A-S167K-HA mutant showed a roughly four-fold increase in 
binding of the H-2K
b
 and H-2D
b
  ligands, compared to the Ly49A-HA receptor (Figures 3.25 
D), and an increase of roughly 40 % with the H-2D
d
 ligand (Figure 3.25 F).  These results 
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indicate that lysine at position 167 promotes ligand binding in Ly49A, despite the fact that it 
exerts an inhibitory effect in Ly49B BALB/c and completely abolishes binding in Ly49B 
C57. 
3.8. Establishing the influence of the HA-tag on Ly49 ligand binding 
During assessment of the role of the 20 additional C-terminal amino acids of BALB/c 
Ly49B (Section 3.5), control cells transfected with the HA-tagged wild type Ly49B BALB/c 
construct consistently stained more weakly with the H-2K
b
, H-2D
b
  and H-2D
d
 tetramers than 
the equivalent untagged construct, even though expression levels, as assessed using the 
monoclonal 2G4 antibody, were very similar in the tagged and untagged transfectants. 
Moreover, it was hypothesised by Scarpellino et al. (2007) that the presence of C-terminal 
HA-tag, may have abolish the ability of Ly49B to bind its ligands. 
In order to assess whether the presence of the HA-tag can affect the way recombinant 
Ly49B proteins fold and, ultimately, the strength of ligand binding, a series of chimera 7 
mutants was expressed with and without the HA-tag and stained using all three tetramers.  
The results of these analyses were combined with results obtained in Section 3.5 (Figure 
3.26). 
 
 
A)                                                               B) 
 
Figure 3.26. Staining of HA-tagged and untagged Ly49B mutants with 2G4 anti-Ly49B. YB2 cells transfected 
with the specified constructs were stained with biotinylated 2G4 monoclonal rat anti-L49B antibody and then 
with AF647 conjugated streptavidin. The staining was repeated at least 3 times for each of the transfectants and 
the numbers in the centre of the blue bars represent average net median fluorescence values. Error bars(SD) 
are shown in black. C57- C57 Ly49B, BALB- BALB/c Ly49B 7 – chimera 7, HA- hemagglutinin tag. A) 
untagged construct B) HA-tagged constructs. 
 
2G4 staining levels were comparable between the HA-tagged and untagged mutants, 
indicating that expression levels of both sets of constructs were roughly the same.  H-2K
b
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staining was roughly 4.5 times stronger for the untagged wild type BALB/c Ly49B 
transfectant than for the equivalent tagged control (Figure 3.27 C and D).  The results of H-
2K
b
 staining for all of the other pairs of constructs indicated that HA-tagged and untagged 
chimeras stained at very similar levels to one another (Figure 3.27 C and D).  
 
  
A)      B) 
  
C)      D) 
Figure 3.27. Staining of HA-tagged and untagged Ly49B mutants with H-2K
b
. YB2 cells transfected with the 
specified constructs were strained with PE-conjugated H-2K
b
 tetramers. A and B) The staining was repeated at 
least 3 times for each of the positive transfectants and at least 2 times for each of the negative transfectants. The 
numbers in the centre of the blue bars represent average net median fluorescence values. Error bars (SD) are 
shown in black. C and D) The intensity of staining was expressed as a percentage of staining with H-2K
b
 
tetramer (Figure 32 A or B) relative to staining with 2G4 (Figure 31 A and B). C57- C57 Ly49B, BALB- 
BALB/c Ly49B 7 – chimera 7, HA- hemagglutinin tag. Kb – H-2Kb MHC class I tetramers, A and C) untagged 
construct B and D) HA-tagged constructs 
 
Results using the H-2D
b
 tetramer were very similar to those found using the H-2K
b
 
tetramer.  Staining was approximately 2 times stronger for the untagged wild type BALB/c 
Ly49B (Figure 3.28 C and D).  The remaining pairs of constructs stained with a similar 
intensity to one another (Figure 3.28 C and D). 
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A)                                                                      B) 
    
C)                                                                     D) 
Figure 3.28. Staining of HA-tagged and untagged Ly49B mutants with H-2D
b
. YB2 cells transfected with the 
specified constructs were stained with PE-conjugated H-2D
b
 tetramers. A and B). The staining was repeated at 
least 3 times for each of the positive transfectants and at least 2 times for each of the negative transfectants. The 
numbers in the centre of the blue bars represent average net median fluorescence values. Error bars (SD) are 
shown in black. C and D) The intensity of staining was expressed as a percentage of staining with H-2D
b
 
tetramer (Figure 33 A or B) relative to staining with 2G4 (Figure 31 A and B). C57- C57 Ly49B, BALB- 
BALB/c Ly49B 7 – chimera 7, HA- hemagglutinin tag. Db – H-2Db MHC class I tetramers. A and C) untagged 
construct B and D) HA-tagged constructs 
 
 
 
The results of staining using the H-2D
d
 tetramer indicated that the untagged wild type 
BALB/c Ly49B receptor associated approximately 4 times more strongly than the tagged 
version (Figure 3.29 C and D).  All other tagged versus untagged pairs stained with similar 
intensities to one another (Figure 3.29 C and D). 
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A)                                                                       B) 
    
C)                                                                      D) 
Figure 3.29. Staining of HA-tagged and untagged Ly49B mutants with H-2D
d
. YB2 cells transfected with the 
specified constructs were stained with PE-conjugated H-2D
d
 tetramers. A and B) The staining was repeated at 
least 3 times for each of the positive transfectants and at least 2 times for each of the negative transfectants. The 
numbers in the centre of the blue bars represent average net median fluorescence values. Error bars (SD) are 
shown in black. C and D) The intensity of staining was expressed as a percentage of staining with H-2D
d
 
tetramer (Figure 34 A or B) relative to staining with 2G4 (Figure 31 A and B). C57- C57 Ly49B, BALB- 
BALB/c Ly49B 7 – chimera 7, HA- hemagglutinin tag. Dd – H-2Dd MHC class I tetramers. A and C) untagged 
construct B and D) HA-tagged constructs 
 
 
In order to further assess the influence of the HA-tag on ligand binding, staining of 
tagged and untagged Ly49A transfectants was performed using the H-2K
b
, H-2D
b
 and H-2D
d
 
tetramers and three monoclonal anti-Ly49A antibodies (Figure 3.30).  Expression levels 
were comparable between HA-tagged and untagged Ly49A, as assessed by staining with all 
three monoclonal antibodies.  Interestingly, the untagged Ly49A transfectant exhibited no 
staining with the H-2K
b
 and H-2D
b
  tetramers, and only a marginal association was detected 
with the tagged version.  Staining using the H-2D
d
 tetramer indicated higher levels of 
association but the tagged Ly49A stained nearly twice as strongly as the untagged version.  
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A)                                                                 B) 
Figure 3.30. Staining of HA-tagged and untagged Ly49A mutants with MHC class I tetramers and 
monoclonal anti-Ly49A antibodies. YB2 cells transfected with A) Ly49A or B) Ly49A-HA were stained with 
JR9, A1 and YE1/48 anti- Ly49A antibodies and then AF647 conjugated chicken anti-rat antibodies or with PE-
conjugated H-2K
b
, H-2D
b
 and H-2D
d
 tetramers. The staining was repeated at least 3 times for each of the 
positive transfectants and at least 2 times for the negative transfectants. The numbers in the centre of the blue 
bars represent average net median fluorescence values. Error bars (SD) are shown in black. HA- hemagglutinin 
tag. Kb - H-2K
b
 MHC class I tetramers , Db - H-2D
b
 MHC class I tetramers Dd – H-2Dd MHC class I tetramers 
 
In summary, it seems that the presence of a C-terminal HA-tag can marginally 
influence the strength of ligand binding by Ly49 receptors.  Interestingly, the tag had an 
inhibitory effect on Ly49B ligand binding, as opposed to the stimulatory effect observed with 
Ly49A.  Most importantly, C-terminal HA-tag does not seem to have ability to completely 
abolish Ly49 ligand binding.  
 
3.9. Analysis of residues influencing ligand and 1A1 binding by Ly49B  
 
3.9.1. Analysis of the nature of Ly49B residues predicted to be responsible for binding of 
1A1 and MHC class I ligands 
Variable residues 166 and 167 were shown here to influence 1A1 anti-Ly49B binding 
and together with residue 251 also ligand binding.  The first candidate amino acid: residue 
166 lies within the C-type lectin receptor domain (CRD).  In C57 residue 166 is leucine, 
whereas in BALB/c it is tryptophan and the BALB/c amino acid is conserved amongst other 
Ly49s; C57 L166 is very much the exception (Appendix I).  Both tryptophan and leucine are 
hydrophobic and non-polar by nature (Berg and Stryer 2002).  Leucine is an aliphatic amino 
acid and contains only carbon and hydrogen atoms in its side chain.  Tryptophan on the other 
hand is indolic, comprising an additional nitrogen atom that forms part of a bicyclic aromatic 
group.  Since this nitrogen atom can donate a hydrogen bond, tryptophan is often found on 
the surface of folded proteins in spite of its hydrophobic nature (Berg and Stryer 2002).  
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Switching tryptophan to leucine could potentially produce dramatic structural changes to the 
region in its immediate proximity, thereby enabling binding by the 1A1 antibody or disabling 
binding of the MHC ligands. 
The second potential residue to be identified was 167, which is lysine in the C57 
isoform and asparagine in the BALB/c form.  All of the other Ly49s contain serine at this 
position, except for Ly49Q, which contains arginine (Appendix I).  Lysine is a polar amino 
acid with a side chain made up of three hydrophobic methylene groups and a positively 
charged amino group at the end (Berg and Stryer 2002).  It is often found buried inside folded 
proteins with only the amino group exposed to the solvent.   Asparagine is also a polar amino 
acid; it is uncharged and is regularly found both on the inside and on the surface of proteins.  
Asparagine often provides a site for carbohydrate attachment, however, in the case of C57 
Ly49B, N167 is not anticipated to be glycosylated since its neighbouring residues differ from 
the canonical N-glycosylation motif (i.e. NX[S/T], where N is asparagine, X is any amino 
acid except proline, S is serine and T is threonine (Berg and Stryer 2002).  Substitution of 
N167 in BALB/c with the lysine residue of C57 could result in structural changes that would 
allow binding of 1A1 or abolish association with MHC class I ligands.   
Perhaps the most dramatic variation amongst the three identified residues appears to 
occur at position 251.  In C57 Ly49B the residue is arginine, whereas in the BALB/c isoform 
and all other Ly49s it is cysteine.  In extracellular proteins cysteine is often involved in the 
formation of disulphide (S-S) bonds, in which pairs of cysteine residues are oxidised to form 
a covalent bond (Berg and Stryer 2002).  Intracellular environments are largely reducing so 
proteins containing disulphide bridges are much rarer.  Cysteine residues in a given 
disulphide bond may be separated by a considerable number of amino acids, with the 
formation of the bridge bringing together distant parts of the protein.  Pairs of cysteine 
residues are therefore extremely important in determining the tertiary structure and stability 
of extracellular proteins.  Cysteines that are not involved in S-S bonds often occur within 
active and binding sites.  The intrinsic sulfhydryl side chain of cysteine is ideally suited for 
coordination of metals, for example in binding of zinc by zinc finger motifs (Berg and Stryer 
2002).  Cysteine also often acts as a nucleophile, i.e. as the reactive centre of an enzyme.  In 
cysteine proteases, such as caspases or papains, cysteine acts as a key catalytic residue 
(Grzonka et al. 2001).   
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Substitution of cysteine to any other amino acid is therefore likely to cause significant 
changes in protein structure and/or function.  However, the exchange in C57 Ly49B to 
arginine may be particularly significant due to its larger size and polarity.  Arginine is 
considered somewhat amphipathic, because the end of its side chain is positively charged, 
while the rest of the side chain is hydrophobic (Berg and Stryer 2002).  As such, the arginine 
backbone and the proximal part of its side chain are sometimes buried internally with the 
charged end exposed.  However, most of the time arginines are found on the surface of 
proteins. 
Further evidence for the significance of cysteine substitution to arginine at position 
251 in C57 Ly49B stems from the fact that arginine residues form salt bridges with 
negatively charged amino acids.  Salt bridges are classified as non-covalent interactions that 
rely on a combination of hydrogen bonds and electrostatic interactions (Berg and Stryer 
2002).  They play an important role in stabilizing entropically unfavourable protein 
conformations.  The ability of arginine to form multiple hydrogen bonds means that it is also 
often found in protein active centres, for example in src 2 homology (SH2) domains (Yeo 
2006).  In light of the considerable differences between cysteine and arginine, it is 
unsurprising that substitution of cysteine at position 251 resulted in the loss of MHC class I 
ligand binding in Ly49B C57.  Interestingly the results presented here did not reveal any 
effect on 1A1 binding. 
3.9.2. In silico modelling of Ly49B residues proposed to be responsible for 1A1 
antibody and ligand binding using published Ly49A dimer crystal structure and 
Ly49A-H-2D
d
 co-crystal structure 
 
Crystallographic studies provide telling information concerning interacting residues of 
receptors and their ligands.  Unfortunately, at present no crystal structure exists for Ly49B. 
However, assuming that Ly49B folds in a similar manner to other Ly49s, information can be 
inferred from available crystal structures of other Ly49s.  Figure 3.31 shows the dimeric 
crystal structure of the carbohydrate binding domains of the best characterised Ly49 receptor, 
Ly49A (Tormo et al. 1999).  Residues corresponding to Ly49B residues 166, 167 and 251 
have been highlighted in red, light blue and pink respectively.   
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Figure 3.31. Crystal structure of the Ly49A homodimer. Green – Ly49A homodimer.  Red – residue equivalent 
to Ly49B residue 166, light blue – residue equivalent to Ly49B residue 167.  Yellow- residue equivalent to 
Ly49B residue 251. A) Front view.  B) Top view.  C) Side view. (PDB accession- 1QO3). 
 
With reference to Figure 3.31, the first notable observation is that although in the 
linearised molecule residue 245 (equivalent to Ly49B residue 251) is situated 84 and 85 
residues away from residues 160 and 161 (Ly49B residues 166 and 167), respectively, the 
residues are brought into close proximity to one another due to the manner in which Ly49A 
folds.  It is therefore likely that together the three residues are capable of forming a functional 
ligand-binding motif.  Moreover, the residues are located on the surface of the Ly49A dimer, 
which makes them easily accessible to both the ligands and monoclonal antibodies. 
Figure 3.32 shows a co-crystal structure of Ly49A in complex with the MHC class I 
molecule H-2D
d
 (Tormo et al. 1999).  The residues predicted to form hydrogen bonds and 
salt bridges between Ly49A and its ligand are highlighted in blue in the alignment in 
Appendix I.  None of the Ly49A residues corresponding to residues 166, 167 and 251 in 
Ly49B were identified as being in direct contact between Ly49A and its ligand. However,  
Ly49A residues 160 and 161 (equivalent to Ly49B residues 166 and 167) form part of the α1 
alpha helix (Appendix I), which comes into contact with the α3 helix of its putative MHC 
class I ligand.  Ly49A residue 245 is one of five amino acids forming a loop between beta 
sheets 4 and 5 (Appendix I) and is the only one of these five predicted not to be in direct 
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contact with the ligand.  The remaining four are thought to form interactions with residues in 
the α3 helix and β2 microglobulin of H-2Dd.  Since Ly49B residues 166, 167 and 251 are 
predicted to be in close proximity to residues that do appear to come into direct contact with 
the ligand, it is possible that their alteration may significantly influence the structure of 
adjacent regions and, consequently, the ability of the receptor to bind its ligand. 
 
  
Figure 3.32. Crystal structures of Ly49A with the MHC class I ligand H-2D
d
.  Green – Ly49A.  Blue – MHC 
class I H-2D
d
 α chain.  Purple – MHC class I H-2Dd β2 microglobulin.  Orange – peptide in MHC class I 
binding grove.  Red – residue equivalent to Ly49B residue 166, light blue – residue equivalent to Ly49B residue 
167.  Yellow- residue equivalent to Ly49B residue 251.  A), B) and C) – Ly49A-MHC class I H-2Dd complex 
shown from different angles. (PDB accession- 1QO3). 
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In order to visualise the effects of the differing side chains of residues 166, 167 and 
251 in C57 and BALB/c isoforms of Ly49B, appropriate mutations were introduced to the 
Ly49A amino acid sequence and simulated using PyMOL.  In Figure 3.33 the tryptophan 
residue at position 166, which is present in Ly49A (position 160) and BALB/c Ly49B, has 
been replaced with leucine, as occurs in C57 Ly49B.  Figures 3.34 and 3.35 show 
substitution of serine 161 in Ly49A with lysine and asparagine, as occur in C57 and BALB/c 
Ly49B (at position 167), respectively.  Figure 3.36 shows the result of substituting cysteine 
245, which is present in Ly49A and BALB/c Ly49B (at position 251) with arginine, as occurs 
in C57 Ly49B. 
Due to the technical limitations of PyMOL, in silico point mutations do not produce 
steric changes, which could occur in the surrounding region.  However, from the generated 
images it is clear that the C57 and BALB/c Ly49B-specific residues at positions 166, 167 and 
251 have significant structural differences from one another and from the corresponding 
Ly49A residues.  Considering also the differing biochemical properties of these residues 
described in Section 3.9.1, it seems likely that the selected mutations could have a profound 
effect on ligand and antibody binding. 
 
 
Figure 3.33. In silico introduction of a W166L mutation to the Ly49A receptor. A) Ly49A with wild type 
residues at positions equivalent to Ly49B 166 (tryptophan), 167 (serine) and 251 (cysteine).  B) Ly49A with 
tryptophan 166 substituted with the equivalent C57 Ly49B residue, leucine.  Colour coding as in Figure 3.31. 
(PDB accession- 1QO3). 
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Figure 3.34. In silico introduction of an S167K mutation to the Ly49A receptor.  A) Ly49A with wild type 
residues at positions equivalent to Ly49B 166 (tryptophan), 167 (serine) and 251 (cysteine).  B) Ly49A with 
serine 167 substituted with the equivalent C57 Ly49B residue, lysine.  Colour coding as in Figure 3.31 
 
 
Figure 3.35. In silico introduction of an S167N mutation to the Ly49A receptor. A – Ly49A with wild type 
residues at positions equivalent to Ly49B 166 (tryptophan), 167 (serine) and 251 (cysteine).  B) Ly49A with 
residue 167 substituted with the equivalent BALB/c Ly49B residue, asparagine.  Colour coding as in Figure 
3.31. 
 
Figure 3.36. In silico introduction of a C251R mutation to the Ly49A receptor.  A) Ly49A with wild type 
residues at positions equivalent to Ly49B 166 (tryptophan), 167 (serine) and 251 (cysteine).  B) Ly49A with 
residue 251 substituted with the equivalent C57 Ly49B residue, arginine.  Colour coding as in Figure 3.31. 
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It is worth noting that the simulations shown in Figures 3.31-3.36 do not necessarily 
reflect the tertiary structure of Ly49B, as the models were based on Ly49A.  Ly49B shares 
only ~50 % homology with other Ly49s and contains an additional 20 amino acids at its C-
terminus (Appendix I).  It is therefore possible that three residues of interest occupy slightly 
different positions in Ly49B.  Furthermore, the crystals of Ly49A were generated using 
recombinant protein, which was expressed in E. coli and may therefore not have undergone 
the post-translational modifications that would have occurred endogenously.  Ly49 receptors 
are indeed predicted to be glycosylated and the presence of glycans could well affect the 
manner in which they fold.  As such, the interaction sites identified in the crystal structures 
presented here may be slightly different under native conditions. 
 
3.10.  Summary  
The study presented here has shown that residues 166 and 167 are critical for the 
selective binding of the 1A1 antibody to C57 Ly49B and, together with residue 251, play a 
crucial role in the binding of MHC class I tetramers to BALB/c Ly49B.  The residues 
corresponding to Ly49B 166 and 167 residues are also critical for the structure and function 
of Ly49A.  It seems that, in general, Ly49 receptor residues, which do not come into direct 
contact with the ligand, can significantly but indirectly influence the strength of binding.  The 
H-2D
b
 MHC molecule seems to be the primary ligand for Ly49B due to the fact that binding 
is robustly retained upon introduction of alternative residues or manipulation of the 
glycosylation sites, in comparison to H-2K
b
 and H-2D
d
.  C-terminal HA-tag may slightly 
affect the strength of ligand binding by Ly49 receptors but it does not have an ability to 
completely abolish it. Finally, Ly49B ligand binding appears to undergo fine tuning by 
receptor glycosylation. 
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Chapter 4. Molecular nature of Ly49B 
 
  
4.1. Introduction 
 This chapter outlines Western blotting and immunoprecipitation experiments that 
were carried out to investigate the molecular nature of Ly49B and other related receptors.  
The majority of experiments were performed on whole cell lysates of transfectants expressing 
a specific receptor.  The cell extracts were subjected to SDS-PAGE analysis, transferred to 
nitrocellulose membrane and blotted with a monoclonal antibody directed against either the 
receptor of interest or a tag co-expressed with the receptor.  The membranes were then 
blotted with a horseradish peroxidase (HRPO)-conjugated secondary antibody directed 
against the primary antibody.  The proteins of interest were visualised using enhanced 
chemiluminescence (ECL) reagent, which contains luminol - a compound that is converted to 
3-aminophthalate upon interaction with HRPO, causing emission of light at 428nm.  This 
emission can then be captured on photographic film.  
In some of the experiments, the receptor of interest was immunoprecipitated from 
whole cell lysates using appropriate antibodies prior to Western blotting.  This approach, 
combined with surface labeling of the receptor, is a traditional staple for investigating the 
molecular nature of other Ly49 receptors.  In such experiments the surface label is used to 
detect the receptor of interest.  One drawback of this approach is that only the surface-
associated proteins are subjected to analysis.  Here, an alternative method was used, which 
enables visualization of both the intracellular and surface-associated receptor populations.  
This approach has provided new insights into the biochemistry of Ly49 receptors. 
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4.2. Ly49B exists in multiple molecular forms in cells transfected with Ly49B 
constructs. 
C57 Ly49B-FLAG transfected RNK cells were lysed in buffer containing a non-ionic 
surfactant; Triton X-100. The reduced (R) lysate samples containing β-mercaptoethanol 
(2ME), which reduces disulphide bonds and untreated non-reduced (NR) samples were 
analysed by 15 % SDS-PAGE, then blotted to nitrocellulose membranes.  The membranes 
were incubated with N1027 rabbit anti-FLAG followed by N1197 HRPO bovine anti-rabbit 
immunoglobulin (Ig) and imaged with ECL reagent. Two bands running at ~110 kDa and 150 
kDa were revealed in the NR lysate and a single band running at ~47 kDa in the R material 
(Figure 4.1A).  The bands were not detected in lysates of RNK cells transfected with Ly49H 
or in lystaes of YB2 cells transfected with Ly49B bearing a C-terminal HA tag, suggesting 
that the bands detected in RNK-C57 Ly49B-FLAG lysates represented Ly49B.  Comparison 
of reduced and non-reduced RNK-C57 Ly49B-FLAG samples suggests that Ly49B may form 
dimers or multimers or that it may associate with other proteins through the formation of 
disulphide bonds.  The 47 kDa band is likely to represent the Ly49B monomer.   
Prolonged film exposure revealed a faint band of ~47 kDa in the NR material, 
suggesting that free monomeric Ly49B may be present at low concentrations in living cells 
(Figure 4.1B).  Alternatively, the appearance of the 47 kDa band in the non-reduced samples 
may have resulted from 2ME spillover from the reduced samples.  Prolonged film exposure 
revealed an additional faint band of ~55 kDa in the reduced material, as well as faint bands in 
the upper part of the gel, which may represent residual non-reduced material. 
 
Figure 4.1. N1027 anti-FLAG blot of NR and R lysates of RNK-Ly49B-FLAG, YB2-Ly49B-HA, RNK-Ly49H 
and YB2/0 cells.  Cell lysates at 1.5 x10
4
 cells/µl were run for 1 h at 200 V on a 15 % SDS-PAGE gel and 
transferred for 1 h at 200 V onto nitrocellulose membrane using wet transfer method.  The membranes were 
incubated for 1 h at 4 °C with N1027 anti-FLAG antibody at 1/ 5000 dilution and then for 1 h at room 
temperature with N1197 HRPO bovine anti-rabbit Ig at 1/2500 dilution.  Images were developed using Pierce 
ECL reagent for 1 min (A) and 2 min (B). M= molecular weight marker, NR= non-reduced, R=reduced, RNK-
F=RNK-C57 Ly49B-FLAG, YB2-H=YB2-Ly49H, RNK-H=RNK-Ly49H. 
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 To further investigate the specificity of the Ly49B detection in Western blots, 
membranes with the same cell lysates were incubated with N1028 rabbit anti-HA followed by 
N1197 HRPO bovine anti-rabbit Ig.  As shown in Figure 4.2, untreated NR lysate from YB2-
C57 Ly49B-HA cells revealed 2 bands running at ~110 kDa and ~150 kDa, which were at 
equivalent positions to the bands detected with anti-FLAG antibody.  Moreover, in the NR 
samples another band was detected at ~47 kDa, which suggested again, that free monomeric 
Ly49B may be present in the living cells. R material contained a strong band at ~47 kDa with 
much fainter bands running at ~110 kDa and ~150 kDa, representing most likely residual non 
reduced Ly49B material.  Lysates of RNK-Ly49B-FLAG cells or other control cells did not 
contain band at ~110 kDa or ~47 kDa, although some weak non-specific bands were present 
at ~80 kDa and ~150 kDa.     
 
Figure 4.2. N1028 anti-HA blot of NR and R lysates of YB2-Ly49B-HA, RNK-Ly49B-FLAG, RNK-Ly49H 
and YB2/0 cells. Cell lysates at 1.5 x104 cells/µl were run for 1 h at 200 V on a 15 % SDS-PAGE gel and 
transferred for 1 h at 200 V onto nitrocellulose membrane using wet transfer method.  The membranes were 
incubated for 1 h at 4 °C with N1028 anti-HA antibody at 1/5000 dilution and then for 1h at room temperature 
with N1197 HRPO bovine anti-rabbit Ig at 1/2500 dilution.  Image was developed using Pierce ECL reagent for 
2 min. M= molecular weight marker, NR=non-reduced, R=reduced, RNK-F=RNK-C57 Ly49B-FLAG, YB2-
H=YB2-Ly49H, RNK-H=RNK-Ly49H. 
 
Interestingly, monoclonal antibody (mAb) 2G4 anti-Ly49B, turned out to be effective 
in detection of bands on the membranes containing lysates of Ly49B-transfected YB2 cells 
that were not observed in lysates of control cells (Figure 4.3).  This was slightly surprising 
because mAbs such as 2G4, which have been raised by using live cells for immunisation, are 
thought to be poor reagents for Western blotting. Such mAbs usually recognize 
discontinuous, conformational epitopes on properly folded proteins, which can be disrupted 
following denaturation in SDS.  One possible explanation is that following protein transfer to 
the nitrocellulose membrane, SDS was washed off and Ly49B spontaneously refolded to the 
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extent that enabled reconstitution of the 2G4 epitope.  Another possibility is that the 2G4 
epitope is, in fact, continuous epitope and its conformation was not drastically affected 
following Ly49B denaturation. 
The banding pattern detected by 2G4 was clearly specific for Ly49B-transfected cell 
lysates but it was also strikingly different from that revealed with the N1027 rabbit anti-
FLAG and N1028 rabbit anti-HA polyclonal Abs.  The NR lysates contained bands at 
positions equivalent to previously detected bands at ~110 kDa, ~150 kDa, but also 
additionally contained a band at ~200 kDa, whereas the R lysates contained not only 
previously detected band at ~ 47 kDa but also a clear band at ~55 kDa.  Importantly, HA-
tagged BALB/c Ly49B or untagged BALB/c Ly49B extracts samples contained virtually 
identical multiple banding pattern, indicating that the observed heterogeneity of Ly49B is not 
an artefact caused by the presence of a C-terminal tag.  It is worth noting that the bands 
observed in lysates of cells transfected with HA-tagged Ly49B ran at a slightly higher 
position than bands from cells transfected with untagged Ly49B.  This further confirms that 
the multiple bands detected in this experiment undeniably represented multiple molecular 
forms of Ly49B and no other protein.  Some non-specific bands were revealed in all of the 
tested samples at ~75 kDa.  YB2/0 samples contained an additional non-specific band at ~80 
kDa. 
 
Figure 4.3. N1184 2G4 anti-Ly49B blot of NR and R lysates of YB2-Ly49B, YB2-Ly49B-HA, RNK-Ly49H 
and YB2/0 cells.  Cell lysates at 1.5 x10
4
 cells/µl were run for 1 h at 200 V on a 15 % SDS-PAGE gel and 
transferred for 1 h at 200 V onto nitrocellulose membrane using wet transfer method.  Membranes were 
incubated overnight at 4 °C with N1184 rat 2G4 anti-Ly49B antibody at 1/2500 dilution and then 1 h at room 
temperature with N1196 HRPO goat anti-mouse IgG and N1194 HRPO anti-biotin antibody both at 1/5000 
dilution.  Image was developed using Pierce ECL reagent for 1 min.  M=molecular weight marker, NR=non-
reduced, R=reduced, YB2-BH = C57 YB2-Ly49B-HA, YB2-B =YB2-BALB/c Ly49B, RNK-H=RNK-Ly49H. 
 
Further investigation revealed that another monoclonal anti-Ly49B antibody, referred 
to as 1A1, which is specific for C57 Ly49B, was also able to detect Ly49B multiple banding 
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pattern in Western blot experiments (Figure 4.4).  The pattern was essentially identical to 
that detected by 2G4, but as expected from the specificity of 1A1, the bands were only 
observed in extracts of cells transfected with the C57 Ly49B and not the BALB/c Ly49B.  
Blotting with 2G4 on the other hand, revealed bands in lysates of YB2 cells that have been 
transfected with the Ly49B BALB/c or Ly49B BALB/c-HA. The specificity of 1A1 for C57 
Ly49B samples only, further confirmed that the multiple bands detected in Western blot 
experiments with various antibodies described above represented Ly49B.  Notably, the 
relative intensity of the multiple bands in BALB/c samples was different to the relative 
intensity of bands in C57 sample.  In particular, in the non-reduced Ly49B BALB/c samples 
a band at ~150 kDa was much stronger than the bands at ~110 and ~200 kDa. However, 
longer exposure to ECL revealed that those bands undoubtedly were present in the lysate.  
Moreover, the mobility of C57-HA bands was slightly retarded in comparison to BALB/c-
HA bands and untagged Ly49B ran faster than the HA-tagged version. 
 
Figure 4.4. N1176 biotin 2G4 anti-Ly49B and N869 biotin 1A1 anti-Ly49B blot of R and NR YB2-C57 
Ly49B-HA cell lysates. YB2-C57 Ly49B-HA, YB2-BALB/c Ly49B-HA, YB2-BALB/c Ly49B and YB2/0 lysates at 
2000 cells/µl were run for 1.5 h at 200 V on 15 % SDS-PAGE gels and transferred for 1.5 h at 200 V onto a 
nitrocellulose membranes by wet transfer method.  Membranes were incubated overnight at 4 °C with N1176 
biotin 2G4 anti-Ly49B antibody at 1/2500 dilution or N869 biotin 1A1 anti-Ly49B antibody at 1/1000 dilution, 
followed by incubation at room temperature for 1 h with N1194 HRPO anti-biotin antibody at 1/2500 dilution.  
Images were developed using Thermo ECL reagent for 20 sec (A) and 5 min (B).  M= molecular weight marker, 
NR=non-reduced, R=reduced, CH=YB2-C57 Ly49B-HA, BH=YB2-BALB/c Ly49B-HA, B=YB2-BALB/c Ly49B, 
0=YB2/0, 2G4=N1176 biotin 2G4, 1A1=N869 biotin 1A1. 
 
 To extend investigation of the specificity of antibodies for Ly49B in Western blot 
experiments, a blot was performed on YB2-C57 Ly49B-HA lysates with 2G4, 1A1 and three 
different anti-HA antibodies in parallel to one another (Figure 4.5).  In the case of reduced 
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samples, N1028 anti-HA antibody recognised only one band at ~47 kDa.  2G4 recognised 
two bands at ~47 kDa and ~55 kDa.  Results with the 1A1 antibody were comparable to those 
obtained for 2G4 antibody.  The N1229 biotin anti-HA antibody bound preferentially to a 
band of~47 kDa and N1222 biotin anti-HA to a band of ~55 kDa but they also associated to a 
lesser extent with bands at ~55 kDa and ~47 kDa, respectively.  In the case of non-reduced 
samples, a band of ~200 kDa was revealed by all of the antibodies.  N1028 anti-HA 
additionally recognised a band at ~110 kDa.  A weak band at a similar position was also 
present in samples incubated with 2G4, N1222 anti-HA and N1229 anti-HA antibodies.  All 
of the antibodies, with the exception of N1028 anti-HA, bound to a protein of ~150 kDa.  
These results indicate that different antibodies can bind different molecular weight forms of 
Ly49B with varying strength.  
 
Figure 4.5. N1028 anti-HA, N1176 biotin 2G4 anti-Ly49B, N869 biotin 1A1 anti-Ly49B, N1229 biotin rabbit 
anti-HA and N1222 biotin 16.43 anti-HA blot of R and NR YB2-C57 Ly49B-HA lysates.  Cell lysates at 2000 
cells/µl were run for 1.5 h at 200 V on 15 % SDS-PAGE gels and transferred for 1.5 h at 200 V onto 
nitrocellulose membranes using wet transfer method.  Membranes were incubated overnight at 4 °C with N1028 
anti-HA antibody at 1/100,000 dilution, N1176 biotin 2G4 rat anti-Ly49B antibody at 1/5000 dilution, N869 
biotin rat 1A1 anti-Ly49B at 1/1000 diltion, N1229 biotin anti-HA antibody at 1/100,000 and N1222 biotin 
16.43 anti-HA antibody at 1/100.000 dilution. Membranes treated with biotinylated antibodies were incubated 
for 1 h at room temperature with N1192 HRPO SA at 1/5000 dilution and N1028 treated membrane with N1197 
HRPO bovine anti-rabbit IgG at and N1194 HRPO anti-biotin antibody at 1/5000 dilution.  Images were 
developed using Pierce ECL reagent for 20 sec. M=molecular weight marker, R=reduced, NR=non-reduced, 
AH1=N1028 anti-HA, 2G4=N1176 biotin 2G4, 1A1=N869 biotin 1A1, AH2=N1229 biotin rabbit anti-HA, 
AH3=N1222 biotin 16.43 anti-HA. 
 
To further explore this notion, YB2-C57 Ly49B-HA cells were lysed and subjected to 
immunoprecipitation with sepharose protein G beads coated with N1028 anti-HA, N1109 
16.43 anti-HA or N1184 2G4 anti-Ly49B antibodies.  Figure 4.6 shows an N1176 biotin 2G4 
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anti-Ly49B blot of protein samples immunoprecipitated from the lysates using sepharose 
protein G beads.  The samples on the left side of the panel contain proteins that did not 
associate with the beads and remained in the supernatant (SN) following 
immunoprecipitation.   The samples on the right hand side of the panel contain proteins 
eluted from the beads (labelled BEADS).   
 
Figure 4.6. N1176 biotin 2G4 anti-Ly49B blot of NR and R C57 Ly49B-HA immunoprecipitated from YB2-
C57 Ly49B-HA lysates using sepharose protein G beads coated with a range of antibodies.  Samples of 
immunoprecipitated material prepared from YB2-C57 Ly49B-HA lysates at 2000 cells/µl using sepharose 
protein G beads coated with N1028 anti-HA, N1109 16.43 anti-HA, N1184 2G4 rat anti-Ly49B or PBS were run  
for 1.5 h at 200 V on 15 % SDS-PAGE gels and transferred for 1.5 h at 200 V onto nitrocellulose membranes by 
wet transfer.  Membranes were incubated overnight at 4 °C with N1176 biotin 2G4 rat anti-Ly49B antibody at 
1/2500 dilution followed by N1194 HRPO anti-biotin antibody at 1/2500 dilution for 1h at room temperature.  
Images were developed using Pierce ECL reagent for 1 min.  M= molecular weight marker, NR=non-reduced, 
R=reduced, AH1=N1028 anti-HA, AH2=N1129 16.43 anti-HA 2G4=N1184 2G4 rat anti-Ly49B, 
SN=supernatant collected following incubation of the antibody covered protein G beads with YB2- C57 Ly49B-
HA lysates, prior to elution. BEADS =material eluted from the antibody covered protein G beads. 
 
SN samples collected following incubation with PBS control beads contained three 
non-reduced (~110 kDa, ~150 kDa and ~200 kDa) and two reduced (~47 kDa and ~55 kDa) 
bands similar to those previously observed in blots with the 2G4 antibody, suggesting that all 
of the molecular weight forms of Ly49B were present in the lysate.  The corresponding 
BEADS samples indicated that there was no non-specific Ly49B binding.  N1028 anti-HA 
antibody-coated beads associated with proteins, which appeared on the blot as a predominant 
band of ~47 kDa in the reduced samples or three bands at ~110 kDa, ~150 kDa and ~200 kDa 
in the non-reduced samples.  The corresponding SN samples contained a reduced band at ~55 
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kDa and a predominant, non-reduced band at 150 kDa, as well as a weaker non-reduced band 
at ~200 kDa.  These results suggest that the N1028 antibody preferentially binds the lowest 
molecular weight form of Ly49B.   
Beads coated with the second anti-HA antibody, N1109 16.43 anti-HA or with the 
2G4 antibody, were able to associate with all molecular forms of Ly49B since virtually all 
bands were absent in the SN samples.  The corresponding eluted samples contained all of the 
expected putative Ly49B bands, except the band at 200 kDa.  The observation that this band 
was not retained in the SN samples and the fact that it did not appear in the eluted samples 
suggests that the highest molecular form of Ly49B observed in Western blot experiments may 
not be stable.   
These extensive analyses provide evidence to support the theory that Ly49B exists in 
transfected cells in multiple molecular weight forms, which are capable of associating with 
each other or other proteins through the formation of disulphide bonds.  Various antibodies 
specific for C-terminal tags, as well as monoclonal anti-Ly49B antibodies are able to 
recognise different molecular weight forms of Ly49B on Western blots with varying strength. 
4.3. Multiple molecular weight forms of Ly49B represent differentially 
glycosylated Ly49B   
Ly49B contains four predicted N-glycosylation motifs (Appendix I), with asparagines 
that could potentially serve as glycan attachment points at positions 94, 105, 114 and 177.  
YB2/0 cells were transfected with C57 Ly49B-HA, BALB/c Ly49B and BALB/c Ly49B-HA 
mutants, in which all four of the N-glycosylation motifs were disrupted by mutating the 
critical asparagine residues (N) to glutamines (Q).  Figure 4.7 shows an N1176 biotin 2G4 
blot of lysed NR and R Ly49B glycosylation mutants and wild type controls.  YB2-BALBc 
Ly49B-HA and YB2-C57 Ly49B-HA lysate samples contained bands at positions analogous 
to those previously identified as Ly49B.  YB2-C57 Ly49B lysate sample contained bands at 
positions marginally smaller than those identified for the YB2-C57 Ly49B-HA counterpart. 
As with BALB/c constructs (Figures 4.3 and 4.4), the presence of the C-terminal HA tag 
appeared to slightly reduce the speed of migration of C57 Ly49B on SDS-PAGE gels.  
Interestingly, all of the glycosylation mutant variants of Ly49B appeared as one 
predominant band of ~80 kDa for the non-reduced samples and ~34 kDa for the reduced 
samples.  Both HA-tagged forms ran marginally higher than the untagged variants.  A weak 
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200 kDa band could be observed in all of the non-reduced glycosylation mutant samples and 
in reduced YB2-Ly49B C57 and YB2-C57 Ly49B-HA glycosylation mutant samples.  
 
Figure 4.7. N1176 biotin 2G4 anti-Ly49B blot of NR and R Ly49B glycosylation mutants. YB2- C57 Ly49B, 
YB2-C57 Ly49B-N94Q-N105Q-N114Q-N177Q, YB2- C57 Ly49B-HA, YB2-C57 Ly49B-N94Q-N105Q-N114Q-
N177Q-HA, YB2- BALB/c Ly49B-HA, YB2-BALB/c Ly49B-N94Q-N105Q-N114Q-N177Q-HA lysates at 5000 
cells/ul were run  for 1.5 h at 200 V on 15 % SDS-PAGE gels and transferred for 17 min at 1.3 A and 25 V to  
nitrocellulose membranes using the Trans-Blot Turbo system.  Membranes were incubated overnight at 4 °C 
with N1176 biotin 2G4 rat anti-Ly49B antibody at 1/2000 dilution and then N1243 HRPO anti-biotin antibody 
at 1/1000 dilution for 1 h at room temperature.  Image was developed using Thermo ECL reagent for 20 sec.  
M= molecular weight marker, NR=non-reduced, R=reduced, C=YB2- C57 Ly49B, CG=YB2-C57 Ly49B-
N94Q-N105Q-N114Q-N177Q, CH=YB2- C57 Ly49B-HA, CHG=YB2-C57 Ly49B-N94Q-N105Q-N114Q-
N177Q-HA, BH=YB2- BALB/c Ly49B-HA, BHG=YB2-BALB/c Ly49B-N94Q-N105Q-N114Q-N177Q-HA. 
 
The predicted molecular weight of Ly49B is ~34 kDa but the smallest molecular form 
observed for wild type Ly49B in Western blot experiments was ~47 kDa.  The results 
presented here demonstrate that the difference between the predicted and the observed 
molecular weight of Ly49B is most likely due to the presence of glycans at the N-
glycosylation motifs.  In light of the observation that only one predominant band was 
observed for the reduced and non-reduced Ly49B glycosylation mutants, as opposed to two 
bands observed for reduced samples and three bands observed for non-reduced samples in 
lysates containing wild type protein, it is reasonable to conclude that the multiple molecular 
weight forms of Ly49B represent differentially glycosylated Ly49B.  Notably, the C57 and 
BALB/c HA-tagged glycosylation mutants ran at virtually identical positions, unlike their 
wild type counterparts, suggesting that the differences observed for the wild type proteins 
might be due to different kinds of glycans being attached to C57 and BALB/c forms of 
Ly49B. 
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Figure 4.8. Western blot of biotinylated NR and R C57 Ly49B-HA immunoprecipitated from YB2-C57 
Ly49B-HA lysates using protein G beads coated with 2G4 anti-Ly49B. Samples of immunoprecipitated 
material prepared from biotinylated and non-biotinylated YB2-C57 Ly49B-HA lysates at 5000 cells/µl using 
sepharose protein G beads coated with N1184 2G4 rat anti-Ly49B or isotype control were run in duplicates for 
40 min at 200 V on 15 % SDS-PAGE gels and transferred for 17 min, at 1.3 A and 25 V to nitrocellulose 
membranes using the Trans-Blot Turbo system.  The membranes were incubated overnight at 4 °C with N1176 
biotin 2G4 rat anti-Ly49B antibody at 1/2000 dilution or PBS, followed by N1194 HRPO anti-biotin antibody at 
1/2000 dilution for 1 h at room temperature.  Images were developed using Thermo ECL reagent for 1 min.  
M=molecular weight marker, NR=non-reduced, R=reduced, 2G4=N1184 2G4 rat anti-Ly49B, Iso=N1089 MR3 
rat IgG2c, Anti-Biotin HRPO=N1194 HRPO anti-biotin antibody,  B=biotinylated, NB=non-biotinylated, YB2-
BH=YB2-C57 Ly49B-HA. 
 
 To further address the question of what the multiple molecular forms of Ly49B 
observed in Western blot experiments are likely to be, YB2/0 and YB2-C57 Ly49B-HA cells 
were surface biotinylated, lysed and subjected to immunoprecipitation using sepharose 
protein G beads coated with 2G4 antibody or isotype control.  Figure 4.8 shows a blot with 
the biotinylated samples and non-biotinylated control samples incubated with N1194 HRPO 
anti-biotin antibody in conjunction with either PBS or N1176 biotin 2G4 rat anti-Ly49B as 
the primary layers.  The right hand side of the panel, which contains samples incubated with 
biotinylated 2G4 antibody followed by anti-biotin HRPO antibody, shows two strong bands 
at ~47 kDa and ~55 kDa in the reduced samples and two strong bands at ~110 kDa and ~150 
kDa in non-reduced samples, following immunoprecipitation from biotinylated and non-
biotinylated YB2-C57 Ly49B-HA lysates.  The biotinylated, non-reduced YB2-C57 Ly49B-
HA sample contained an additional faint band at ~200 kDa.   The bands were at positions 
analogous to those previously identified as multiple molecular weight forms of Ly49B.  No 
bands were present in lanes that contained samples, which had been immunoprecipitated with 
isotype coated beads from YB2-C57 Ly49B-HA or YB2/0 lysates.  Moreover, 2G4 coated 
beads were unable to immunoprecipitate any proteins from YB2/0 lysates, suggesting that the 
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proteins immunoprecipitated from YB2-C57 Ly49B-HA lysates were indeed Ly49B. The left 
hand side panel of Figure 4.8 contains samples incubated with PBS control, followed by 
N1194 HRPO anti-biotin antibody.  No bands were detected in the case of non-biotinylated 
cell lysate samples, suggesting that the N1194 antibody is specific for biotin.  
 Strikingly, the biotinylated, reduced samples that were immunoprecipitated from 
YB2-C57 Ly49B-HA cell lysates contained a band at ~55 kDa, but lacked the ~47 kDa 
Ly49B band.  The non-reduced samples also contained ~150 kDa and ~200 kDa bands but 
lacked the band at 110 kDa, suggesting that the “missing” molecular forms were not 
biotinylated.  Since the experimental design allowed biotinylation of only the surface 
proteins, it is reasonable to conclude that the reduced ~55 kDa and non-reduced ~110 kDa 
molecular forms of Ly49B are not expressed on the cell surface and were only released 
following cell lysis.  
 To extend the analysis of the different molecular forms of Ly49B, YB2-C57 Ly49B-
HA cells were lysed and treated for 1 h at 37 °C either with the endoglycosidase enzyme, 
PNGase F, which removes all glycans attached to asparagines residue within N-glycosylation 
motifs, or with Endo H enzyme, which specifically cleaves high mannose from N-linked 
glycoproteins.  An N1176 biotin 2G4 blot of NR and R C57 Ly49B-HA treated with either 
PNGase F or Endo H is shown on Figure 4.9.  Development with the N1243 anti-biotin 
antibody revealed the same range of Ly49B bands as previously identified (Figures 4.3-4.6 
and 4.7) in the untreated samples, although the 200 kDa band  was barely visible, suggesting 
that the highest molecular form of Ly49B may not be stable.  PNGase F-treated samples 
contained only one band in the reduced and non-reduced samples; at ~34 kDa and ~80 kDa 
respectively.  The position of these bands was analogous to the position of bands found with 
the Ly49B N-glycosylation mutants, providing further evidence that the multiple molecular 
forms of Ly49B are indeed differentially glycosylated Ly49B.  The reduced samples treated 
with Endo H enzyme contained two bands at ~34 kDa and ~55 kDa and the non-reduced 
samples contained two bands at ~80 kDa and 150 kDa.  It appears that only the lowest 
reduced and non-reduced molecular weight forms of Ly49B observed on Western blots were 
sensitive to Endo H.  
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Figure 4.9. N1176 biotin 2G4 anti-Ly49B blot of NR and R C57 Ly49B-HA treated with PNGase F and Endo 
H enzymes. YB2-C57 Ly49B-HA lysates at 5000 cells/µl were treated with PNGase F and Endo H at 25,000 
U/ml, at 37 °C for 1 h, were run  for 1.5 h at 200 V on 15 % SDS-PAGE gels and transferred for17 min at 1.3 A 
and 25 V to nitrocellulose membranes using the Trans-Blot Turbo system.  Membranes were incubated 
overnight at 4 °C with N1176 biotin 2G4 rat anti-Ly49B antibody at 1/2000 dilution and then for 1 h at room 
temperature with N1243 HRPO anti-biotin antibody at 1/1000 dilution.  Image was developed using Thermo 
ECL reagent for 5 sec.  M=molecular weight marker, NR=non-reduced, R=reduced, P=PNGase F, E= Endo H. 
 
As explained in detail in the Introduction (Section 1.3), the process of N-
glycosylation is a multi-stage event; as the glycoprotein travels through different intracellular 
compartments to the cell surface various glycans are attached, cleaved and replaced by other 
glycans at the same glycosylation motif.   Immature glycoproteins, localised in the ER are 
often associated with mannose polymers and for that reason are referred to as high mannose 
glycoproteins.  Taking into account results presented in Figures 4.8 and 4.9, it is possible to 
conclude that the lowest reduced and non-reduced molecular weight forms of Ly49B detected 
on Western blots could represent immature, intracellular, high mannose forms of Ly49B and 
that the larger species are surface-associated mature receptors.   
To establish which of the predicted Ly49B N-glycosylation motifs undergo 
glycosylation, BALB/c Ly49B mutants, which contained glutamine rather than asparagine at 
each of the individual motifs, were transfected into YB2/0 cells and examined by Western 
blotting.  Figure 4.10 shows an N1176 biotin 2G4 blot of NR and R BALB/c Ly49B single 
glycosylation mutants.  All of the reduced samples ran at a lower position that wild type 
BALB/c Ly49B, suggesting that glycans are attached at each of the individual glycosylation 
motifs.  Interestingly, the lane with reduced YB2-BALB/c Ly49B-N114Q lysate sample 
contained 3 bands, rather than 2, as was the case with the wild type sample and all of the 
other mutants.  The lowest band in this sample ran at ~42 kDa and was not observed in any 
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other sample.  This suggests that glycosylation of asparagine 114 may have a positive effect 
on the glycosylation of other motifs.  In the absence of a glycan at asparagine 114, 
glycosylation of the remaining motif(s) may be impaired.  Alternatively, the presence of a 
glycan at position 114 may dictate what kinds of glycans are attached to the remaining 
motifs.  In the absence of a glycan at position 114, glycans of varying size may be attached at 
the remaining glycosylation motifs, which resulted in a greater heterogeneity of band sizes in 
the YB2-BALB/c Ly49B-N114Q lysate samples.   
 
Figure 4.10. N1176 biotin 2G4 anti-Ly49B blot of NR and R BALB/c Ly49B single glycosylation mutants. 
YB2-BALB/c Ly49B, YB2-BALB/c Ly49B-N94Q, YB2-YB2-BALB/c Ly49B-N105Q, YB2-BALB/c Ly49B-N114Q 
and YB2-BALB/c Ly49B-N177Q lysates at 1.5x10
4
 cells/µl were run  for 1.5 h at 200 V on 15 % SDS-PAGE gels 
and transferred for 17 min at 1.3 A and 25 V to nitrocellulose membranes using the Trans-Blot Turbo system.  
Membranes were incubated overnight at 4 °C with N1176 biotin 2G4 rat anti-Ly49B antibody at 1/2000 dilution 
and then for 1 h at room temperature with N1242 HRPO anti-biotin antibody at 1/2000dilution.  Images were 
developed using Thermo ECL reagent for 10 min (A) and 15 min (B).  M=molecular weight marker, NR=non-
reduced, R=reduced, WT =YB2- BALB/c Ly49B, 94 =YB2-BALB/c Ly49B-N94Q, 105=YB2-YB2-BALB/c 
Ly49B-N105Q, 114 =YB2-BALB/c Ly49B-N114Q, 177 =YB2-BALB/c Ly49B-N177Q.  
 
The results obtained for the non-reduced samples are somewhat contradictory to those 
obtained for the reduced samples.  The bands detected in YB2-BALB/c Ly49B-N94Q and 
YB2-BALBc Ly49B-N105Q lysates ran at a slightly lower position than the wild type 
BALB/c Ly49B, but the bands detected in YB2-BALB/c Ly49B-N114Q and YB2-BALB/c 
Ly49B-N177Q lysates appeared to run at a very similar position to the wild type.  This 
discrepancy might simply be due to the lower resolving capacity of high molecular weight 
species on 15 % acrylamide SDS-PAGE gels.    
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4.4. Differentially glycosylated Ly49B forms exist in native cells expressing 
Ly49B. 
Unlike other Ly49s, which are expressed on NK cells, Ly49B was found to be 
expressed predominantly on myeloid cells including monocytes and macrophages (Gays et al. 
2006).  However, Ly49B expression may be induced on the surface of mature NK cells 
cultured with IL-12 and IL-18 and on immature NK cells (Gays et al. 2006).  To check 
whether or not Ly49B expressed in native cells can be detected by Western blotting using 
anti-Ly49B mAbs and, if so, whether or not the banding pattern is similar to that detected in 
transfected cell lysates, C57 spleen (S) and bone marrow (BM) cells were cultured for 10 
days with macrophage colony stimulating factor (MCSF) to obtain cultures rich in 
macrophages (MQ).  One third of the MQ culture was then incubated for 2 days with either 
interferon alpha (IFN-α) or lipopolysaccharide (LPS), both of which have previously been 
shown to stimulate expression of Ly49B (Gays et al. 2006).  Next, Ly49B expression levels 
were assessed by flow cytometry, as shown in Figure 4.11.  The panels on the left hand side 
show scatter plots with gates surrounding the cells of interest and indicate that the cells 
exhibited high side light scattering, which is characteristic for myeloid cells.  The right hand 
panels show that the cells of interest expressed the F4/80 membrane protein on their surface; 
F4/80 being one of the best characterised murine macrophage and monocyte markers 
(McKnight et al. 1996).  The panels in the centre show that all of the MQ cells expressed low 
levels of Ly49B on their surfaces.    
Following flow cytometric analysis, the cells were lysed and examined by Western 
blotting.  Figure 4.12 shows N1176 biotin 2G4 blots of NR YB2/0 and YB2-C57 Ly49B-HA 
cell lysates, as well as samples containing lysates of IFN-α and LPS-treated C57 spleen and 
bone marrow cells.  Unexpectedly, a large band at ~80 kDa was detected in all of the non-
reduced and reduced native cells samples, which was not present in the YB2/0 or YB2-C57 
Ly49B-HA samples.  All of the non-reduced samples contained a non-specific band at ~75 
kDa.  The bands at ~110 kDa and ~150 kDa observed in the non-reduced samples, which 
were similar to Ly49B bands detected in transfected cell lysates, were revealed in native cell 
lysates after prolonged exposure (Figure 4.12 B).  The ~110 kDa band was stronger than that 
at ~150 kDa in all of the native cell lysate samples.  As well as the strong band at ~80 kDa, 
the reduced native cell samples also contained a very weak band at ~47 kDa (Figure 4.12 B).  
Collectively, these results suggest that Ly49B might exist in native cells predominantly as a 
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molecular form of ~80 kDa; this form does not exist in transfected cells and is not amendable 
to reduction.  The 110 kDa and 150 kDa non-reduced forms and the 47 kDa reduced form of 
Ly49B are also likely to exist in native cells but in much smaller proportions.  
 
Figure 4.11. Staining of C57 spleen and bone marrow (BM) macrophages with 2G4 anti-Ly49B antibody.  
C57 spleen and bone marrow cells were harvested and cultured with 5 % macrophage colony stimulating factor 
(MCSF) for 10 days.  The cells were then divided into three cultures, two of which were cultured for 2 days with 
either 10
4
 U/ml IFN-α or 2 mg/ml LPS.  Cells were then harvested and incubated with a saturating 
concentration of N415 2.4G2 anti-CD16/32 at a final dilution of 1/100 to block FcR, followed by N382 Biotin 
F4/80 at a final dilution of 1/500. The cultures were then divided into four samples, which were stained with the 
following: A) medium, B) medium, C) N1059 AF647 MR3 IgG2c isotype control at final 1/500 dilution, D) 
N1058 AF647 2G4 anti-Ly49B at final 1/500 dilution.  Samples B-D were additionally stained with N883 PE 
streptavidin at a final dilution of 1/1000.  In parallel with this, staining of two samples of YB2-C57 Ly49B-HA 
cells was performed with medium and N1058 AF647 2G4 anti-Ly49B a at final dilution of 1/500.  The black 
peaks in the “2G4 anti-Ly49B” histograms in the centre of the panel represent the medium control. The red 
peaks represent cells stained with 2G4 anti-Ly49B and the blue peaks cells stained with isotype control.  The 
black peaks in the “F4/80” histograms on the right hand side of the panel represent cells stained with F4/80 
followed by medium control and the red peaks cells stained with Biotin F4/80 followed by PE streptavidin.  Red 
numbers in the right hand corner of the histograms represent net median fluorescence values of the cells stained 
with the reagent indicated as red peaks and the blue numbers represent net median fluorescence values of the 
cells stained with the reagents indicated as blue peaks. 
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Figure 4.12. N1176 biotin 2G4 anti-Ly49B blot of NR and R cell lysates prepared from YB2/0, YB2-C57 
Ly49B-HA transfectants and C57 spleen and bone marrow cells cultured with MCSF followed  by either 
INF-α or LPS. YB2/0 and YB2-C57 Ly49B-HA cell lysates at 2000 cells/µl and C57 spleen and bone marrow 
cells cultured with MCSF followed by IFN-α or LPS at 5000 cells/µl were run for 1.5 h at 200 V on 15 % SDS-
PAGE gels and transferred for 15 min at 1.3 A and 25 V to nitrocellulose membranes using the Trans-Blot 
Turbo system.  Membranes were incubated overnight at 4 °C with N1176 biotin 2G4 anti-Ly49B antibody at 
1/2000 dilution followed incubation for 1 h at room temperature with N1194 HRPO anti-biotin antibody at 
1/2000 dilution.  Images were developed using Thermo ECL reagent for 5 min (A) and 20 min (B).  
M=molecular weight marker, NR=non-reduced, R=reduced, 0=YB2/0, BH=YB2-C57 Ly49B-HA, SP=spleen 
cells, BM=bone marrow cells, I=IFN-α, L=LPS. 
 
Figure 4.13 shows repeat flow cytometric staining of C57 spleen MQs with 2G4 anti-
Ly49B mAb (Figure 4.13 A) and staining of the BALB/c fetal liver NK cell line, LNK, using 
a variety of anti-Ly49 mAbs (Figure 4.13 B). The LNK cell line has previously been shown 
to contain Ly49B transcripts (Gays et al. 2006). 
The presence of Ly49B was detected in all of the tested samples of C57 spleen MQs 
(Figure 4.13 A).  The net median fluorescence value for IFN-α-treated C57 spleen MQs 
stained with 2G4 mAb was approximately twice that of LPS-treated and untreated 
counterparts, suggesting that Ly49B was up-regulated in the presence of IFN-α but not LPS.  
Only Ly49B and not any of the other tested Ly49s was shown to be expressed on LNK cells 
(Figure 4.13 B). 
 Western blot on NR YB2/0, YB2-Ly49B-HA, LNK cell lysates and cell lysates 
prepared from C57 spleen MQs, which were untreated or treated with either IFN-α or LPS 
was developed with N1176 biotin 2G4 anti-Ly49B or N869 biotin 1A1 anti-Ly49B, followed 
by N1194 HRPO anti-biotin antibody (Figure 4.14).  The YB2-C57 Ly49B-HA pattern with 
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three bands at ~110 kDa, ~150 kDa and ~200 kDa was observed for blots developed with the 
2G4 and 1A1 mAbs.   
 
 
Figure 4.13. Staining of C57 spleen macrophages with 2G4 anti-Ly49B antibody (A) and LNK cells with a 
variety of monoclonal anti-Ly49 antibodies (B).  A) C57 spleen cells were harvested and cultured with 5 % 
macrophage colony stimulating factor (MCSF) for 10 days.  The cells were split into three cultures, two of 
which were cultured for 2 days in the presence of 10
4
 U/ml IFN-α or 2 mg/ml LPS. Cells were then harvested 
and incubated with a saturating concentration of N415 2.4G2 anti-CD16/32 at a final dilution of 1/100 to block 
FcR followed by incubation with N382 Biotin F4/80 at a final dilution of 1/500. Cultures were further divided 
into four samples and stained with one of the following: A) medium, B) medium, C) N1059 AF647 MR3 IgG2c 
isotype control at final 1/500 dilution, D) N1058 AF647 2G4 anti-Ly49B at final 1/500 dilution.  Samples B-D 
were then stained with N883 PE streptavidin at a final dilution 1/1000.  In parallel, staining of two samples of 
YB2-C57 Ly49B-HA cells was performed with medium or N1058 AF647 2G4 anti-Ly49B at final dilution of 
1/500.  Black peaks in the “2G4 anti-Ly49B” histograms in the centre of the panel represent medium control, 
red peaks represent cells stained with 2G4 anti-Ly49B and blue peaks represent cells stained with isotype 
control.  The black peaks in the “F4/80” histograms on the right hand side of the panel represent cells stained 
with F4/80 followed by medium control and the red peaks cells stained with Biotin F4/80 followed by PE 
streptavidin.  Red numbers in the right hand corner of the histograms represent net median fluorescence values 
of the cells stained with the reagent indicated as red peaks and the blue numbers represent net median 
fluorescence values of the cells stained with the reagents indicated as blue peaks B) LNK cells were harvested 
and stained with a) medium, b) N538 JR9 anti-Ly49A at a final dilution of 1/1000, c) N156 4D11 anti-Ly49G at 
a final dilution of 1/10,000, d) N865 CM4 anti-Ly49E/F at a final dilution of 1/10, e) N837 2G4 anti-Ly49B at a 
final dilution of 1/30.  The cells were then stained with N1217 AF647 chicken anti-rat at a final dilution of 
1/1,000.  Black peaks in the histograms represent medium control and red peaks represent cells stained with the 
monoclonal anti-Ly49 antibodies. Red numbers in the right hand corner of the histograms represent net median 
fluorescence values of cells stained with monoclonal antibodies. 
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Figure 4.14. N1176 biotin 2G4 anti-Ly49B and N869 biotin 1A1 anti-Ly49B blots of NR cell lysates prepared 
from YB2/0, YB2-C57 Ly49B-HA transfectants, LNK cells and C57 spleen cells cultured with MCSF 
followed by INF-α or LPS. YB2/0 and YB2-C57 Ly49B-HA cell lysates at 2000 cells/µl and LNK cells and C57 
spleen cells cultured with MCSF followed  by either IFN-α or LPS  at 5000 cells/µl were run  for 40 min at 200 
V on 15 % SDS-PAGE gels and transferred for 1.5 h at 200 V onto nitrocellulose membranes using wet transfer 
method. Membranes were incubated overnight at 4 °C with N1176 biotin 2G4 anti-Ly49B antibody at 1/1000 
dilution or N869 biotin 1A1 anti-Ly49B at 1/250 dilution followed by N1194 HRPO anti-biotin antibody at 
1/2000 dilution for 1 h at room temperature.  Images were developed using Thermo ECL reagent for 1 min (A) 
and 15 min (B).  M=molecular weight marker, 0=YB2/0, BH=YB2-C57 Ly49B-HA, SP=spleen cells, I=IFN-α, 
L=LPS. 
 
The 2G4 blot of three MQ samples revealed a strong band at ~80 kDa and a weaker, 
slightly larger in size band, surprisingly neither of which was detected by 1A1 mAb, 
suggesting that these bands may not in fact have been Ly49B.  Longer exposure of the 2G4 
blot revealed two bands at ~110 kDa and ~150 kDa in the SPI sample.  Both bands are likely 
to represent Ly49B as they were also detected by 1A1.  The 1A1 mAb additionally detected a 
high molecular weight band at ~200 kDa (Figure 4.14 B).   
The longer exposure of the 1A1 blot revealed that Ly49B bands may be present in SP 
and SPL samples (Figure 4.14 B).  The fact that the SPI sample contains stronger bands than 
SP and SPL samples correlates with stronger 2G4 staining of this sample detected by flow 
cytometry (Figure 4.13 A).  All of the Ly49B bands detected in SP samples ran slightly faster 
than YB2-C57 Ly49B-HA sample, which was most likely due to the presence of the HA tag.  
The results obtained for spleen MQ samples suggest that Ly49B may be present in the same 
multiple molecular forms on native myeloid cells as observed in transfected cells.   
Consistent with the specificity of the 1A1 antibody for C57 Ly49B, no bands were 
detected in the BALB/c LNK sample on the blot developed with 1A1 (Figure 4.14).  The 
2G4 blot contained strong bands at ~80 kDa and one just above it.  These are unlikely to have 
been specific due to the fact they ran at similar positions to the non-specific bands that were 
detected in MQ samples.  In addition to these bands, a strong band was detected at ~145 kDa; 
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this position corresponds to the main NR band detected previously for BALB/c Ly49B in 
transfected YB2 cells (Figures 4.3 and 4.4).  It seems that, as with C57 spleen MQ cells, 
BALB/c Ly49B can be detected on Western blots in samples prepared from the fetal LNK 
cell line in a similar form to that found in transfected cells. 
4.5. NK cell receptors tend to exist in multiple molecular forms in YB2/0 
transfectants.  
The results obtained for Ly49B suggest that other Ly49 and NK cell receptors could exist 
in multiple molecular weight forms. To address this question, as well as to validate results 
obtained for Ly49B, four additional HA-tagged C57 Ly49s (A, E, G and Q) were transfected 
onto YB2/0 cells, as well as a HA-tagged Clrg receptor, which is encoded in the NK gene 
complex and, like the Ly49 receptors belongs to C-type lectin superfamily.  Cell lysate 
samples were prepared in parallel to Ly49B-HA lysate and examined by Western blot using 
N1229 biotin anti-HA antibody (Figure 4.15).   
4.5.1. Assessment of Ly49B molecular forms 
The results for YB2-C57 Ly49B-HA lysates were similar to those observed in 
previous experiments.  The non-reduced sample contained three strong bands at ~110 kDa, 
~150 kDa and ~200 kDa.  The reduced sample contained two bands at ~47 kDa and ~55 kDa 
and very weak bands at ~110 kDa, ~150 kDa and ~ 200 kDa, which was most likely residual 
non-reduced material. 
4.5.2. Assessment of Ly49A molecular forms 
The samples containing non-reduced YB2-Ly49A-HA lysate contained a relatively 
weak band at ~80 kDa, and a particularly strong band between 100-140 kDa.  The reduced 
sample contained a very weak band of ~80 kDa, a prominent band between 50 and 60 kDa, a 
weak band at ~49 kDa and a moderate intensity band slightly greater than 40 kDa.  The band 
at ~80 kDa could be residual non-reduced material or simply a non-specific band, since a 
band of a similar size was detected in YB2/0 lysates.   
As described in the introduction, there was some discrepancy between the Ly49A 
monomer and dimer sizes identified by previous studies using Western blotting, but generally, 
there was only one band observed for the Ly49A monomer and one for the Ly49A dimer 
(Takei 1983, Chan et al. 1986, Chan et al. 1988, Nagasawa et al. 1987, Mason et al. 1996, 
134 
 
Ortaldo et al. 1999, Roland et al. 1992, Yokoyama et al. 1989, Chang et al. 1996).  The 
monomer size was in the range of 42-55 kDa and the dimer in the range of 82-95 kDa.   
 
Figure 4.15. N1229 biotin anti-HA blot of NR and R YB2-C57 Ly49B-HA, YB2-Ly49A-HA, YB2-Ly49E-HA, 
YB2-Ly49G-HA, YB2-Ly49Q-HA and YB2-Clrg-HA cell lysates. YB2-C57 Ly49B-HA, YB2-Ly49A-HA, YB2-
Ly49E-HA, YB2-Ly49G-HA, YB2-Ly49Q-HA and YB2-Clrg-HA lysates (all at 2000 cells/µl, except for YB2-
Ly49G-HA and YB2-Clrg-HA, which were both at 8000 cells/µl)  were run  for 1.5 h at 200 V on 15 % SDS-
PAGE gels and transferred for 1.5 h at 200 V to nitrocellulose membranes by wet transfer.  Membranes were 
incubated overnight at 4 °C with N1229 biotin anti-HA antibody at 1/25,000 dilution and then for 1 h at room 
temperature with N1194 HRPO anti-biotin antibody at 1/2500 dilution.  Images were developed using Pierce 
ECL reagent for 1 min (A) and 15 min (B).  M=molecular weight marker, NR=non-reduced, R=reduced, 
B=YB2-C57 Ly49B-HA, A=YB2-Ly49A-HA, E=YB2-Ly49E-HA, G=YB2-Ly49G-HA, Q=YB2-Ly49Q-HA, 
Clrg=YB2-Clrg-HA, 0=YB2/0. 
 
4.5.3. Assessment of Ly49G molecular forms 
The non-reduced sample of YB2-Ly49G-HA lysate contained a clear high molecular 
weight band of ~200 kDa and two bands at ~100 kDa and ~92 kDa.  Longer exposure 
revealed two bands of ~40 kDa in close proximity to one another, suggesting that Ly49G 
might exist as a monomer in living cells. The reduced sample contained prominent bands at 
~40 kDa and ~200 kDa, as well as a very weak band at ~ 80 kDa, which may simply be non-
specific since a band of similar size was also detected in YB2/0 cells.  Previous studies have 
found bands of 40 kDa or 43 kDa in reduced samples of Ly49G and bands of 86 kDa or 97-
110 kDa in non-reduced samples (Mason et al. 1996, Ortaldo et al. 1999, Mason et al. 1988, 
Chang et al. 1999).   
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4.5.4. Assessment of Ly49Q molecular forms 
The non-reduced sample of YB2-Ly49Q-HA lysate contained a prominent band of 
~100 kDa, which upon longer exposure stretched between ~80-140 kDa.  The reduced sample 
of Ly49Q-HA contained two dispersed bands between at ~45 kDa and 55 kDa.  A previous 
study identified a reduced band at ~45-60 kDa and non-reduced bands of ~130 kDa and ~200 
kDa (Toyama-Sorimachi et al. 2004).  Interestingly, a different study identified a relatively 
well defined band of ~82 kDa in non-reduced samples (Scarpellino et al. 2007).  
4.5.5. Assessment of Clrg molecular forms 
Two bands were observed for the reduced sample of YB2-Clrg-HA lysate at ~35 kDa 
and ~38 kDa.  The non-reduced sample contained two bands at ~77 kDa and ~200 kDa.  
4.5.6. Assessment of Ly49E molecular forms 
The non-reduced YB2-Ly49E-HA lysate sample contained one clearly defined band at 
~90 kDa, which agrees well with previously published data (Van Beneden et al. 2001).  An 
additional a strong band of between 100 kDa and 140 kDa was also clearly visible.  
Unexpectedly, the reduced sample contained prominent bands at similar positions to those 
found in the non-reduced sample, suggesting that Ly49E may be more resistant to 2ME 
treatment that other Ly49s.  An additional band of moderate intensity was observed at ~39 
kDa, as well as a very weak band at ~49 kDa.  A band was previously observed in reduced 
samples of Ly49E at ~46 kDa (Van Beneden et al. 2001).  
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Figure 4.16. Western blot of biotinylated NR C57 Ly49B-HA and Ly49E-HA immunoprecipitated from YB2-
C57 Ly49B-HA lysates or YB2-Ly49E-HA lysates respectively, using protein G beads coated with anti-HA 
antibody. Samples of immunoprecipitated material prepared from biotinylated and non-biotinylated YB2-C57 
Ly49B-HA or YB2-Ly49E-HA lysates at 2000 cells/µl using sepharose protein G beads coated with N1184 2G4 
rat anti-Ly49B or N1141 CM4 anti-Ly49E/F were run in duplicates for 1.5 h at 200 V on 15 % SDS-PAGE gels 
and transferred for 17 min at 1.3 A and 25 V to nitrocellulose membranes using the Trans-Blot Turbo system.  
Membranes were incubated overnight at 4 °C with N1229 biotin anti-HA antibody at 1/10.000 dilution or PBS 
and then for 1 h at room temperature with N1243 HRPO anti-biotin antibody at 1/1000 dilution.  Images were 
developed using Thermo ECL reagent for A) 5 min B) 2min C) 20sec.  M=molecular weight marker, NR=non-
reduced, Biotin Anti-HA=N1229 biotin anti-HA, Anti-Biotin HRPO=N1243 HRPO anti-biotin, B=biotinylated, 
NB=non-biotinylated, BH=C57 Ly49B-HA, EH=Ly49E-HA. 
 
To extend the analysis of multiple molecular forms of NK cell receptors, surface 
biotinylated and non-biotinylated YB2-Ly49E-HA and YB2-C57 Ly49B-HA cells were lysed 
and examined by Western blotting.  Membranes containing NR lysate samples were 
incubated with anti-HA HRPO in conjunction with biotin anti-HA or PBS control (Figure 
4.16).  Results obtained for Ly49B-HA samples were similar to those shown in Figure 4.8.  
No bands were observed in the non-biotinylated YB2-Ly49E-HA sample tested with anti-
biotin antibody alone.  The equivalent biotinylated YB2-Ly49E-HA sample contained one 
band at ~140 kDa.  Both biotinylated and non-biotinylated YB2-Ly49E-HA samples tested 
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with anti-biotin antibody in conjunction with anti-HA antibody contained two bands at ~140 
kDa and ~90 kDa.  These results suggest that, as with Ly49B, the smallest non-reduced 
molecular form of Ly49E observed on Western blots is likely to be intracellular, whereas the 
larger one appears to be surface-associated.  A more comprehensive analysis of the individual 
NK cell receptors is required to formally establish whether or not the multiple molecular 
weight forms detected by Western blotting in Figure 4.15 represent the receptors at different 
stages of glycosylation.   
4.6. Summary 
The results presented here suggest that Ly49B monomers have a tendency to form 
homodimers or associations with other proteins through the formation of disulphide bonds.  
The large molecular weight band observed in some of the experiments indicates that Ly49B 
may also form multimers under certain circumstances.  The visualisation of a monomeric 
form of Ly49B in some of the non-reduced samples represents an important observation and 
suggests that Ly49B may exist as a monomer in endogenous cells. 
Ly49B monomers and dimers appeared in Western blots as multiple bands.  Analyses 
of Ly49B glycosylation mutants and of wild type protein digested with PNGase revealed that 
the multiple molecular forms of Ly49B represent the receptor at different stages of N-
glycosylation. Digestion with high-mannose-specific Endo-H enzyme and surface 
biotinylation experiments revealed that the smallest molecular weight form in the reduced 
and non-reduced samples represent immature, intracellular forms of the receptor, while the 
larger species represent mature, surface-associated proteins.  Both forms were identified in 
transfected and native cells. 
Preliminary results indicate that immature, intracellular and mature, extracellular 
forms of other Ly49s and also perhaps other NK cell receptors may be detectable in Western 
blot experiments.  Detailed analysis of individual receptors using immunoprecipitation, 
surface labelling and Endo-H digestion is required to unambiguously establish whether or not 
this is the case. 
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Chapter 5. Purification and refolding of Ly49B. 
 
5.1. Introduction 
 
Protein crystallisation is an inherently challenging process, requiring milligram 
quantities of pure, homogeneous, correctly folded protein.  Certain features make some 
proteins harder to crystallise than others, including flexible, dynamic domains, post-
translational modifications, a tendency to multimerise and existing natively in a 
transmembrane state; features which all apply to Ly49 receptors.  In spite of this, crystal 
structures of Ly49A, Ly49C, Ly49G, Ly49I, and Ly49L have been solved to date (Tormo, et 
al. 1999; Deng et al. 2008; Dimasi et al. 2002; Back et al. 2009). 
 As outlined in Section 1.8. structure of Ly49B may differ significantly from other 
Ly49s and it would be advantageous to obtain its crystal structure in order to understand its 
biochemistry.  In this chapter a method is described for obtaining pure, correctly folded 
Ly49B with the potential for use in crystallisation.  The method involves cloning of the 
extracellular portion of Ly49B, followed by optimisation and implementation of an E. coli 
expression system.  Procedures for isolation, solubilisation and refolding of Ly49B from 
bacterial inclusion bodies are outlined.  Next, the purification using gel filtration, anion 
exchange and/or affinity chromatography is described.  Finally, an immunoassay and circular 
dichroism were employed to assess the integrity of the re-folded protein. 
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5.2. Construct design and cloning 
 
 The Ly49B constructs used in this study were designed based on strategies applied to 
other Ly49s that have been crystallised to date.  In the majority of previous studies the full 
length extracellular (EC) portion of the protein has been used, but the stalk region was 
problematic for crystallization, most likely due to its inherent flexibility.  The first Ly49 
crystal structure to be solved, Ly49A, contained only the natural killer domain (NKD), which 
was obtained by limited proteolysis of the refolded full length EC portion (Tormo et al. 
1999).  Since then, subsequent attempts to crystallise Ly49s have all included both the full 
length EC portion and the truncated NKD homologous to that of Ly49A.  It has proven 
possible to crystallise the full length EC portion of some Ly49s (Deng et al. 2008).  However, 
the diffraction pattern of the stalk region was obtained only for Ly49L and, even then, it 
contained only a fraction of the stalk (Back et al. 2009).  Therefore, two sets of constructs 
were prepared for crystallisation of Ly49B; one containing the full length EC portion and one 
containing just the NKD sequence and cloned to pET24a vector. 
Table 5.1. Ly49B constructs designed for this study.  Full sequences of primers are listed in the materials and 
methods. 
Construct number Construct name 
 
Primers used for 
amplification 
Construct 
size (bp) 
Approximate 
protein size (kDa) 
1A Ly49B EC C57 KP1, KP5 675 28 
1B Ly49B ECFX C57 KP2, KP5 687 29 
1C  Ly49B NKD C57 KP3, KP5 462 18 
1D Ly49B NKDFX C57 KP4, KP5 474 19 
2A Ly49B EC BALB/c KP1, KP5 675 28 
2B Ly49B ECFX BALB/c KP2, KP5 687 29 
2C Ly49B NKD BALB/c KP3, KP5 462 18 
2D Ly49B NKDFX BALB/c KP4, KP5 474 19 
 
 To simplify the purification process, an additional set of homologous constructs was 
designed to incorporate the N-terminal polyhistidine (His) tag encoded by pET28b.  The 
primers used for amplification of these constructs contained sequences corresponding to the 
Factor Xa cleavage site directly upstream from the start of the EC and NKD sequences, to 
facilitate removal of the His-tag and any extra residues encoded by pET28b between the tag 
and the NdeI cloning site. 
 Since comparison of the Ly49Bs from C57 and BALB/c strains is one of the key aims 
of this project, it was also necessary to prepare constructs using DNA from both of these 
strains.  The primers designed for amplification of the EC and NKD regions of C57 Ly49B 
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were aligned against the BALB/c sequence and showed 100 % homology, so it was possible 
to use the same primers for amplification of both constructs.  The 8 constructs required for 
this study are summarised in Table 5.1. 
The constructs above were successfully amplified from the plasmids containing full 
length C57 and BALB/c Ly49B, then visualised by agarose gel electrophoresis (Figure 5.1).  
After setting up cloning reactions, the plasmids were amplified, purified and subjected to 
double restriction digests to produce unique restriction patterns characteristic for plasmids 
containing the cloned sequences or not (Figure 5.2).  Positive clones were sent for 
sequencing to confirm the presence and integrity of the cloned regions.  All of the constructs 
cloned into pET24a were found to possess the correct sequences.  However, of the constructs 
that were cloned into pET28b only Ly49B ECFX C57 was correct.  All of the remaining 
pET28b constructs had additional bases incorporated between the His-tag sequence and that 
of the construct, resulting in frame shift mutations which rendered the constructs unusable for 
protein expression.  Several attempts were made to produce the correct pET28b constructs 
but all were unsuccessful.  Since the extra bases seemed to originate from the primer 
sequences upstream of the NdeI restriction site, it was speculated that the NdeI enzyme may 
have been cleaving the construct at the incorrect site.  Unfortunately, even after using a new 
stock of NdeI the extra bases were still present.  Due to time constraints, expression 
experiments were therefore carried out using the pET24a constructs and the one intact 
pET28b construct. 
 
 
 
 
Figure 5.1. Verification of PCR amplification of C57 constructs by agarose gel electrophoresis.  M indicates 
the lane containing the DNA ladder with some of the main band sizes highlighted on the left.  Analogous 
verification was also performed for BALB/c constructs. Ly49B EC C57 construct contains full length 
extracellular portion of Ly49B (675 bp), Ly49B ECFX C57 contains full length extracellular portion of Ly49B 
and  Factor Xa cleavage site (687 bp), Ly49B NKD C57 contains only NK domain (642 bp) and Ly49B NKDFX 
C57 construct contains NK domain and Factor Xa cleavage site (474 bp). 
 
 
141 
 
 
 
 
 
Figure 5.2. Restriction patterns of Pvu II/Sal I - digested pET28b plasmids with and without the NKDFx C57 
insert.  Plasmids containing the construct are recognisable due to the 450 bp shift in the middle band.  Plasmid 
preps of clones 2, 3, 4 and 5 were all found to contain the desired constructs.  Clone numbers are indicated 
along the top from 1-10.  M indicates the DNA ladder with some of the main increments shown on the left.  The 
sizes of the bands of the digested plasmids are shown on the right with critical bands highlighted in red. 
 
5.3. Ly49B expression 
 Expression of heterologous recombinant proteins can be an extremely challenging 
process, the success of which is often dependent upon the selection of an appropriate 
expression system.  The most commonly exploited and best understood involves utilising E. 
coli strains, such as those listed in the Materials and Methods.  The main advantages of such 
systems include high yields of recombinant protein, the ease and speed of cultivation and the 
tight control over protein expression (Zerbs et al. 2009).  
However, using E. coli for expression of complex eukaryotic proteins such as Ly49s 
can be problematic, as bacteria do not support a number of processes specific to higher 
organisms, including the formation of disulphide bonds and post-translational modifications 
such as glycosylation.  Basic bacterial expression systems also lack chaperones that may be 
needed for correct folding of some proteins.  Consequently, the expression of eukaryotic 
proteins in E. coli often leads to the formation of insoluble inclusion bodies (IBs) in the 
cytoplasm or periplasm of the bacterium (Pain 1996; Burgess 2009; Arie et al. 2006).  In such 
cases, the expressed protein is packed into high density structures, which are held together by 
non-covalent interactions, and are clearly visible under a light microscope.  Although the 
conformation of proteins contained within IBs is not completely random, it is usually far 
from the native form.  To obtain the protein in the native conformation, it is necessary to 
denature and refold the protein, which can be extremely problematic.  For instance, IBs can 
be difficult to disrupt and establishing the correct conditions under which the protein readily 
refolds into its native state is both time-consuming and labour-intensive.  Furthermore, the 
yields obtained on recovery from inclusion bodies are typically very low, so downstream 
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applications, like crystallisation, which require large amounts of protein are compromised. 
One advantage of extracting proteins from IBs is the relative ease of isolation from 
endogenous bacterial proteins, which can be achieved quite simply by multiple rounds of 
centrifugation, because IBs are denser than the other components of the cell.  
Alternative expression systems to E. coli include yeast, insect or mammalian cell 
lines, or even cell-free expression systems (Cregg et al. 2009; Geisse and Fux 2009; Goren et 
al. 2009; Jarvis 2009).  The main advantages of these systems are the production of soluble 
protein, rather than inclusion bodies, and the ability to carry out post-translational 
modifications.  However, such systems are not without their drawbacks; yields are typically 
very low and the processes are time consuming.  Moreover, eukaryotic cell cultures can be 
difficult to maintain, often requiring specialist equipment.  
Taking into account the above considerations, and the fact that all Ly49s crystallised 
to date have been expressed recombinantly in E. coli, a bacterial system was also chosen for 
Ly49B.  The candidate strains that were screened for suitability included the standard 
expression strain E. coli BL21 and a number of its derivatives.  All were compatible with the 
pET vector expression system. 
Several strains were tested on a small scale to establish which one gave the highest 
protein yield and whether or not Ly49B was expressed in E. coli in the soluble fraction, rather 
than as inclusion bodies.  E.coli BL21 CodonPlus (RIL) was chosen for initial tests as it 
contains extra copies of the genes that encode rare tRNAs that most frequently limit 
translation of eukaryotic proteins in E. coli.  In addition, the BL21 Tuner strain, which 
contains a mutation in the permease gene resulting in homogenous IPTG uptake by all 
bacteria in the population, and the Origami 2 strain, which facilitates formation of disulphide 
bonds in the bacterial cytoplasm, were chosen for expression trails.  Unfortunately, none of 
the strains were able to produce soluble Ly49B.  Phase contrast microscopy image shown in 
Figure 5.3 illustrated that Ly49B accumulated in the cytoplasm of the bacteria in the form of 
inclusion bodies.  Comparison of the micrographs of induced and uninduced cells revealed 
low levels of Ly49B expression even without induction by IPTG, probably because of the 
inherently leaky T7 promoter.  These results suggest that Ly49B has no observable toxic 
effect on the bacterium.  
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Figure 5.3. Phase contrast image of induced and non-induced E.coli BL21(DE3)Tuner cells transfected with 
an expression plasmid encoding Ly49B. The inclusion bodies marked with red arrow are visible as dark 
clusters inside the cells. Some of the non-induced bacteria contain inclusion bodies due to inherently leaky T7 
promoter.  
Since the expression of recombinant proteins is known to be greatly affected by 
growth conditions, the strains were tested using different IPTG levels, variable lengths of 
induction and a range of temperatures.  Induction of Ly49B expression with different levels 
of IPTG (0.1 mM to 1 mM) had no observable effect on the amount of protein produced in 
any of the strains tested (Figure 5.4).  There was also little observable difference between 
expression levels at different time points post-expression at 30˚C (1-6 hours and overnight).  
Dropping the temperature to 16 °C did not improve expression levels; it simply increased the 
time required for the culture to reach a suitable density for harvesting (~16 hours).  The 
expression levels were similar for all of the constructs in all of the strains tested, but the E. 
coli Tuner strain gave the most consistent results and was therefore chosen for large scale 
experiments.   
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Figure 5.4. Ly49B expression test in BL21 Tuner and Origami 2 E.coli stains with varing amounts of IPTG.  
10 ml cultures of E.coli BL21 Tuner and E.coli Origami 2 strains transformed with pET28 Ly49B ECFx C57 
plasmid were grown at 37 °C, 200 rpm, until OD reached 0.6. The cultures were then inoculated with 0.1, 0.5 or 
1 mM IPTG and incubated for 15 h at 16 °C, 200 rpm. 1 ml samples were harvested, disrupted by sonication 
and analysed on 15 % SDS-PAGE.   S=soluble fraction, I=insoluble fraction, M= molecular weight marker, 
T0=before induction with IPTG, T15=15h post-induction with IPTG, 1, 0.5, 0.1=concentration of IPTG in mM.  
 
 
 
5.4. Crude purification and solubilisation of Ly49B from inclusion bodies 
The first construct to be expressed on a large scale was Ly49B EC C57 (Figure 5.5) 
following the small-scale expression procedure.  Transformed BL21 Tuner cells were grown 
under selective conditions in 2 l of LB broth at 37 °C until the A600 reached 0.6.  The 
temperature was then dropped to 30˚C and the cells induced with 1 mM IPTG for 3 hours.  
Cells were harvested by centrifugation, resuspended in 1xPBS buffer and the culture was 
disrupted by sonication.   
 
 
 
 
 
Figure 5.5. Expression of Ly49B EC C57 in E. coli BL21 
Tuner strain. S=soluble fraction, I=insoluble fraction, T0-
=before induction with IPTG, T3= 3 h post-induction with IPTG, 
M= molecular weight marker 
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The cell membranes and soluble proteins were removed by performing multiple 
rounds of washing in Triton X-100 buffer (0.5 % Triton X-100, 50 mM Tris (pH8.0), 100 
mM NaCl) followed by homogenisation and centrifugation.  To avoid any possibility that 
Triton X-100 could interfere with protein folding, an extra wash was performed using 
detergent free buffer.  The bacterial proteins were progressively removed from the Ly49B 
preparation at each wash step (Figure 5.6).  After the last wash step Ly49B was solubilised 
and the disulphide bonds were reduced.  Measurement of the optical density at 280 nm at this 
point indicated that roughly 150 mg of total protein was recovered from 2 l of culture.  
 
Figure 5.6. Preparation of Ly49B inclusion bodies. M- molecular weight marker, I- insoluble fraction before 
washing, 1-6 subsequent washing steps (soluble material in the supernatant), 7I-insoluble fraction in wash 7, G-
Ly49B solubilised in guanidine 
5.5. Development of refolding strategy. 
 Appropriate conditions for protein refolding need to be determined empirically.  For 
instance, the methods used in the respective publications for Ly49 proteins are summarised in 
Table 5.2. In general, the refolding steps for Ly49 receptors listed in Table 5.2 involved 
reoxidation of intrachain disulphide bonds in the presence of glutathione (5 mM oxidised and 
0.5 mM reduced or 0.8 mM oxidised and 3 mM reduced) and dilution into 400-600 mM L-
arginine to help prevent protein aggregation.  In the case of Ly49I this process was carried 
out over 48 hours at 4 °C.  The Ly49I refolding buffer also contained 2 mM EDTA to chelate 
any divalent cations that could promote proteolysis by contaminant proteases and the Ly49L 
refolding buffer contained 30 % (v/v) glycerol to prevent aggregation. 
In the next step Ly49 refolding solutions were dialyzed at 4 °C into 25 mM Tris-HCl 
(pH8.0) and 150 mM NaCl or 25 mM MES (pH 5.5) and 150 mM NaCl.  The presence of 
NaCl provided ionic strength to the solution, inhibited ionic interactions and suppressed 
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aggregation.  In all cases, the Ly49 receptors were purified using size exclusion columns 
and/or by ion exchange affinity chromatography. 
Table 5.2. Methods used to solubilise, refold and purify Ly49 receptors.  
Receptor Solubilisation and 
denaturation 
Refolding Purification Reference 
Ly49A 6 M guanidine 
hydrochloride (GuHCL), 
0.1 mM DTT 
Reoxidation in the presence 
of  glutathione (5 mM 
oxidised and 0.5 mM 
reduced)  and dilution into 
0.4 M L-arginine, Dialysis to 
TBS (25 mM Tris HCL pH8 
and 150 mM NaCl) 
Affinity 
chromatography,  
Anion exchange 
chromatography, 
Size exclusion 
chromatography 
Tormo et 
al.1999 
Ly49C 6 M guanidine 
hydrochloride (GuHCL), 
0.1 mM DTT 
Reoxidation in the presence 
of  glutathione (5 mM 
oxidised and 0.5 mM 
reduced)  and dilution into 
0.4 M L-arginine, Dialysis to 
TBS (25 mM Tris HCL pH8 
and 150 mM NaCl) 
Anion-exchange 
chromatography, 
Size exclusion 
chromatography 
Deng et 
al. 2008 
Ly49G 6 M guanidine 
hydrochloride (GuHCL), 
0.1 mM DTT 
Reoxidation in the presence 
of  glutathione (5 mM 
oxidised and 0.5 mM 
reduced)  and dilution into 
0.4 M L-arginine, Dialysis to 
TBS (25 mM Tris HCL pH8 
and 150 mM NaCl) 
Anion-exchange 
chromatography, 
Size exclusion 
chromatography 
Deng et 
al. 2008 
Ly49I 4 washes with 50 mM Tris 
HCl (pH 8),0.5 % Triton-
X-100, 100 mM NaCl, 1 
mM EDTA, 1 mM DTT, 
one wash with the same 
buffer + 2 M urea. 
Solubilisation into 100 
mM Tris, 6 M guanidine, 
10 mM EDTA and 0.1 mM 
DTT 
Folding in vitro at 4 C by 
slow dilution into 1 l of 0.6 
M arginine, 100 mM Tris –
HCl (pH 8), 2 mM EDTA, 5 
mM reduced glutathione and 
0.5 mM oxidised 
glutathione. After 48 h, the 
folding mixture was 
concentrated to a volume of 
30 ml and dialyzed at 4 C 
against 25 mM Mes  (pH 
5.5) ,150 mM NaCl 
Size-exclusion 
chromatography, 
Anion-exchange 
chromatography 
Dimasi et 
al. 2002 
Ly49L 6 M guanidine  Dilution into 30 % glycerol, 
0.4 M arginine, 3 mM 
reduced glutathione and 0.8 
mM oxidised glutathione   
Ion exchange 
chromatography, 
Size exclusion 
chromatography 
Back et 
al. 2009 
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The difference in sequence and function of Ly49B compared to other Ly49s indicates 
the conditions required for its refolding will also differ.  Nevertheless, the protocols used to 
refold other Ly49s provided guidance for developing a protocol for Ly49B, which will be 
outlined below. 
 
Attempt #1 
Figure 5.7. Refolding and purification of Ly49B 
using rapid dilution and gel filtration.  2 ml of 
Ly49B EC C57 solubilised in denaturing buffer (6 M 
guanidine hydrochloride, 50 mM Tris (pH 8.0), 100 
mM NaCl, 10 mM EDTA) at a concentration of 20 
mg/ml was added drop wise to 500 ml of refolding 
buffer 1 (Materials and Methods, Table 2.7) with 
continuous stirring, and incubated for 16 h at 4 °C.  
The protein was then concentrated to 2 ml volume 
using 50 ml Centricon concentrator (Vivacel) with a 
10 kDa MW cut off.  The concentrated Ly49B was 
applied to a pre-equilibrated Superdex-75 10/300 gel 
filtration column (GE Healthcare) attached to an 
ÄKTA chromatographic system (GE Healthcare) with 
buffer containing 200 mM NaCl and 50 mM Tris 
(pH8.0) at 0.5 ml/min. 3 ml eluted fractions were 
collected and analysed for UV absorbance. Centricon 
image adapted from http://www.labplus.co.kr, 
Superdex-75 10/300 column image adapted from 
http://chromatography-online.co.uk.  
 
The first attempt to refold and purify Ly49B is described in detail in Figure 5.7.  A 2 
ml aliquot of Ly49B EC C57, solubilised in denaturing buffer, was refolded by rapid dilution 
into 500 ml of refolding buffer 1 (see Materials and Methods) and incubated for 16 hours at 
4˚C with continuous stirring.  The sample was then concentrated to 2 ml volume using a 
Centricon concentrator to enable purification by gel filtration.  Unfortunately, the 
concentration step was extremely time-consuming due to the filter becoming increasingly 
blocked.  Furthermore, based on the A280 reading, approximately 50 % of the protein was lost 
during this step; presumably due to precipitation on the Centricon membrane.  The remaining 
sample was purified by size exclusion using a Superdex-75 gel filtration column.  The 
correctly folded Ly49B monomer was expected to elute in the time predicted for a protein of 
roughly 30 kDa, indicated by a clear, sharp peak on the UV absorbance (A280) trace.  The 
aggregated protein was predicted to elute in the void volume. Unfortunately, as shown on 
Figure 5.8, virtually all of the protein was lost during purification. 
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500ml
16h 4°C
Rapid dilution
Concentration 
Gel filtration 
chromatography
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Figure 5.8. Size exclusion chromatographic purification of refolded Ly49B EC C57.  Aggregated protein was 
eluted in the void volume.  Ly49B produced two negligible peaks.  The fractions with greatest UV absorbance 
comprised nucleotides, which were not removed during the wash step and eluted due to the change in 
conductivity  
 
Attempt #2 
Figure 5.9 describes details of the second attempt to refold and purify Ly49B.  Ly49B 
ECFX C57, expressed with an N-terminal His-tag, was solubilised in denaturing buffer.  To 
avoid the problems previously encountered when concentrating a large volume of protein 
solution, refolding was performed by dialysis rather than rapid dilution.   Based on the A280 
reading, approximately 20 % of the protein precipitated during dialysis.  Use was made of the 
construct’s poly-histidine tag, by incorporating an additional purification step.  Affinity 
chromatography was performed using a nickel-charged HiTrap chelating column and the 
samples were analysed by SDS-PAGE (Figure 10).   
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Figure 5.9. Refolding and purification of Ly49B by dialysis, affinity chromatography and gel filtration 
chromatography. 2 ml of Ly49B ECFX C57, solubilised in denaturing buffer (6 M guanidine hydrochloride, 50 
mM Tris (pH 8.0), 100 mM NaCl,), was dialysed with continuous stirring for 16 h at 4 °C into 500 ml of 
refolding buffer 1 (Materials and Methods, Table 2.7). The protein solution was applied at 1 ml/min to a pre-
equilibrated nickel-charged 5 ml HiTrap Chelating HP column (GE Healthcare) attached to an ÄKTA 
chromatographic system and eluted over a linear 30 ml gradient of 0-500 mM imidazole in 25 mM Tris-HCl 
(pH 8.0), 500 mM NaCl at 1 ml/min. 3 ml fractions were collected, analysed by SDS-PGAE and the peak 
fractions were pooled together and concentrated to 2 ml volume using a 50 ml Centricon concentrator (Vivacel) 
with a 10 kDa MW cut off insert.  Ly49B was purified using a pre-equilibrated Superdex-75 10/300 gel filtration 
column (GE Healthcare) attached to an ÄKTA chromatographic system (GE Healthcare) with buffer containing 
200 mM NaCl and 50 mM Tris (pH 8.0) at 0.5 ml/min. 3 ml fractions were collected following purification. 
Centricon image adapted from http://www.labplus.co.kr , Superdex-75 10/300 column image adapted from 
http://chromatography-online.co.uk, Hi-Trap Chelating HP column image adapted from 
http://www.gelifesciences.com 
 
 
Figure 5.10. 10 % SDS analysis of Ly49B ECFX C57 purified 
by affinity chromatography.  M=molecular weight marker, 13-
19=numbers of fractions containing Ly49 
 
 
 
Following purification on the chelating column, 3x3 ml eluted protein fractions were 
pooled together and Ly49B was purified by gel filtration as described in the Materials and 
Methods.  Unfortunately, the purified Ly49B appeared to be incorrectly folded as the UV 
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absorbance spectrum showed broad, irregular peaks.  Moreover, the amount of protein 
recovered was negligible. 
Attempt #3 
 
Figure 5.11. Refolding of Ly49B by dialysis, affinity chromatography and gel filtration chromatography. 2 ml 
of Ly49B ECFX C57, solubilised in denaturing buffer (6 M guanidine hydrochloride, 50 mM Tris (pH 8.0), 100 
mM NaCl,), was dialysed with stirring for 16 h at 4 °C into 500 ml of refolding buffer 1 (Materials and 
Methods, Table 2.7). The protein solution was applied at 1 ml/min to a pre-equilibrated nickel-charged 5 ml 
HiTrap Chelating HP column (GE Healthcare) attached to an ÄKTA chromatographic system and eluted over a 
linear 30 ml gradient of 0-500 mM imidazole in 25 mM Tris-HCl (pH 8.0), 500 mM NaCl at 1 ml/min.  3 ml 
fractions were collected; the peak fractions were pooled together and dialysed with continuous stirring for 16 h 
at 4 °C into 1 l of gel filtration buffer containing 200 mM NaCl and 50 mM Tris (pH 8.0).  Ly49B was then 
concentrated to 2 ml volume using a 50 ml Centricon concentrator (Vivacel) with a 10 kDa MW cut off insert 
and purified using a pre-equilibrated Superdex-75 10/300 gel filtration column (GE Healthcare) attached to an 
ÄKTA chromatographic system (GE Healthcare) at 0.5 ml/min. 3 ml fractions were collected following 
purification and the peak fractions were analysed by 15 % SDS-PAGE. Centricon image adapted from 
http://www.labplus.co.kr , Superdex-75 10/300 column image adapted from http://chromatography-online.co.uk, 
Hi-Trap Chelating HP column image adapted from http://www.gelifesciences.com. 
 
It is possible that the second attempt failed because the protein aggregated under gel 
filtration conditions.  In the next attempt (described in Figure 5.11) the His tag-purified 
preparation of Ly49B ECFX C57 was first dialysed into gel filtration buffer over 16 hours, 
which was gentler method to mix the protein with gel filtration buffer.  However, ~90 % of 
the protein still precipitated.  The remaining protein was purified by gel filtration using the 
S75 column, as previously described.  Figure 5.12 shows that Ly49B ECFX C57 eluted over 
7x3 ml fractions 65-85 minutes post-injection.  
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Figure 5.12. Gel filtration of Ly49B ECFX C57  
 
Two predominant peaks were present on the trace at 75 and 85 minutes, most likely 
representing Ly49B dimer and monomer populations respectively. The fractions were 
analysed by 15 % SDS-PAGE (Figure 5.13) and pooled giving a total of 400 µg of Ly49B, 
which was insufficient for crystallisation.  However, the apparent purity and integrity of the 
protein meant that it was suitable for the developing of an assay to assess whether or not the 
Ly49B preparation was folded correctly.  
 
Figure 5.13. 15 % SDS-PAGE analysis of Ly49B ECFX C57 purified by gel filtration. M=molecular weight 
marker, 9-16=numbers of fractions containing Ly49B. 
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Subsequent attempts  
Numerous other refolding attempts were made using a range of buffers (described in 
Materials and Methods Table 4), varying the starting amount of protein (from 7 mg to 100 
mg), refolding by dialysis or rapid dilution and concentrating using a large scale concentrator, 
rather than a Centricon.  Different constructs were tested and ion exchange columns used 
with untagged constructs.  However, all of these strategies gave low yields due to protein 
aggregation and the production of partially-folded or incorrectly folded Ly49B.  
Nevertheless, it was possible to set up preliminary crystallisation screens in 96 well formats.  
Ly49B NKD C57 protein concentrated to 4 mg/ml and 5.6 mg/ml was screened for 
crystallisation using JCSG, PACT and STRUCTURE pre-made grid screens (Molecular 
Dimensions), set up in sitting drops using the Mosquito Crystallisation robot (TTPLabtech).  
Ly49B EC C57 protein was also subjected to crystallisation screening at 4.5 mg/ml in the 
same way as for Ly49B NKD C57.  Unfortunately, no crystals were obtained.  
5.6. Assessment of the refolded Ly49B  
5.6.1. Assessment of the refolded Ly49B using pull-down assay 
 The proteins folding patterns in the native conditions are precisely defined but the 
potential folding patterns for a given protein outside of its natural environment are numerous.  
It is therefore necessary to assess whether or not in vitro refolding faithfully reproduces the in 
vivo conformation.  As discussed previously, the gel filtration trace provides an indication of 
a protein’s integrity; a tendency not to aggregate is an indicator of stable folding, though the 
conformation may not represent the most stable thermodynamic form.  A functional assay 
therefore ought to be applied whenever possible, for instance, by comparing the catalytic 
activities of refolded and native enzymes.   Unfortunately, the assessment of the activity of 
extracellular portion of Ly49B would be difficult, as it is not an enzyme, lacks a signalling 
domain and is not attached to the cells whose action it regulates.  Instead, the tendency of 
monoclonal antibodies to bind to properly-folded proteins (e.g. Bogdanov et al. 1996; 
Middelberg 2002)-was used in this study. 
To address the question whether or not Ly49B ECFX C57 was folded correctly an 
assay was developed using nickel charged agarose beads.  Since Ly49B ECFX C57 was His-
tagged, mixing equimolar amounts of the protein and the monoclonal 2G4 anti-Ly49B 
antibody with an excess of the Ni agarose beads was expected to lead to crosslinking of the 
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three components.  As shown in Figure 5.14 the antibody on its own did not bind the beads, 
whereas Ly49B alone and Ly49B mixed with the antibody did bind to the beads.  Since 
virtually all the antibody was occupied by the refolded Ly49B, these results suggested that 
the majority of the protein refolded correctly.  Unfortunately, this assay is only applicable to 
the tagged protein.   
 
 
Figure 5.14. Ly49B binding assay. NiNTA beads 
were incubated with refolded Ly49B  ECFX C57 
(B), 2G4 anti-Ly49B antibody (A) or with both of 
those components together (A+B). Supernatant 
samples were collected following the incubation 
period. The beads were then washed and the bound 
protein was eluted with 200 mM Imidazole. Eluted 
protein samples (right hand side of the molecular 
weight marker) and the samples collected prior to 
elution (left hand side of the molecular weight 
marker)  were analysed by 15 % SDS-PAGE A= 
2G4 anti-Ly49B antibody, B=Ly49B ECFX, 
M=molecular weight marker. H=heavy chain of the 
antibody, L=light chain of the antibody.  
 
5.6.2. Assessment of the refolded Ly49B using circular dichroism (CD) 
 The immunoassay described in Section 5.6.1. is suitable only for His-tagged proteins. 
The presence of a polyhistidine tag can interfere with the crystallisation process and/or affect 
protein structure. It is thus preferable to use untagged proteins for structural studies.  In those 
cases where a tag is necessary for purification, it is often best to remove it prior to 
crystallisation and it is imperative to check that the protein’s integrity has not been affected 
during the process.  Circular dichroism (CD) is often used as a means of assessing folding of 
proteins and does not rely on the presence of a tag.  In CD, protein samples are subjected to 
left and right circularly polarised light and the difference between the absorption of the two is 
measured.  Differences arise due to structural asymmetry (Berg et al. 2002). Peptide bonds 
act as chromophores and the secondary structure of proteins is determined by analysis in the 
far UV spectrum (190-250nm) (Berg et al. 2002).  Each protein structure generates 
characteristic CD spectrum; the unfolded proteins generate pattern characteristic for a simple 
peptide bond (Gokce et al. 2005).  Figure 5.15 shows typical spectra for a correctly folded 
alpha helix, a beta sheet and a random coil structure. 
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Figure 5.15. Typical CD spectra for an alpha helix, a beta sheet and a 
random coil structure. Figure adapted from http://www.ap-
lab.com/circular_dichroism.htm 
 
 
 
 
Figure 5.16 shows CD spectra of unfolded and re-folded Ly49B EC C57.  Following 
solubilisation of Ly49B EC C57 from inclusion bodies, an aliquot of sample was retained for 
CD analysis, while the remainder of the protein was used for refolding and purification.  
Solubilised and refolded samples of Ly49B EC C57 were then compared by CD analysis at 1 
mg/ml.  The solubilised sample gave a spectrum typical for a protein dissolved in the 
presence of guanidine hydrochloride (Smith et al. 1997).  The refolded sample produced a 
spectrum typical of an ordered protein, containing elements of beta sheets, alpha helices and 
random coils, which is consistent with the content of secondary structures for Ly49B EC C57 
construct predicted by GOR IV secondary structure prediction server (30 % alpha helix, 20 % 
beta sheet and 52 % random coil) and previously determined structures of other Ly49s.  
 
Figure 5.16. Circular dichroism spectra of unfolded and re-folded Ly49B EC C57 at 1 mg/ml. Blue trace= 
folded protein, red trace = unfolded protein. 
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5.7. Summary  
 
In this chapter a method is presented for recombinant expression of the extracellular 
portion of Ly49B in E. coli, followed by refolding and purification.  Unfortunately, none of 
the tested E. coli strains were able to support expression of soluble protein, most likely due to 
the lack of appropriate chaperones required for eukaryotic protein folding, as well as the 
bacteria’s inability to support eukaryotic-specific post-translational modifications, such as 
glycosylation.  Ly49B was deposited in the cytoplasm of the bacteria in the form of inclusion 
bodies.  Following induction tests, it was established that the E. coli Tuner (DE3) strain was 
most efficient at Ly49B expression and was therefore used for subsequent large scale 
preparations. 
Extracting and reconstituting Ly49B from inclusion bodies was the most problematic 
part of the procedure due to the large quantities of protein that were lost during this process.  
For the untagged version of Ly49B refolding was performed by rapid dilution into a large 
volume of refolding buffer.  The protein was then concentrated and purified by gel filtration.  
For the tagged version of the protein it was possible to refold by dialysis, thereby avoiding 
the lengthy concentration process.  Purification was therefore performed using affinity 
chromatography, followed by dialysis into gel filtration buffer and a second round of 
purification by gel filtration chromatography.  Both procedures gave low yields. However, 
enough protein was obtained to set up several crystallisation trials.  The remaining protein 
was used to develop a method for confirming the integrity of the refolded protein using an 
immunoassay and circular dichroism.  Further optimisation is needed to increase yields of the 
refolded Ly49B. However, the method described here represents a good starting point for 
auxiliary optimisation. 
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6. Discussion 
A monoclonal anti-Ly49B antibody named 1A1 was previously found to bind only the 
C57 form of Ly49B but not the BALB/c form (Gays et al. 2006).  The study presented here 
shows that MHC class I tetramers selectively associate with BALB/c but not C57 Ly49B 
isoform.  These observed differences suggest that the two forms of Ly49B may possess 
different three dimensional structures and perhaps fulfil different roles.  Since the two forms 
differ by 12 amino acids, it follows that one or more of these variable residues are responsible 
for the selective mode of binding of MHC class I ligands and the 1A1 antibody.  The 
existence of these two naturally occurring variants presented a unique system for studying 
interactions between Ly49 molecules and their ligands.   
Until now the majority of studies that have aimed to identify interaction sites between 
Ly49s and their ligands were based on available crystal structures of either Ly49s or related 
C-type lectin-like molecules (Kielczewska et al. 2007, Deng et al. 2008, Sundback et al. 
2002, Lian et al. 1999, Dam et al. 2003).  Sequence alignments in combination with crystal 
structures have been used to identify putative residues involved in ligand binding, which were 
then mutated to assess their effect on ligand binding.   
Crystallography has also been directly used to identify residues responsible for Ly49 
ligand binding.  Co-crystal structures of Ly49A-H-2D
d
 and Ly49C-H-2K
b
 complexes have 
been solved, which have enabled identification of Ly49 residues that form hydrogen bonds or 
salt bridges with residues in MHC class I ligands (Tormo et al. 1999, Dam et al. 2003). 
The benefits of crystallography in identifying interaction sites are manifest; three 
dimensional models enable visualisation of proteins and modelling of the manner in which 
they sterically fit with other molecules.  However, crystallographic approaches are not 
without limitations and it is worth bearing these in mind when considering such data.  For 
example, growing protein crystals requires milligram quantities of pure, soluble, homogenous 
protein.  Ly49s and MHC class I molecules are heavy glycosylated and exist endogenously as 
transmembrane molecules; features which can significantly interfere with crystallisation.  The 
Ly49s and their ligands, whose crystal structures were solved, were expressed without their 
transmembrane and intracellular domains.  The proteins in these studies were recombinant 
and expressed in E. coli, which does not support glycosylation.  It is therefore possible that 
under native conditions, where full-length proteins are expressed and undergo glycosylation, 
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interactions sites differ from those identified by crystallography.  Neighbouring proteins, 
located within the membrane, may also affect receptor-ligand interactions.  It is important to 
consider that under native conditions proteins might exhibit greater mobility due to dynamic 
interactions with the local environment so residues responsible for ligand binding may vary 
depending on the adopted conformation.  In a crystal, on the other hand, proteins are 
immobilized and, as such, the structure represents only a “snapshot” of the interaction.  For 
these reasons the putative interaction sites, which have been identified to date using crystal 
structures, must be treated with caution and verified by a combination of other approaches.  
The best such example of this is Ly49A, whose co-crystal structure with H-2D
d
 ligand 
revealed two interaction sites (Tormo et al. 1999).  Subsequent studies using different 
methods have since demonstrated that only one of these sites is functional (Doucey et al. 
2004, Back et al. 2011). 
One of the key advantages of this study is that the residues responsible for ligand and 
monoclonal antibody binding by Ly49B have been narrowed down to 12 variable amino 
acids between C57 and BALB/c forms.  Systematic replacement by side directed mutagenesis 
of C57-specific residues with BALB/c-specific residues, followed by assessment of the 
mutated proteins for binding of both MHC class I ligands and the monoclonal 1A1 antibody, 
allowed precise identification of residues responsible for forming interactions. 
The work presented here indicated that two variable amino-acids at positions 166 and 
167 are able to affect binding of the monoclonal 1A1 antibody.  Together with residue 251, 
these same two residues appeared to determine binding of MHC class I tetramers.  The C57 
residue at position 166 was shown to be necessary and sufficient for binding of the 1A1 
antibody to chimeric Ly49B molecules, unless the remaining 11 variable residues were all of 
BALB/c origin.  In order to maintain the integrity of the 1A1 epitope in the BALB/c 
background, introduction of the C57 residue at position 167, as well as 166, was required.  
This finding suggests that even though variable residues other than 166 and 167 do not 
directly influence 1A1 binding, they may indirectly affect the conformation of the 1A1 
epitope.  Since the presence of C57 residues at positions 166 and 167 can induce 1A1 binding 
in the BALB/c Ly49B background, one can conclude that these residues may play a critical 
role in the overall folding and function of Ly49B.  Indeed, it was found that the combination 
of BALB/c residues at positions 166, 167 and 251 was optimal for binding of all three of the 
tested MHC class I tetramers.  Interestingly, binding was strongest for mutants with BALB/c 
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residues at positions 166, 167 and 251 and C57 residues at all of the remaining variable 
positions.  
Staining of cells expressing chimeric Ly49B mutants with MHC class I tetramers 
have shown that H-2D
b
 binding was less restricted by the sequence of the variable Ly49B 
residues than H-2K
b
 and H-2D
d
 binding.  These results explain to some extend the hierarchy 
of tetramer binding to wild type BALB/c Ly49B; H-2D
b
 was found to bind most strongly out 
of all tested ligands, while the H-2K
b
 and H-2D
d
  were binding at a similar level to each 
other, roughly 40 % weaker than H-2D
b
.   
Taking into consideration the results obtained for Ly49A mutants (Section 3.7), it 
seems that residues equivalent to Ly49B residues 166 and 167 are also critical for the 
structure and function of Ly49A.  This finding was somewhat surprising since these residues 
were not identified as important for forming ligand interactions in a published co-crystal 
structure of Ly49A and H-2D
d
 (Tormo et al. 1999).  However, as shown in Appendix I, these 
residues form part of the α-1 helix and are positioned right next to the β1-sheet, creating a 
“hinge” in Ly49A.  Furthermore, both α-1 and β-1 contain residues that were shown in the 
crystal structure to come into contact with the MHC class I ligand.  It is possible that 
introducing changes at the “hinge” of Ly49A and in proximity to residues critical for ligand 
binding may have a dramatic effect on the overall folding of the protein and, through this, on 
ligand and antibody binding.  Moreover, as previously mentioned, it is probable that the 
contact residues identified in the crystal structure are slightly different to those found in 
native conditions.  Ly49C K225 and I226 residues were identified by a mutagenesis study to 
be important for ligand binding even though they were shown not to be directly involved at 
the ligand binding site in a co-crystal structure of Ly49C/H-2K
b
 (Sundback et al. 2002).  
Kielczewska et al. have shown that residues, which lie on the interface of the Ly49H dimer, 
also affect ligand binding (Kielczewska et al. 2007).  Considering targeted mutagenesis of 
receptors from a broader context, point mutations introduced to a glucocorticoid receptor at 
distant positions from the co-activator binding surface and ligand binding pocket have been 
shown to improve transcriptional activity and affinity for aldosterone, respectively (Carlson 
et al. 2005). 
The C57 and BALB/c forms of Ly49B contain an additional 20 amino acids at the 
molecules’ C-terminus in comparison to other Ly49s.  Curiously, binding of the control 2G4 
anti-Ly49B antibody to mutants, which were deprived of this region, was completely 
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abolished, suggesting that the 2G4 epitope lies within this 20 residue region or that its correct 
folding is dependent on the C-terminus.  Binding of MHC class I tetramers was not affected, 
suggesting that this region is not important for ligand binding.   
However, the role of the C-terminus in ligand binding was apparent when staining of 
transfectants expressing HA-tagged and untagged molecules was compared.  HA-tagged 
Ly49B stained weaker with all three MHC class I tetramers than its untagged counterpart.  As 
with previous results, the effect was least noticeable for the H-2D
b
 tetramer.  In the case of 
Ly49A staining, the presence of the HA-tag had a positive effect on binding.  These results 
suggest that either the presence of the HA-tag at the C-terminus affects folding of Ly49 
receptors or it directly interferes with ligand binding. Interestingly, one study suggested that 
the presence of HA-tag was able to completely abolish ligand binding by Ly49B (Scarpellino 
et al. 2007).  This study shows that HA-tag may influence ligand binding but is unlikely to 
prevent it.  
Several Ly49s and other NK cell receptors have been shown to exist as disulphide-
linked dimers on the cell surface (Appendix II).  This study reveals that Ly49B also has a 
tendency to multimerise, both in transfected and in native cells.  SDS-PAGE analyses of 
material containing Ly49B glycosylation mutants and de-glycosylated wild type Ly49B show 
that, in the presence of 2ME, Ly49B migrates at the predicted molecular weight of ~34 kDa, 
while non-reduced material migrates at ~80 kDa, which is slightly larger than the combined 
weight of two monomers.  This observation suggests that Ly49B monomers may associate 
with a different, slightly larger protein through the formation of disulphide bridges, or that 
Ly49B forms homodimers whose migration by SDS-PAGE is slightly retarded due to the 
presence of disulphide bridges in between two monomers and within the globular domains.  
The second explanation would seem more likely due to the tendency of the protein to 
dimerise during purification of the extracellular portion of Ly49B, as observed by SDS-
PAGE analysis of the purified fractions and from gel filtration traces.  The fact that other 
members of the Ly49 family have been shown to dimerise by immunoprecipitation, Western 
blotting, and X-ray crystallography adds further weight to the possibility that Ly49B forms 
dimers.  Migration of protein complexes on SDS-PAGE is known to be affected by the 
presence of disulphide bonds (Dunker and Kenyon 1976). SDS denaturation is often referred 
to as “reconstructive denaturation”, because it does not result in complete unfolding of the 
protein, but rather in aggregation of the detergent particles on its hydrophobic surfaces, which 
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forces proteins into stretched conformation (Imamura 2006).  Rath et al. showed that 
differential solvation by SDS may result from replacing detergent-protein contacts with 
protein-protein contacts (Rath et al. 2009), such as those provided by disulphide bonds.   
Interestingly, some of the Western blot experiments presented here show that Ly49B 
may engage in complexes larger than dimers, which appear as a large molecular weight band 
of ~200 kDa in SDS-PAGE analyses.  The same tendency has been observed for Ly49A and 
Ly49Q by other groups (Takei 1983; Toyama-Sorimachi et al. 2004).  In the experiments 
presented here the 200 kDa Ly49B band was not present in all experiments and was 
diminished following immunoprecipitation and incubation at 37 °C for 1 h, suggesting that 
the complex may not be stable.  It is also possible that the 200 kDa band represents protein 
aggregation, which developed following cell lysis, rather than true Ly49B multimers. 
The Ly49B monomer was observed in non-reduced samples in some, but not all, 
experiments, suggesting that the monomeric Ly49B may exist in living cells under certain 
conditions.  However, it is possible that this observation may have resulted from 2ME spill-
over from neighbouring, reduced samples.  Interestingly, the Ly49G monomer was also 
observed in a non-reduced sample, and in this case the gel did not contain any reduced 
samples, which excluded the possibility that the obtained result was caused by 2ME spill-
over.  The non-reduced sample of Ly49G was analysed in parallel with four other Ly49 
receptors and the Clrg NK cell receptor on the same gel; monomeric forms could not be 
observed in any of the other samples, even after prolonged exposure.  Furthermore, 
monomeric Ly49G has also been observed in non-reduced samples by another group (Mason 
et al. 1988). 
The observation that Ly49B and/or other Ly49 receptors could potentially exist in 
living cells in the form of monomers, dimers and oligomers raises the possibility that each of 
these molecular forms fulfils a different role.  KIR receptors, human functional orthologues 
of Ly49s, exist as monomers and tend to cluster in a doughnut shape configuration around 
central LFA-1/ICAM-1 receptor clusters at NK cell immune synapses (Davis et al. 1999).  
This clustering is thought to be necessary for effective signal transduction.  Dendritic cell 
SIGN receptors, which like Ly49s are C-type lectin-like molecules, have been found in 
different states of organisation (monomers to oligomers), depending on the developmental 
stage of the cells that they are expressed on (Cambi 2003).  Moreover, the adhesion molecule, 
P-selectin, exists in platelets and epithelial cells as monomers and dimers;  the P-selectin 
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monomers have been shown to exhibit distinct biochemical properties to individual subunits 
in P-selectin homodimers and are therefore thought to fulfil different roles (Barkalow et al. 
2000). 
Glycosylation plays an important role in both the folding and the function of many 
eukaryotic proteins (Taylor et al. 2006).  Surface expression of C57 and BALB/c Ly49B 
mutants, in which all of the glycosylation motifs were disrupted, was shown here, by flow 
cytometric analysis, to be compromised in comparison to wild type counterparts.  This result 
suggests that glycosylation is not absolutely required for Ly49B expression, but may be 
important, for correct folding and stability of Ly49B.  Eukaryotic chaperones called calnexin 
and calreticulin act as quality control checkers for the majority of glycosylated proteins and 
prevent egress of misfolded proteins from the ER to the Golgi apparatus (Taylor et al. 2006).  
Aberrant glycosylation of proteins has been shown to affect protein interactions with the 
aforementioned chaperones (Molinari and Helenius 2000, Deprez et al. 2005, Daniels et al. 
2003).  It is possible that the refolding experiments performed here, using Ly49B expressed 
as inclusion bodies, gave low yields partially due to the fact that the refolded protein did not 
contain glycans facilitating its folding and stability. 
The Ly49B monomers and dimers were shown here by Western blotting to exist in 
transfected and native cells in multiple molecular weight forms, which represent the receptor 
at different stages of N-glycosylation.  The smallest molecular weight forms identified in the 
reduced and non-reduced samples in Western blot experiments represent immature, 
intracellular, high-mannose forms of the receptor, while the larger forms represent surface-
associated, mature forms.   The intracellular form has never been shown before for any other 
Ly49 receptor, mainly because of the methodologies used for investigating the molecular 
nature of Ly49s.  Traditionally, the majority of experiments have been performed on surface-
labelled Ly49s, enabling visualisation of the surface associated forms only.  Another 
example, where a multiple banding pattern was overlooked, concerns YE1/48 anti-Ly49A 
affinity purification of Ly49A from MBL-2 cells (Chan and Takei 1988).  Purified material 
was analysed by non-reducing SDS-PAGE and visualised by silver staining.  The sample 
contained a predominant band at ~95 kDa, a clear band at 200 kDa and a weak band at ~85 
kDa.  The band at ~95 kDa was thought to be Ly49A and the 200 kDa band was thought to 
be non-specific aggregation or Ly49A multimer.  The weak band was thought to represent an 
impurity, rather than a differentially glycosylated form of Ly49A.  An example of an 
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experiment that did allow visualisation of intra- and extracellular Ly49 receptors was 
performed by Ortaldo et al., who used anti-phosphotyrosine antibody for blots of non-
reduced Ly49A, Ly49C, Ly49D and Ly49G2, which had been immunoprecipitated using 
monoclonal antibodies from NK cells of different mouse strains (C57, BALB/c, CB6F1, 
C3H/HeJ, DBA2 and AKR) (Ortaldo et al. 1999).  Phosphorylated Ly49A, Ly49C and G2 
appeared as multiple bands, which varied slightly in size between different strains.  This 
variation was thought to be due to different glycosylation patterns in each of the strains.   
However, the authors did not comment on the multiple banding pattern seen in the individual 
samples of the detected Ly49s from each mouse strain.   
The existence of a relatively abundant pool of intracellular, immature NK receptors, 
as well as surface-associated mature forms, may be important for the function that NK cells 
fulfil.  It may not be favourable for the cell to constitutively display all available receptors on 
the surface, but the existence of an intracellular reservoir would enable a rapid increase in the 
number of surface-associated receptors when required, for example in a pathological 
situation.  Rather than investing energy in de novo synthesis of receptors, glycan modification 
of existing, intracellular proteins would allow instantaneous export of the protein to the 
surface.  It is worth noting that the high mannose form of Ly49B is more abundant in the C57 
strain than in BALB/c, suggesting that the receptor may fulfil different roles in the two 
strains. 
The co-existence of immature and mature versions of a protein in similar quantities 
has been reported for other eukaryotic proteins.  One example of a protein that exhibits a 
multiple banding pattern in Western blot experiments is the MHC-DM molecule, which 
facilitates peptide loading of classical MHC class II molecules in the endosomal 
compartments of antigen presenting cells.  MHC-DM is a heterodimer composed of two 
chains: DMα and DMβ.  DMα appears as a doublet in Western blot experiments, but only 
when co-expressed with DMβ (Denzin et al. 1996, Van Ham et al. 1996, Sanderson et al. 
1996).  A recent publication revealed that the smaller band represents a high mannose, 
immature form of the protein, while the larger band represents a mature form of DMα, which 
arises from a glycan modification at N15 (Lith and Benham 2006).  This example shows that 
molecular forms of proteins at different stages of glycosylation can co-exist in similar 
proportions within the same cell. 
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Another intriguing example is that of the D
2 
dopamine receptor, which is expressed in 
two differentially spliced forms: long and short (Fishburn et al. 1995).  Pulse chase 
experiments have shown that the short form of the protein is processed from the ER to the 
cell surface much faster than the long form.  Moreover, the short form exists predominantly 
as a mature surface-associated protein, while a proportion of the long form of the protein 
remains intracellularly as an immature, high mannose form.  Mature and immature variants of 
the long form of the D
2
 receptor co-exist natively in similar proportions, as observed here for 
Ly49B.  It is not clear why the long form of the D2 receptor is retained in the ER more 
efficiently than the short form, but it is likely to be related to their differing biochemical 
properties and the respective functions that they fulfil. 
The role of Ly49 glycosylation in ligand binding has previously been assessed for 
Ly49D and Ly49G2 (Mason et al. 2003).  It was shown that unglycosylated Ly49D and 
Ly49G2 bind H-2D
d
 MHC class I ligand more strongly than controls.  The presence of 
carbohydrates at a glycosylation motif, which is specific to Ly49D and Ly49G2 (NTT221-
23) and adjacent to the MHC binding site identified in a Ly49A-H-2D
d
 co-crystal, was shown 
to lower the affinity of these receptors for H-2D
d
.  A recent study has shown that differential 
glycosylation of the human activating NK cell receptor, NKp30, may allow the receptor to 
recognise a series of different ligands (Hartman et al. 2011). 
Ly49B contains four predicted N-glycosylation motifs, three of which reside in the 
predicted stalk region of the protein and the fourth in the CRD (Appendix I).  Mutants with 
the four sites disrupted, individually and together, were created and analysed using Western 
blotting and flow cytometry.  BALB/c Ly49B mutants with all glycosylation sites disrupted 
associated with all of the tested MHC class I tetramers to a similar extent as the wild type 
protein, suggesting that Ly49B glycosylation is not a prerequisite for ligand binding.  Small 
variations in binding levels can be attributed to much lower expression levels of the mutant 
receptors, compared to the wild type. 
Western blot analysis has shown that all of the individual Ly49B motifs are 
glycosylated.  Mutation of N94 did not have a significant effect on binding of any of the 
tetramers, suggesting that the presence of carbohydrates at this position does not affect ligand 
binding.  Single glycosylation mutants, N105Q and N114Q, bound all three tetramers more 
strongly than the wild type protein, confirming that glycans are present at these positions and, 
furthermore, that even though they are not required for ligand binding, they appear to fine 
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tune the process of association.  Interestingly, the two glycosylation motifs reside in the stalk 
region of Ly49B, which suggests that either the ligands come into direct contact with the 
stalk or that the glycans at these positions can affect the overall folding of Ly49B.  The 
majority of Ly49s contain two conserved glycosylation motifs in the stalk region, but in 
Ly49B one of these motifs is shifted by four residues in relation to the conserved position 
(Appendix II).  The same motif contains a conserved cysteine in Ly49s other than Ly49B, 
which may be involved in disulphide bond formation and therefore is unlikely to be 
glycosylated.  This motif was shown experimentally not to be glycosylated in Ly49D (Mason 
et al. 2003).  Moreover, Ly49B contains one more, non-conserved glycosylation motif in the 
stalk region. Ly49B was shown to be incapable of associating with its ligand in cis 
(Scarpellino et al. 2007).  It would be interesting to investigate whether the stalk 
glycosylation at these positions may prevent Ly49B ligand binding in cis.  
The glycosylation motif containing asparagine at position 177 is specific to Ly49B 
and resides in the CRD.  As such, as with Ly49D and Ly49H, it was predicted that the motif 
may play a role in Ly49B’s association with ligands.  Binding of the H-2Kb and H-2Dd 
tetramers to the single N177Q glycosylation mutant was unaffected, but weaker for the H-
2D
b
 tetramer.  It seems that glycosylation of asparagine at position 177 is yet another factor 
which promotes preferential binding of the H-2D
b
 MHC class I molecule over H-2K
b
 and H-
2D
d
.  As with the Ly49D and Ly49H receptors, carbohydrates attached to Ly49B at specific 
positions may play a role in fine tuning of ligand binding.   
In summary, this study has shown that BALB/c Ly49B binds to a variety of tested 
MHC class I tetramers, whereas C57 Ly49B does not bind any of the tetramers. Variable 
Ly49B residues 166 and 167 influence binding of a monoclonal 1A1 anti-Ly49B antibody 
and together with the variable residue 251 also ligand binding.  C-terminal HA-tag can 
marginally affect ligand binding by Ly49 receptors, but has not got the ability to completely 
abolish ligand binding.   
Moreover, this study revealed that Ly49B has the ability to dimerise, or even 
multimerise, on the cell surface.  Differentially glycosylated forms of Ly49B co-exist in 
similar proportions in the intra- and extracellular compartments of cells that express this 
receptor.  Ly49B glycosylation is not essential for surface expression of Ly49B but is 
beneficial and most likely promotes correct folding and stability.  The presence of glycans is 
not required for ligand binding, but may play a role in the fine tuning of ligand binding. 
165 
 
The data presented here reveal new insights regarding the structure and function of 
Ly49B and other Ly49 receptors.  In depth knowledge of NK cell regulation is necessary for 
the development of new therapies in our fight against pathogens and cancer; this study brings 
us one step closer to achieving this end. 
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6.1. Future work  
Ly49B residues 166, 167 and 251 were shown here to be important for ligand 
binding.  Modelling of these residues onto known crystal structures of other Ly49s, has 
shown that the equivalent residues lay on the surface of the proteins and that all three are 
brought into close proximity with one another upon folding.  Residues equivalent to Ly49B 
166 and 167 were shown to be important for Ly49A ligand binding, despite the fact that they 
were not identified as contact residues in a Ly49A-H-2D
d
 co-crystal structure.  Moreover, the 
residue equivalent to Ly49B 167 was shown to facilitate Van der Waals interactions with the 
ligand in a co-crystal structure of Ly49C and H-2K
b 
(Deng et al. 2008).  Taking into 
consideration these findings, it would be interesting to create a series of Ly49 mutants, 
similar to the Ly49A mutants used here, which would enable investigation of residues 
equivalent to Ly49B 166, 167 and 251 in terms of whether or not they also play a role in 
ligand binding of other Ly49s. 
Solving a crystal structure of Ly49B would be pivotal in terms of understanding its 
biochemistry.  Since receptor glycosylation seems to be important for surface expression of 
Ly49B, it is possible that glycosylation may also be needed for optimal folding and stability.  
Using an expression system that supports glycosylation, for example HEK293 cell line or 
insects, could enable the production and purification of large quantities of correctly folded 
Ly49B.  Since protein glycosylation can interfere with the crystallisation process, it would be 
advisable to run crystal trials with de-glycosylated protein following purification, as well as 
with fully glycosylated protein.  As well as crystallisation, pure, glycosylated, soluble Ly49B 
could be used in other biochemical experiments, for example in assessing the exact kinetics 
of ligand binding using surface plasmon resonance. 
Ly49B was shown here to exist in transfected and native cells in differentially 
glycosylated, intra- and extracellular forms, which were present in roughly equal abundance.  
Preliminary experiments have shown that this may also be the case for other Ly49 and NK 
cell receptors.   To unambiguously establish that this is in fact the case, detailed analysis, 
using the same methods applied here for Ly49B, would be necessary for each of the 
receptors.  It would be interesting to see whether or not monoclonal antibodies previously 
developed against other Ly49s can be used in Western blotting experiments in the same 
manner as anti-Ly49B 2G4 and 1A1 mAbs and if they are able to bind differentially 
glycosylated forms of the same receptor, assuming such forms exist.  An intriguing question 
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to address would be whether or not the proportions of intra- and extracellular Ly49 receptors 
change in different circumstances.  One way of doing this would be to compare lysates 
prepared from activated and non-activated NK cells in Western blot experiments using 
antibodies that are capable of recognising differentially glycosylated Ly49 receptors. 
As mentioned in the discussion, assessing the ability of Ly49B glycosylation 
mutants to bind ligands that are expressed by the same cell would enable determination of 
whether or not glycosylation of the stalk region of Ly49B prevents the wild type receptor 
from binding in cis.  To resolve this question, tetramer binding assays could be performed 
using Ly49B glycosylation mutant-transfected cells deficient or proficient for MHC class I 
receptor expression.  Comparison of the tetramer binding pattern between the two groups 
would provide an indication as to the importance of stalk glycosylation in preventing Ly49B 
interactions with its ligand in cis. 
Finally, it is important to explicitly establish whether Ly49B is able to form 
homodimers or if it associates with an alternative protein.  In order to achieve this, one could 
employ cells that have been transfected with Ly49B constructs expressed from two different 
plasmids; with each construct carrying a different molecular tag.  Transfectant cell lysates 
could then be subjected to sequential immunoprecipitation with antibodies against the two 
tags.  If immunoprecipitated lysates contain material which can be detected by Western 
blotting using the second antibody, it would indicated that Ly49B is indeed capable of 
forming homodimers.  Results could be further confirmed by mass spectrometric analysis of 
purified, non-reduced Ly49B receptor. 
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Appendix  I) Alignment of all known C57 Ly49 receptor amino acid sequences, as well as that of BALB/c Ly49B.  
Light green = intracellular region.  Yellow = transmembrane region.  White = stalk region.  Light blue = NK domain (NKD).  Purple = residues showing variation between the C57 and 
BALB/c isoforms of Ly49B.  Red and blue = glycosylation motifs, with critical asparagine residues highlighted in red,  Dark green = cysteine residues contained within the Ly49B sequence 
and conserved cysteines, Blue, purple and green dots indicate cysteine pairs that form disulphide bonds, Bold = WAW motif, highly conserved amongst other Ly49s, and equivalent Ly49B 
residues,  Underline = ITIM motif in Ly49Bs, Grey = residues present in other Ly49s corresponding to highlighted Ly49B residues, Turquoise = residues that were identified to form direct 
contacts with ligands in co-crystal structures of Ly49C-H-2K
b
 and Ly49A-H-2D
d, as stated in table 1.1.  Blue arrows = β sheets in Ly49A, identified by X-ray crystallography.  Regions 
annotated with blue α symbols = α helices in Ly49A, identified by X-ray crystallography. 
 
                     *        20         *        40         *        60         *        80         *       100       
Ly49A     : MSEQEVTYSMVRFHKSAGLQKQVRPEETKGPREAGYRRCSFHWKFIVIALGIFCFLLLVAVSVLAIKIFQYDQQK-KLQEFLNHHNNCS-NMQSDINLKD :  98 
Ly49B     : MSEQEVTYTTLRFHKSSGLQNPVRPEETQRPRDVGHRECSVPWKFIVIVLGILCFLLLVTVAVLVIHIFRDGQEKHEQEKTLNNLRQEYQVMKNDSSLME : 100 
Ly49BBALB : MSEQEVTYTTLRFHKSSGLQNPVRPEETQRPRDVGHRECSVPWKFIVIVLGILCFLLLLTVAVLVIHIFRDGQEKHEQEKTLNNLRQEYQVMKNDSSLME : 100 
Ly49C     : MSEPEVTYSTVRLHKSSGLQKLVRHEETQGPREVGNRKCSAPWQLIVKALGILCFLLLVTVAVLAVKIFQYNQHKQEINETLNHHHNCS-NMQRAFNLKE :  99 
Ly49D     : MTEQEDTFSAVRFHKSSGLQNEMRLKETRKPEKARLRVCSVPWQLIVIALGILISLRLVTVAVLMTNIFQYGQQKHELKEFLKHHNNCS-IMQSDINLKD :  99 
Ly49E     : MSEPEVTYSTVRLHKSSGLQRLVSHEEIQGPGEAGYRKCSVPWQLTVRSLGIFCFLLLVTVAVLAVKIFQYSQHKQEIHETLNHNHNCS-NMQSDIKLKE :  99 
Ly49F     : MSEPEVTYSTVRLHKSSRLQKLVRHEETQGPREAGYRKCSVCWQLIVKALGILCFLLLITVAVLAVKIFQYGQHNQEIHETLNYHHNCS-NMQSDFNLKE :  99  
Ly49G     : MSEQEVTYSTVRFHESSRLQKLVRTEEPQRPREACYREYSVPWKLIVIACGILCFLLLVTVALLAITIFQHSQQKHELQETLNCHDNCS-PTQSDVNLKD :  99 
Ly49H     : MSEQEVTFPTMRFHKSSGLNSQVRLEGTQRSRKAGLRVCSVPWQLIVIALGILCSLRLVIVAVFVTKFFQYSQHKQEINETLNHRHNCS-NMQRDFNLKE :  99 
Ly49I     : MNEPEVTYSTVRLHKSSGLQKLVRHEETQGPREAGNRKCSVSWQLIVKALGILCFLLLVIVAVLTIKIFQYSQHKQEINETLNHYHNCS-NMQSDFNLKE :  99 
Ly49J     : MSELEVTYSTVNLHKSSGLQKLVRHEETQGPREAGNRKCSIYWQLIVKALGILCFLLLVIVAVLAVKIFQYSQHKQEINETLNHHHNCS-NMQRDFNLKE :  99 
Ly49Q     : MSEQEVTYSTVRFHKSSGLQNQVRPEDNQGSREAGHKECSIPWHLIVIAFGILCVLLLVIVAVLVTNILQYKQEKHELQETLNCHHNCS-TMQNDINAKE :  99 
 
                                                            β0         β1         α1                  α2      
                                                                             αααααααααα          αααααααααα                                                                                                           
                     *       120         *       140         *       160         *       180         *       200       
Ly49A     : EMLKNKSIEC----DLLESLNRDQNRLYNKTKTVLDSLQHTGRGDKVYWFCYGMKCYYFVMDRKTWSGCKQTCQSSSLSLLKIDDEDELKFLQLVVPSDS : 194 
Ly49B     : EMLRNKSSECKALNDSLHYLNREQNRCLRKTKIVLDCSQNKGKQVEGYWFCCGMKCYYFIMDDKKLKGCKQICQAYNLTLLKTNDEDELKFLKSQLQRNT : 200 
Ly49B-BALB: EMLRNKSSECKALNDSLHYLNREQNRCLRKTKIVLDCSQNKGKQVEGYWFCCGMKCYYFIMDDKKWNGCKQICQDYNLTLLKTNDEDELKFLKSQLQRNT : 200 
Ly49C     : EMLTNKSIDCRPSNETLEYIKREQDRWDSKTKTVLDSSRDTGRGVK-YWFCYSTKCYYFIMNKTTWSGCKANCQHYSVPILKIEDEDELKFLQRHVIPEN : 198 
Ly49D     : ELLKNKSIEC----NLLESLNRDQNILCDKTRTVLDYLQHTGRGVKVYWFCYGMKCYYFVMDRKPWSRCKQSCQNSSLTLLKIDDEDELKFLQLVVPSDS : 195 
Ly49E     : EMLRNKSIDCSPGEELLESLNREQNRWYSETKTDLDSSQDTGTGVK-HWFCYGTKCFYFIMSKNTWSGCKQTCQHYSLPLVKIEDEDELKFLQFQVISDS : 198 
Ly49F     : EMLTNRSIDSRPGNELLESLNREQNRGYSETKTDLDSSQDTGTGVK-YWFCYRTKCYYFIMNKNTWSGCKQNCQHYSLPLVKIDDENELKFLQFQVIPDS : 198 
Ly49G     : ELLRNKSIECRPGNDLLESLSRDQNRWYSETKTFSDSSQHTGRGFEKYWFCYGIKCYYFNMDRKTWSGCKQTCQISSLSLLKIDNEDELKFLQNLAPSDI : 199 
Ly49H     : EMLTNKSIDCRPSYELLEYIKREQERWDSETKSVSDSSRDTGRGVK-YWFCYGTKCYYFIMNKTTWSGCKANCQHYSVPIVKIEDEDELKFLQRHVILES : 198 
Ly49I     : EMLTNKSIDCRPSNELLDYIKREQDRWNSETKTVLDSSRDTGRGVK-HWFCYGTKCYYFIMNKTTWSGCKANCQHYSVPIVKIEDEDELKFLQRHVIPES : 198 
Ly49J     : EMLTNKSIDCRPSNELLEYIKREQDRWNSETNTILDSSRDTGGGVK-YWFCYSTKCYYFIMNKTTWSGCKANCQHYSVPIVKIEDEDELKFLQRHVIPES : 198 
Ly49Q     : EMLRNMPLECSTGDDLLKSLNREQKRWYSETKSVLNSSKHPGGSLEIHWFCYGIKCYYFIMNKKGWRKCKQICEHYSLSLLKIDAEDELKFLQLQVTPDS : 199 
 
 
184 
 
                β2       β2’                      β3      β4        β5                                                                                                           
                                    
                     *       220         *       240         *       260         *       280                
Ly49A     : CWVGLSYDNKKKDWAWIDNRPSKLALNTRKYNIRDGGCMLLSKTRLDNGNCDQVFICICGKRLDKFPH*-------------------- : 262 
Ly49B     : YWIALTHHESKEESQQIGDRPSKPVSAARNSVPNREKCAYLNSFSTEEDDRARNHGCICEKRLNKFPIPGSCAKGRTQSALQRDEDES* : 288 
Ly49B-BALB: YWISLTHHKSKEESQQIGDRPSKLDSAARNSVPNRQKCAYLSSFSTEEDDCARTHGCICEKRLNKFPIPGSCAKGRTQSALQRDEDES* : 288 
Ly49C     : YWIGLSYDKKKKEWAWIDNGPSKLDMKIRKMNFKSRGCVFLSKARIEDIDCNIPYYCICGKKLDKFPD*-------------------- : 266 
Ly49D     : CWIGLSYDNKKKDWAWIDNRPSKLALNTTKYNIRDGGCMFLSKTRLDNNYCDQSFICICGKRLDKFPH*-------------------- : 263 
Ly49E     : YWIGLSYDKKKKQWAWIDNGPSKLDMKTRKMNFKPGGCIFLSKTRLEDTNCNNSYFCICGKKLDHFPG*-------------------- : 266 
Ly49F     : YWIGLSYDKEKKEWAWIDNGQSKLDMKIRKMNFKPGGCVFLSKRRLEDTNCKNSHYCICGKKLDKFPH*-------------------- : 266 
Ly49G     : SWIGLSYDNKKKDWVWIDNGPSKLALNTTKYNIRDGLCMSLSKTRLDNGDCDKSYICICGKRLDKFPH*-------------------- : 267 
Ly49H     : YWIGLSYDKKKKEWAWIHNGQSKLDMKIKKMNFTSRGCVFLSKARIEDTDCNTPYYCICGKKLDKFPD*-------------------- : 266 
Ly49I     : YWIGLSYDKKKKEWAWIDNGQSKLDMKTRKMNFKSRGCVFLSKARIEDTDCNIPYYCICGKKLDKFPD*-------------------- : 266 
Ly49J     : YWIGLSYDKKKKEWAWIDNGPSKLDMKIRKMNFKSRGCVFLSKARIEDTDCNIPYYCICWKKLDKFPD*-------------------- : 266 
Ly49Q     : YWIGFSFDKKSEKWTWIENGTSKYALNMSTYNVKSGECVFLSKTRLENNKCEHVYPCICEKRLDKFPDSLPNNS*-------------- : 273 
185 
 
 
Appendix II) Characterisation of Ly49s and other NK cell receptors from murine strains by immunoprecipitation and Western blotting.  
 
Predicted MW 
of monomer 
(kDa) 
Monomer size 
(kDa) 
Dimer size(kDa) Cell type Surface 
labelling 
Tags % of 
the gel 
IP 
antibodies 
Detecting 
antibodies 
References  
Ly49A (mouse) 
30.7 44-54 (+ over 
200 band) 
90-95 (+over  200 
band) 
EL-4 125 I or s35 
met 
- 7.5 YE1/48 - Takei 1983 
30.7 45-55 (+ over 
200 band) 
90-95 (+ over 200 
band) 
Normal thymocytes and 
splenocytes, MBL-2, EL-4 
125I - 10 
12.5 
YE1/48, 
YE1/32 
- Chan and Takei 1986 
30.7 42-45 
(Reduced to 30 
with EndoF) 
85 (+ over 200 band)  C6VLB, normal splenocytes 
and thymocytes  
125I - 10, 
12.5 
A1 - Nagasawa et al. 1987 
30.7 45-55 (reduced 
to 32 with 
EndoF) 
90-95 (+ over 200 
band) 
EL-4,MBL-2 125I - 10 YE1/48 - Chan and Takei 1988 
30.7 44 85 EL-4, COS 125I - 10 A1 - Yokoyama et al. 1989 
30.7 47 97 IL-2 activated NK cells 125I - 10 A1 - Mason et al. 1996 
30.7 - 82-90 C1498 - VSV 8 Anti-VSV Anti-VSV, rabbit  
anti-pan-class I Abs 
Scarpellino et al. 2007 
 
30.7 - 95 and 110 IL-2 activated NK cells - - 10 YE1/48  Biotin Anti-
phosphotyrosine, 
HRPO SA 
Ortaldo et al. 1999 
30.7 44 (reduced to 
32 with 
PNGase F) 
88 EL-4 125I  10 1A - Chang et al. 1996 
30.7 45-50 85-90 (+ over 200 
band) 
EL-4, M14T cells 125I - 10 JR9-318 - Roland and Cazenave  
1992 
186 
 
Ly49B (mouse) 
33.5 - 100 C1498 - VSV 8 Anti-VSV Anti-VSV, rabbit  
anti-pan-class I Abs 
Scarpellino et al. 2007 
Ly49C/I (mouse) 
31.3 (Ly49C) 
31.2      (Ly49I) 
50-54 108-110 IL-2 activated NK cells 125I - - SW5E6 - Sentman et al. 1989 
31.3 (Ly49C) 
31.2      (Ly49I) 
50-54 110 IL-2 activated NK cells 125I - 10 SW5E6 - Mason et al. 1996 
31.3      (Ly49C) - 129 C1498 - VSV 8 Anti-VSV Anti-VSV, rabbit  
anti-pan-class I Abs 
Scarpellino et al. 2007 
31.3 (Ly49C) 
31.2      (Ly49I) 
 110 IL-2 activated NK cells - - 10 SW5E6 Biotin Anti-
phosphotyrosine, 
HRPO SA 
Ortaldo et al. 1999 
Ly49D (mouse) 
27.8 48-52 97-100 IL-2 activated NK cells 125I - 10 12A8 - Mason et al. 1996 
27.8 - 97-100 IL-2 activated NK cells - - 10 12A8  Biotin Anti-
phosphotyrosine, 
HRPO SA 
Ortaldo et al. 1999 
Ly49E (mouse) 
30.8 46 (reduced to 
31 with N-
glyco-F) 
~90 IL-2 activated FD17 
thymocytes , HEK-T cells 
 Biotin - - 4D12 HRPO-SA Van Beneden et al. 
2001 
Ly49G2 (mouse) 
31.1 - 85-89 Liver and spleen NK cells 125I - 7.5 4D11 - Mason et al.1988 
31.1 40 97 IL-2 activated NK cells 125I - 10 4D11 - Mason et al. 1996 
31.1 - 97-110 IL-2 activated NK cells - - 10 4D11 Biotin Anti-
phosphotyrosine, 
HRPO SA 
Ortaldo et al. 1999 
31.1 43  (+ over 200 86 A-LAK Biotin - 10 Cwy-3 - Chang et al. 1999 
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band) 
Ly49I (mouse) 
31.2 - 110 C1498 - VSV 8 Anti-VSV Anti-VSV, rabbit  
anti-pan-class I Abs 
Scarpellino et al. 2007 
 
 
Ly49P (mouse) 
30.5 - 97-110 IL-2 activated NK cells - - 10 YE1/48, 
YE1/32, 
4E5 
Biotin Anti-
phosphotyrosine, 
HRPO SA 
Makrigiannis et al. 
1999 
Ly49Q (mouse) 
31.8 45-60 130 and 200 COS7 Biotin FLAG - Anti-FLAG HRPO-SA, anti-FLAG Toyama-Sorimachi et 
al. 2004 
31.8 - 82 C1498 - VSV 8 Anti-VSV Anti-VSV, rabbit  
anti-pan-class I Abs 
Scarpellino et al. 2007 
 
NKR-P1C (Rat) 
24.9 45 (reduced to 
28 with 
PGNase F) 
90 IL-2 activated NK cells Biotin - 10 STOK27 HRPO-SA Keveberg et al. 2006 
KRH1 (Rat) 
26.6 37 (reduced to 
26.6 with 
PNGase F) 
75 IL-2 activated NK cells Biotin - 10 STOK9 HRPO-SA Naper et al. 2002 
Ly49i2 (Rat) 
32.6 47-49 (reduced 
to 35 with 
EndoF)  
100-110 (reduced to 
50-55 with Endo F) 
IL-2 activated NK cells Biotin - 10 STOK1/2 HRPO-SA Naper et al. 1998 
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Appendix III. Staining of Ly49B mutants. The numbers represent intensity of staining expressed in fluorescence intensity units. The bold 
numbers represent average values and the underlined numbers represent standard deviation (SD). 
 
Name  AA code name Kb Db Dd N837 2G4 N1176 2G4 N838 1A1 N1222 anti-HA 
C57 VLKAAEPVENRN 0 0 0     
  0 0 0 415 492 580  
  0 0 0 262 330 397  
  0 0 0 308 476 366 0 
  0 0 0 314 423 325  
  0 0 0 386 312 408  
  0 0 0 224 248 252  
  0 0 0 363 317 288  
  0 0 0 371 395 511  
  0 0 0 635 547 818  
  0 0 0 364 393 438 0 
  0 0 0 118 99 176  
189 
 
         
C57-HA         VLKAAEPVENRN-HA 0 0 0     
  0 0 0 353 382 502 241 
  0 0 0 493 462 560  
     308 266 386 237 
     172  393 328 
     273   222 
      305  328 
  0 0 0 200   407 
      292 283 317 
     447  971  
      318 294  
     575  824 915 
  0 0 0 353 338 527 374 
  0 0 0 143 72 250 227 
         
190 
 
BALB LWNDSKLDQSCT 63 128 81     
  45 59 35     
  104 97 65 595    
  19 22 98 263    
  130 220 138 501    
  115 222 87 559    
  86 156 92 606  0  
  311 479 358 591    
  53 332 215 449    
  139 375 188 459 454 0  
  144 426 165 493 288 0  
  111 529 221 539 549 0  
  91 305 153 147 375 0  
  106 396 139 334 273 0  
  66 180 75 219 311 0  
  135 303 182 412 383 0  
191 
 
  172 278 196 535 419 0  
  87 228 107 319 412 0  
  114 264 150 566 580 0  
  68 184 116 494 356 0  
  113 259 159 439 412 0  
  138 317 207  516   
  157 325 220  472   
     211  0  
  54 122 69  297  0 
  60 137 81  353  0 
  105 209 132  408   
  99 227 146  580   
  84 166 103  334  0 
  134 223 163  418   
  185 328 241  455   
  196 333 265  658  0 
192 
 
  112 253 150 437 423 0 0 
  56 118 70 141 103 0 0 
         
BALB-HA        LWNDSKLDQSCT-HA 33 102 80     
  22 145 28    510 
  30 131 53     
  27 79 31 605    
  3 17 6 327    
  14 47 12 396    
  14 77 14 862    
  6 89 19 472   439 
  9 101 10 366 382  467 
  46 184 51 628 595 0  
  52 211 61 521 525 0 467 
  54 174 71  426  366 
  42 129 53  353  419 
193 
 
  16 74 23  340  412 
  19 80 22  390  427 
  11 59 19  296  376 
  25 106 35 522 413 0 431 
  16 53 23 175 100 0 46 
         
C57-V59L       LLKAAEPVENRN 0 0 0 317 365 392  
  0 0 0 279 228 241  
     162  214  
  0 0 0 253 297 282  
  0 0 0 81 97 96  
         
BALB-N167K     LWKDSKLDQSCT 0 2 0 198    
  0 0 0 390 356 0  
  0 1 0 294 356 0  
  0 1 0 136    
194 
 
         
BALB-N167S     LWSDSKLDQSCT 13 70 23 149    
  20 94 26 364 292   
  12 82 24  349   
  9 57 12  400   
  13 67 16  480   
  13 74 20 257 380   
  4 14 6 152 80   
         
1 LWNDSKLDENRN 0 0 0 201 217 0  
  0 0 0 151 150 0  
  0 0 0 176 184 0  
  0 0 0 35 47 0  
         
2 VLKAAEPVQSCT 0 0 0 476 403 463  
     201  235  
195 
 
  0 0 0 339 403 349  
     194  161  
         
2.1 LLKAAEPVQSCT 0 0 0 862  979  
  0 2 0 359 472 390  
     305  350  
  0 1 0 509 472 573  
  0 1 0 307  352  
         
2.2 VWKAAEPVQSCT 0 14 0 693  0  
  0 11 0 340 407 0  
  0 23 0 390 379 0  
  0 10 0  346   
  0 9 0  343   
  0 13 0 474 369 0  
  0 6 0 191 30 0  
196 
 
         
2.3 VLNAAEPVQSCT 40 125 3 1024  767  
  29 147 3 467 235 498  
  23 105 2  446   
       308  
  16 88 0  389   
  26 58 0 989 336 463  
  27 105 2 827 352 509  
  9 34 2 312 90 191  
         
3 LWNAAEPVENRN 0 0 0     
  0 0 0 90 111 0  
  0 0 0 90 111 0  
  0 0 0     
         
3.1 VWNAAEPVENRN 0 0 0     
197 
 
  0 0 0 208 259 0  
  0 0 0 208 259 0  
  0 0 0     
         
3.2 LLNAAEPVENRN 0 0 0     
  0 0 0 423 308 284  
     300  264  
  0 0 0 362 308 274  
  0 0 0 87  14  
         
3.3 LWKAAEPVENRN 0 0 0   0  
  0 0 0 190 212   
  0 0 0 190 212 0  
  0 0 0     
         
3.4 VLNAAEPVENRN 0 0 0     
198 
 
  0 0 0 252 314   
     202  211  
  0 0 0 227 314 211  
  0 0 0 35    
         
3.5 VWKAAEPVENRN 0 0 0     
  0 0 0 80 91 0  
  0 0 0 80 91 0  
  0 0 0     
         
4 VLKDSKLDQSCT 0 0 0     
  0 2 0 397 297 281  
  0 0 0 401 356 230  
     259  87  
  0 1 0 352 327 199  
  0 1 0 81 42 101  
199 
 
         
4.1 LLKDSKLDQSCT 0 0 0     
  0 0 0 289 369 163  
  0 0 0 467 383 292  
     180  131  
  0 0 0 312 376 195  
  0 0 0 145 10 85  
         
4.2 VWKDSKLDQSCT 0 9 0     
  0 24 0 243 412 0  
  0 2 0 586  0  
  0 12 0 415 412 0  
  0 11 0 243  0  
         
4.3 VLNDSKLDQSCT 7 33 0     
  13 99 0 319 419 0  
200 
 
  0 20 0 521  0  
  7 51 0 420 419 0  
  7 42 0 143  0  
         
4.4 LWKDSKLDQSCT 0 4 0   0  
  0 0 0 195 220 0  
  0 0 0 404    
  0 1 0 300 220 0  
  0 2 0 148  0  
         
4.5 LLNDSKLDQSCT 8 31 0     
  10 104 0 348 427 0  
  0 27 0 545  0  
  6 54 0 447 427 0  
  5 43 0 139  0  
         
201 
 
5 VLKDSKLDENRN 0 0 0 516 407 274  
  0 0 0 260 290 251  
  0 0 0 388 349 263  
  0 0 0 181 83 16  
         
6 LWNAAEPVQSCT 321 623 378 647 579 0  
  174 313 207 455 489 0  
  222 393 308  459   
  239 443 298 551 509 0  
  75 161 86 136 62 0  
         
6.1 VWNAAEPVQSCT 289 386 303 1024  0  
  317 747 498 641 591 0  
  342 629 471 624 379 0  
  307 515 327  520   
  314 569 400 763 497 0  
202 
 
  22 155 99 226 108 0  
         
7 LWNAAEPVENCN 334 311 379 733  0  
  285 356 369 379 507 0  
  145 170 187  234   
  196 219 286  288   
  240 264 305 556 343 0  
  85 85 89 250 145 0  
         
7.1 VWNAAEPVENCN 463 401 511 1015  0  
  575 613 689 575 530 0  
  359 407 135  414   
  430 426 515  375   
  457 462 463 795 440 0  
  90 101 234 311 81 0  
         
203 
 
7.2 VLNAAEPVENCN 16 27 0 862  927  
  7 27 0 412 414 369  
  9 32 0  324   
  6 21 0  307   
  10 27 0 637 348 648  
  5 5 0 318 58 395  
         
7.3 VWKAAEPVENCN 22 146 96 1121  0  
  70 196 103 489 467 0  
  34 121 43  385   
  45 126 61  442   
  43 147 76 805 431 0  
  20 34 29 447 42 0  
         
7-HA LWNAAEPVENCN -HA 281 427 364 545 507 0 463 
  112 145 140 248 271 0 91 
204 
 
  175 194 196  322  250 
  189 255 233 397 367 0 268 
  85 151 117 210 124 0 187 
         
7.1-HA         VWNAAEPVENCN -HA 266 303 287 870  0  
  313 450 392 442 446 0 414 
  223 359 308 343 259 0 259 
  248 284 284  252  235 
  263 349 318 552 319 0 303 
  38 74 51 280 110 0 97 
         
7.2-HA  VLNAAEPVENCN -HA 5 17 0 832  935  
  2 21 0 390 355 443 347 
  5 20 0 303 319 350 233 
  2 9 0  271  252 
  4 17 0 508 315 576 277 
205 
 
  2 5 0 284 42 314 61 
         
7.3-HA   VWKAAEPVENCN -HA 48 145 65 944  0  
  36 263 77 607 640 0 560 
  30 141 75 177 471 0 386 
  32 125 61  150  472 
  37 169 70 576 420 0 473 
  8 64 8 384 249 0 87 
         
BALB-A          111 256 161 390    
  58 168 116  325   
  34 100 49  252   
  68 175 109 390 289   
  39 78 56  52   
         
BALB-B          150 210 164 402    
206 
 
  149 259 201  340   
  75 122 98  207   
  125 197 154 402 274   
  43 69 52  94   
         
BALB-C          270 446 223 496    
  173 363 243  427   
  139 236 174  339   
  194 348 213 496 383   
  68 106 36  62   
         
BALB-D          77 159 98 322    
  43 98 82  314   
  33 66 49  205   
  51 108 76 322 260   
  23 47 25  77   
207 
 
         
BALB-BC         99 130 80 293    
  48 89 49  226   
  29 42 27  161   
  59 87 52 293 194   
  36 44 27  46   
         
BALB-ABCD-HA   2 12 5 69  0  
  2 8 5  46  37 
  0 9 4  56  48 
  2 9 6  56  45 
  2 10 5 69 53 0 43 
  1 2 1  6  6 
         
C57-ABCD        0 0 0 21  10 0 
  0 0 0  10  0 
208 
 
  0 0 0  10 8 2 
      10 7 0 
  0 0 0 21 10 8 1 
  0 0 0  0 2 1 
         
C57-ABCD-HA     0 0 0 16  8  
  0 0 0  12  12 
      8 6 8 
      10 11 10 
  0 0 0 16 10 8 10 
  0 0 0  2 3 2 
         
BALB-20-H       11 49 23  0   
  10 30 23  0   
  31 73 44 0    
  17 51 30 0 0   
209 
 
  12 22 12  0   
         
BALB-20-H-HA    20 93 34  0  151 
  14 57 17  0  125 
  18 56 21 0   232 
  17 69 24 0 0  169 
  3 21 9  0  56 
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Appendix IV. Staining of Ly49A mutants. The numbers represent intensity of staining expressed in fluorescence intensity units. The bold 
numbers represent average values and the underlined numbers represent standard deviation (SD). 
Name  Kb Db Dd N538 JR9 N509 A1 N358 YE1/48 N1222 anti-HA 
Ly49A  0 0 214 43 30 38  
 0 0 162 27 22 37  
 0 0 164 28 16 42  
 0 0 180 33 23 39  
 0 0 29 9 7 3  
        
Ly49A HA 3 3 328 27 45 47 359 
 3 6 317 23 36 36 359 
 4 6 325 26 35 34 340 
 3 5 323 25 39 39 353 
 1 2 6 2 6 7 11 
        
Ly49A-W166L-HA 0 0 0 0 0 0  
 0 0 0 0 0 0 61 
211 
 
 0 0 0 0 0 0 24 
 0 0 0 0 0 0 48 
 0 0 0 0 0 0 44 
 0 0 0 0 0 0 19 
        
Ly49A-S167K-HA 19 24 570     
 12 21 455 47 47 51 324 
 7 13 343 27 29 32 248 
 10 15 439 25 28 33 307 
 12 18 452 33 35 39 293 
 5 5 93 12 11 11 40 
 
